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1. INTRODUCTION 
 
Cancer is a highly complex disease involving abnormalities in regulatory circuits, 
which tightly modulate normal cell proliferation and homeostasis. As a consequence, 
virtually all human tumors show at least six common features that involve the ability 
to sustain chronic proliferation, to evade growth suppressors, to resist programmed 
cell death (apoptosis), to allow unlimited replicative potential, to induce angiogenesis 
and to activate tissue invasion and metastasis (Hanahan and Weinberg, 2000). 
Recently, it has been shown that, in addition to these hallmarks, tumor formation may 
also benefit from the inflammatory microenvironment and from changes in cell 
metabolism to sustain deregulated cell proliferation (Hanahan and Weinberg, 2011).   
From a molecular point of view, oncogenic transformation is a multistep process 
characterized by a gradual alteration of normal cells into cancerous cells and requires 
alterations in various cellular processes including both activation of oncogenic 
pathways and inhibition of tumor suppressor pathways, therefore promoting growth 
and survival of cancer cells (Hanahan and Weinberg, 2000).  
One of the most important pathways deregulated in many cancers and important for 
tumor formation and progression is the retinoblastoma (pRb) tumor suppressor 
pathway. 
 
1.1 Retinoblastoma tumor suppressor protein (pRb, Rb1, p110) 
 
pRb is the product of the retinoblastoma-associated gene RB1: it was the first tumor 
suppressor gene to be cloned (Friend et al., 1986; Lee et al., 1987; Fung et al., 1987). 
In familial cases of retinoblastoma, a germline mutation in the RB1 gene is inherited, 
and affected individuals develop retinal tumors in which the loss of the second RB1 
allele is the rate-limiting step. The identification and subsequent cloning of the RB1 
gene launched a new era in cancer genetics, and RB1 was subsequently found to be 
mutated in other human cancers including osteosarcoma. In addition to gene 
mutations, loss of pRb function is also seen in a variety of spontaneous human 
tumors, such as lung cancer, lymphoma and breast cancer (Burkhart and Sage, 2008). 
In mammalian cells pRb belongs to a family of three homologous proteins that 
includes Rbl1 (p107) and Rbl2 (p130), which are structurally and functionally related 
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to pRb (Henley and Dick, 2012). pRb has a major role in the regulation of cell cycle 
progression through its capability to arrest cells in G1 phase and to prevent 
uncontrolled cell proliferation (Goodrick, 2006). In addition, the critical role of pRb 
in tumor suppression is associated with other important functions, which include the 
regulation of specific genes that induce apoptosis, preservation of chromosomal 
stability, and the induction and maintenance of senescence (Burkhart and Sage, 2008 
Burke, et al., 2012; Manning and Dyson, 2012; Sage, 2012). The combination of 
these functions contributes to tumor suppression, therefore functional inactivation of 
pRb can lead in several ways to the development of cancer.  
Moreover, by promoting cell cycle exit and through the direct interaction with 
differentiation transcription factors, such as MyoD, C/EBP or Cbfa1/Runx2, pRb 
controls cellular differentiation during embryogenesis and in adult tissue (Burkhart 
and Sage, 2008, Kim et al., 2011; Gu et al., 1993). 
Finally, most recently, many evidences have underlined a novel and important role 
for Rb proteins in the biology of stem and progenitor cells: pRb in this context 
regulates cell cycle progression, self-renewal features and cell-fate choices (Sage, 
2012). 
In the following sections I will discuss the role of pRb in the control of cell cycle 
progression (1.1.1), the regulation of its function and expression (1.1.2), the impact of 
loss of pRb function in cancer initiation and progression (1.1.3) and the role of 
retinoblastoma protein in stem cell biology (1.1.4). 
 
1.1.1 pRb retinoblastoma protein and the cell cycle 
 
The cell cycle is composed of four phases, the gap before DNA replication (G1), the 
DNA synthetic phase (S), the gap after DNA replication (G2) and the mitotic phase, 
which culminates in cell division (M). The major mission of the cell division cycle is 
a faithful and complete duplication of the genome followed by an equal partitioning 
of chromosomes to subsequent cell generations. The process of cell division is highly 
ordered and regulated by checkpoints that can become activated due to DNA damage, 
exogenous stress signals, defects during the replication of DNA, or failure of 
chromosomes to attach to the mitotic spindle. The final endpoint of these signals is 
the arrest of the cell cycle to provide time for repair. Abrogation of cell cycle 
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checkpoints can result in death for a unicellular organism or uncontrolled 
proliferation and tumorigenesis in metazoans (Nyberg et al., 2002). The tumor 
suppressor pRb plays a critical role in each of these cell cycle checkpoints. 
Retinoblastoma protein is precisely phosphorylated in synchrony with the cell cycle 
progression (Buchkovich et al., 1989; Chen et al., 1989; DeCaprio et al., 1989) 
suggesting that pRb might be a general cell cycle regulator. This hypothesis was 
supported by the observation that exogenous unphosphorylated pRb could arrest cells 
in the G1 phase of the cell cycle (Goodrich et al., 1991; Connell-Crowley et al., 
1997), and that depletion of pRb determined an accelerated G1/S transition (Herrera 
et al., 1996). 
Based on these evidences, the functional characterization of the retinoblastoma 
protein (pRb) as first tumor suppressor focused on its role as a central regulator of 
cell cycle progression and in particular as inhibitor of the G1-S transition of the cell 
cycle for many years (Riley et al., 1994; Weinberg, 1995).  
Although this pRb function can be ascribed to multiple mechanisms, the capacity of 
pRb to arrest cells in G1 is largely due to the inhibition of the transcription of 
multiple genes required for S-phase entry through the control of the activity of E2F 
proteins, a large family of transcription factors responsible for the expression of genes 
related to cell cycle control, cell proliferation, and apoptosis. In addition, pRb recruits 
corepressors that regulate chromatin structure, such as histone deacetylases, 
SWI/SNF chromatin remodelling enzymes and additional chromatin modifiers 
(Chinnam and Goodrich, 2011; Cobrinik, 2005; Nevins, 2001; Iaquinta and Lees, 
2007; Blais and Dynlacht, 2004; Blais and Dynlacht, 2007; Harbour and Dean, 2000; 
Morris and Dyson, 2001; Stevaux and Dyson, 2002) and therefore can control G1-S 
transition also by direct regulation of gene expression programs (Burkhart and Sage, 
2008; van den Heuvel and Dyson, 2008). 
Phosphorylation plays a key role in regulating the activity of the pRb protein. In fact, 
the interaction and the functional inhibition of E2F occur when pRb is in its 
hypophosphosphorylated and active form, and coincides with the ability of pRb to 
arrest cells in G1 (Harbour and Dean, 2000) (Figure 1).  
In particular, during the G1 phase of the cell cycle, mitogenic or growth promoting 
signals drive the accumulation of D-type cyclin and the concomitant formation of 
complexes between cyclin D and Cdk4 or Cdk6 (Sherr, 2000; Classon and Harlow, 
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2002; Longworth and Dyson, 2010) (Figure 1). Active Cdk4 and Cdk6 initiate the 
progressive phosphorylation of pRb at S249, T356, S807, S811 and T826 (Zarkowska 
and Mittnacht, 1997), which impairs the binding of pRb to E2F and, as a 
consequence, promotes the activation of E2F target genes (Ewen et al., 1993; Kato et 
al., 1993) (Figure 1). Importantly, among these target genes, there are E- and A-type 
cyclins, which, in complexes with Cdk2, further promote pRb hyperphosphorylation 
in a positive feedback loop (Hinds et al., 1992) (Figure 1). Once inactivated by 
phosphorylation, pRb remains hyperphosphorylated until mitosis, when the activation 
of phosphatases, such as type 1 and type 2 protein phosphatase complexes (PP1 and 
PP2 respectively), trigger pRb dephosphorylation and restore its regulatory function 
(Vietri et al., 2006; Broceno et al., 2002; Tamrakar et al., 2000; Henley and Dick, 
2012) (Figure 1).  
There are compelling reasons to believe that pRb plays an important role also in 
coordinating progression through mitosis. First, many of the critical factors for G2/M 
control (e.g., Cdk1, cyclin B, Plk1, Cdc20, Mad2) are regulated by the pRb/E2F 
pathway (Zhu et al., 2006). Second, several studies have linked pRb action to mitotic 
control, although a detailed mechanism is still poor understood. For example, pRb is 
proposed to assist in the maintenance of G2/M checkpoints following DNA damage 
by mediating transcriptional repression of Cdk1 and cyclin B (Jackson et al., 2006). 
In addition, a large number of anti-mitogenic or growth inhibitor signals could trigger 
pRb dephosphorylation and activation through the reduction of cyclin expression and 
the induction of Cdk inhibitors, such as p16, p21 and p27 (Wang et al., 1994; Dou et 
al., 1995; Mittnacht, 1998; Knudsen et al., 2000; Avni et al., 2003) (Figure 1). 
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Figure 1. pRb and cell cycle progression. Mitogenic signals stimulate the expression of D-type cyclins and 
a concomitant increase in cyclin-dependent kinase 4 (CDK4) and CDK6 activity. These factors initiate pRb 
phosphorylation, which is augmented by the activity of CDK2 complexes with cyclins A and E. The 
phosphorylation of pRb disrupts its association with E2F promoting G1-S progression. At the transition 
from mitosis to G1, pRb is dephosphorylated through the action of phosphatases. Importantly, a large 
number of anti-mitogenic signals function to prevent pRb phosphorylation either by limiting the activity of 
CDK4, CDK6 and CDK2 complexes or by inducing the activity of CDK inhibitors. (Knudsen and Knudsen, 
2008) 
 
Another mechanism that pRb uses to regulate cell cycle is E2F-indipendent and 
involves the control of the stability of the cell cycle inhibitor p27. In particular, it has 
been reported that pRb recruits and activates the anaphase promoting 
complex/cyclosome APC/C through a direct interaction with the APC/C specific 
factor Cdh1 (Binne al., 2007). APC/C is a complex important for the degradation of 
cell cycle substrates at the G1/S and G2/M checkpoints, such as the S-phase kinase 
associated protein 2 (Skp2), a component of E3 ubiquitin-ligase complex SCF able to 
degrade the CDK inhibitor p27 (Ji et al., 2004). The activation of APC/C complex by 
pRb and the consequent degradation of Skp2 drive the accumulation of p27 and the 
inhibition of the CDK activity to induce cell cycle arrest (Binne al., 2007).  
Finally, pRb functions can also control genomic stability in cells by various 
mechanisms, including regulation of the expression of genes involved in mitosis, but 
also by directly interacting with proteins involved in maintaining the structure of 
chromosomes during G2/M phase (Sherr and McCormick, 2002; Iaquinta and Lees, 
2007; Chinnam and Goodrich, 2011; Viatour and Sage, 2011; Manning and Dyson, 
2012).   
Figure 1. Schematic of RB in cell cycle control
Mitogenic signals stimulate the expression of D-type cyclins (Cyc) and a concomitant increase
in cyclin-dependent kinase 4 (CDK4) and CDK6 activity. These factors initiate RB
phosphorylation, which is augmented by the activity of CDK2 complexes with cyclins A and
E. The phosphorylation of RB disrupts its association with E2F. This inactivation of RB allows
for the expression of a transcriptional programme that enables progression through S-phase
and mitosis. At the transition from mitosis to G1, RB is dephosphorylated through the action
of phosphatases. Importantly, a large number of anti-mitogenic signals function to prevent RB
phosphorylation either by limiting the activity of CDK4, CDK6 and CDK2 complexes or by
inducing the activity of CDK inhibitors.
Knudsen and Knudsen Page 22
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1.1.2 Regulation of pRb function and expression 
 
The variety of roles that pRb plays in many cellular processes reflects the complex 
regulation of its function and expression. In particular, a wide range of post-
translational modifications and a tight control at the post-transcriptional level allow 
pRb to orchestrate its extensive biological roles. 
 
1.1.2.1 Post-translational modifications of pRb 
 
pRb protein can function as an adaptor, nucleating components such as E2Fs and 
chromatin regulating enzymes into the same complex. For this reason, pRb’s 
regulation by post-translational modifications is thought to be critical.  
As well as being phosphorylated, pRb is acetylated, methylated, ubiquitylated, and 
SUMOylated. Acetylation of pRb has been demonstrated to occur at lysines 873 and 
874, and this acetylation might prevent pRb inactivation by phosphorylation (Chan et 
al., 2001). Acetylated pRb might therefore make up a pool of pRb that remains active 
despite the presence of Cdks. Furthermore, double-stranded DNA breaks induce 
acetylation of pRb and acetylation might have a role in differentiation (Nguyen et al., 
2004). pRb can be sumoylated at lysine 720, in the small pocket near the LXCXE 
binding domain, but the function of this sumoylation is still poor understood (Ledl et 
al., 2005). Ubiquitinylation of pRb promotes its degradation and may be used to 
regulate apoptosis (MacDonald and Dick, 2013; Munro et al., 2012) (Figure 4).  
pRb is a nuclear phosphoprotein that contains at least 16 potential Cdk 
phosphorylation sites and can be phosphorylated by different kinases, including 
cyclin D–Cdk4, cyclin D-Cdk6, cyclin A–Cdk2, cyclin E–Cdk2, Chk1-2 (checkpoint 
homologue 1 and 2) and serine/threonine-protein kinase RAF1 (Burkhart and Sage, 
2008). During cell cycle progression pRb is gradually phosphorylated by different 
combinations of cyclin/Cdk complexes inducing the E2F dissociation. Although the 
binding of E2F transcription factors and other partners of pRb seem to be disrupted 
by a random phosphorylation, phosphorylation of specific sites can drive pRb into 
particular structural conformations and selectively inhibit specific pRb functions 
(Munro et al., 2012) (Figure 4). In line with this hypothesis, a recent study has 
revealed that phosphorylation at S608 cause specific conformational changes that 
 7 
alter the direct binding to E2F (Burke, 2012). In addition, phosphorylation at T373 
modifies the LxCxE site of pRb, a binding domain important to interact with histone-
modifying enzyme and cyclin-CDK kinase complexes, and inhibits the interaction 
with transcriptional corepressors recruited to repress the expression of E2F target 
genes (Burke et al., 2012).  
 
      
Figure 4. Schematic representation of pRb post-translational modifications. The location of post-
translational modifications in pRb is shown. The A and B domains, which comprise the pRb pocket, are 
indicated. K, lysine; S, serine; T, threonine. (Munro et al., 2012) 
 
The phosphorylation status and corresponding activity of the retinoblastoma tumor 
suppressor protein (pRb) are modulated also by the activity of CDK inhibitors (CKIs) 
and phosphatase proteins.  
There are two main classes of CKIs, the CIP/KIP family, which consists of p21, p27 
and p57, and the INK4 family, which consists of p16, p15, p18, and p19 (Besson et 
al., 2008). CIP/KIP family members are able to inhibit any cyclin dependent kinases 
that are found in G1, while the INK4A members can bind only Cdk4 and Cdk6 
associated with D-type cyclins (Sherr, 1999). CKI expression is activated by diverse 
signals, such as the induction of p21 by p53 in response to DNA damage (Bunz et al., 
1998), so the function of CDK inhibitors is essential to control cell cycle progression. 
Therefore, loss-of-function mutations affecting CKIs result in the 
hyperphosphorylation and inactivation of pRb promoting the development of various 
tumors (Gordon and Du, 2011). For example, mutations of INK4 locus, that encodes 
for the CDK inhibitors p16, p15 and p19, is frequently altered by deletion or 
epigenetic regulation in several tumor types including bladder cancer and leukemia 
(Sherr, 2012). 
Alternatively, a direct regulation of pRb phosphorylation can be mediated by protein 
phosphatases. Among these the most important is the type 1 protein phosphatase 
(Pp1).  Pp1 is a highly conserved serine/threonine-specific protein phosphatase that is 
abundantly expressed in virtually all cell compartments. Pp1 plays a key role in the 
The regulation of the pRb/E2F pathway by cyclin/
Cdk phosphorylation is intrinsic to cell cycle control.
Cyclin/Cdk complexes are themselves negatively regu-
lated by Cdk inhibitors such as p16INK4A, p21CIP1 and
p27KIP1 (Sherr and Roberts, 2004). Whilst phosphoryla-
tion is recognized as a post-translational modification
that significantly influences pRb activity, it is now
apparent that other types of modification can also
impact upon pRb/E2F. For example, pRb and E2F-1
are modified on lysine residues by post-translational
modifications such as acetylation, methylation, ubiqui-
tination and SUMOylation.
Most of our knowledge of lysine acetylation and
methylation has come from the studies on histones in
chromatin control (Zhang and Reinberg, 2001). The
diversity and extent to which histones can be modified
has led to the concept of the ‘histone code’ (Jenuwein
and Allis, 2001). The ‘histone code’ suggests that the
modification of histone tails is ‘written’ by one set of
enzymes, ‘read’ by effector molecules and ‘erased’ by
another set of enzymes (Jenuwein and Allis, 2001). It is
believed that chromatin control by ‘readers, writers and
erasers’ enables fine-tuning in response to different
physiological contexts. In simple terms, some post-
translational modifications are associated with tran-
scriptional activation and others with repression, which
is facilitated by recruiting ‘reader’ proteins, which then
direct gene activity. Furthermore, additional levels of
complexity exist as single residues can be targeted by
more that one type of modification.
Most significantly, the concept f post-translational
modifications creating a ‘code’ that can impart different
biological activities may not be restricted to histones
(Sims and Reinberg, 2008). The p53 tumour suppressor
protein is a particularly good example, where many of
the enzymes that act upon histones also target p53.
Thus, p53 can be modified by phosphorylation, acetyla-
tion, methylation, SUMOylation and NEDDylation
(Meek and Anderson, 2009). It is also clear that there
is cross-talk between p53 modifications, where different
combinations of modification can promote diverse
outcomes (Meek and Anderson, 2009; Dai and Gu,
2010).
Recent evidence suggests that pRb and E2F-1 are
subjected to additional levels of post-translational
control by phosphorylation, acetylation, methylation,
SUMOylation and ubiquitination. Here, we will discuss
advances in our understanding of the increasingly wide
spectrum of post-translational modifications that act
upon pRb and E2F-1, raising the possibility that a
‘code’ exists which provides greater levels of complexity
on pRb, enabling it to function in diverse physiological
roles.
pRb phosphorylation
pRb is a nuclear phosphoprotein, and the phosphoryla-
tion of pRb on many sites by the cyclin/Cdks has been
extensively documented (Mittnacht, 1998; Adams,
2001). pRb harbours up to 16 potential Cdk consensus
sites (Knudsen and Wang, 1996) (Figure 1). As cells
progress through the cell cycle, pRb is gradually
phosphorylated by different combinations of cyclin/
Cdk complexes. The increase in the level of pRb
phosphorylation results in the dissociation from
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regulation of cell cycle progression and is also involved in other processes, including 
gene expression, muscle contraction, glycogen metabolism and neurotransmission 
(Bollen, 2001; Hubbard and Cohen, 1993). 
The Pp1 holoenzyme generally consists of a catalytic subunit bound to a regulatory 
subunit. The catalytic subunit is highly conserved and is present in mammalian cells 
in four isoforms, α, β (also called δ), γ1, γ2, which are usually associated to form 
multimeric structures (Cohen, 2002; Vietri et al., 2006). It was suggested that among 
the Pp1 isoforms, Pp1δ has the greatest pRb-directed phosphatase activity (Nelson et 
al., 1997) but more recent studies indicated that all three Pp1 isoforms 
dephosphorylate pRb (Rubin et al., 2001). To prevent its premature activation during 
the cell cycle, Pp1 catalytic subunit is subjected to inhibitory regulation by Nipp1 
(nuclear inhibitor of protein phosphatase 1). Nipp1 is a ubiquitously expressed 
nuclear scaffold protein and is the most potent and specific inhibitor of Pp1 (Van 
Eynde et al., 1995; Beullens et al., 1993; Beullens et al., 1992). Nipp1 contains at 
least two binding sites for Pp1 and is complexed to about one-third of the nuclear 
pool of Pp1. However, this complex is inactive and the activation occurs when Nipp1 
is phosphorylated by protein kinase A, protein kinase CK2, and protein tyrosine 
kinases of the Src family (Martin-Granados et al., 2012; Cohen, 2002).  
Another important regulator of Pp1 is Ccnf (Cyclin F). Ccnf is a member of the F-box 
family proteins and constitutes one of the four subunits of the ubiquitin protein ligase 
complex called SCFs (SKP1-cullin-F-box), which functions in phosphorylation-
dependent ubiquitination (D’angiolella et al., 2012). In particular, through the F-box 
domain, Ccnf interacts with other components of the SCF complex promoting the 
ubiquitination and the consequent degradation of target substrates, such as Pp1 
(Tamrakar et al., 2000; D’angiolella et al., 2010; D’angiolella et al., 2012). Ccnf, 
which is involved in the regulation of the G1-S and G2-M checkpoint, was also 
associated to the maintenance of pRb in its hyperphosphorylated status (Beullens et 
al., 1992; Campbell et al., 2007). 
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1.1.2.2 Post-transcriptional regulation 
 
Beyond post-translational modifications, pRb expression and function can be 
modulated also at the post-transcriptional level by miRNAs. 
miRNAs are 18–25 nucleotide non-coding RNAs that bind to the 3’untranslated 
region (UTR) of target mRNAs through an imperfect match to repress their 
translation and stability (He and Hannon, 2004). This is achieved by forming a 
ribonucleoprotein complex, called the RNA-induced silencing complex (RISC), that 
contains proteins of the Argonaute family (Peters and Meister, 2007; Filipowicz et al., 
2008). miRNAs are derived from precursor transcripts, called primary miRNAs (pri-
miRNAs), that are first processed in the nucleus into an intermediate form (pre-
miRNAs) by the Microprocessor protein complex, containing the Drosha and 
DiGeorge syndrome critical region gene 8 (DGCR8; also known as Pasha) proteins. 
The pre-miRNAs are then translocated by the exportin 5-RanGTP shuttle system into 
the cytoplasm, in which they are further processed by Dicer, an RNase III-like 
enzyme, into mature miRNAs (He and Hannon, 2004) (Figure 5). 
 
 
 
Figure 5. Schematic representation of biogenesis of microRNAs. (Winter et al.,2009)  
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pri-miRNA cleavage by the Drosha–DGCR8 microprocessor complex. 
The pri-miRNA is next endonucleolytically cleaved by the nuclear micro-
processor complex formed by the RNase III enzyme Drosha (RNASEN) 
and the DGCR8 (DiGeorge critical region 8) protein (also known as Pasha 
(Partner of Drosha) in D. melanogaster and C. elegans)36 (Fig. 2a). DGCR8/
Pasha contains two double-stranded RNA-binding domains and is essen-
tial for miRNA processing in all organisms tested37–40. An average human 
pri-miRNA contains a hairpin stem of 33 base-pairs, a terminal loop and 
two single-stranded flanking regions upstream and downstream of the 
hairpin. The double-stranded stem and the unpaired flanking regions 
are critical for DGCR8 binding and Drosha cleavage, but the loop region 
or the specific sequences are less important for this step41–43. A single 
nucleotide polymorphism in a miRNA precursor stem can block Drosha 
processing44. Nevertheless, many miRNA sequence aberrations observed 
in human tumours alter the secondary structure without affecting process-
ing, and reveal the structural flexibility of the microprocessor34.
The two RNase domains of Drosha cleave the 5´ and 3´ arms of the pri-
miRNA hairpin39, whereas DGCR8 directly and stably interacts with the 
pri-miRNA and functions as a molecular ruler to determine the precise 
cleavage site41. Drosha cleaves 11 base pairs away from the single-stranded 
RNA/double-stranded RNA junction at the base of the hairpin stem.
Drosha-mediated cleavage of the pri-miRNA occurs co-transcriptionally 
and precedes splicing of the protein-encoding or non-coding host RNA 
that contains the miRNAs. Splicing is not inhibited by Drosha-mediated 
cleavage, because a continuous intron is not required for splicing45,46.
microRNA-specific regulation of the microprocessor complex. 
Drosha-mediated pri-miRNA processing was recently shown to be 
subject to regulation by miRNA-specific mechanisms. Drosha forms 
two different complexes, a small microprocessor complex that contains 
only Drosha and DGCR8 and processes many pri-miRNAs, and a larger 
complex that contains RNA helicases, double-stranded RNA binding 
proteins, heterogeneous nuclear ribonucleoproteins and Ewing’s sarcoma 
proteins38. The RNA helicases p72 and p68 are part of the large Drosha 
complex and might act as specificity factors for the processing of a sub-
set of pri-miRNAs (Fig. 2b). Expression levels of several miRNAs are 
reduced in homozygous p68−/− or p72−/− knockout mice, whereas other 
miRNAs remain unaffected47.
Drosha-mediated cleavage can also be regulated for individual miR-
NAs: the heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) 
binds specifically to pri-miR-18a and facilitates its processing. Loss of 
hnRNP A1 diminishes the abundance of mature miR-18a (Fig. 2c), but 
hnRNP A1 does not have any impact on other miRNAs that are located 
in the same miR-17 genomic cluster, demonstrating the extraordinary 
specificity of miR-18a biogenesis48. hnRNP A1 binds to the conserved 
loop of the pri-miR-18a and changes the hairpin conformation to create 
a more favourable cleavage site for Drosha49. About 14% of the human 
pri-miRNA loops are conserved between different species and could 
provide anchor points for similar regulatory mechanisms.
Transforming growth factor-β (TGF-β) and bone morphogenetic 
factors (BMPs) induce the maturation of miR-21 by regulating the 
microprocessor activity. TGF-β and BMP bring about the recruitment 
3´
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Figure 1 The ‘linear’ canonical pathway of microRNA processing. The miRNA 
processing pathway has long been viewed as linear and universal to all 
mammalian miRNAs. This ca onical maturation includes the production of 
the primary miRNA transcript (pri-miRNA) by RNA polymerase II or III and 
cleavage of the pri-miRNA by the microprocessor complex Drosha–DGCR8 
(Pasha) in the nucleus. The resulting precursor hairpin, the pre-miRNA, is 
exported from the nucleus by Exportin-5–Ran-GTP. In the cytoplasm, the 
RNase Dicer in complex with the double-stranded RNA-binding protein TRBP 
cleaves the pre-miRNA hairpin to its mature length. The functional strand of 
the mature miRNA is loaded together with Argonaute (Ago2) proteins into the 
RNA-induced silencing complex (RISC), where it guides RISC to silence target 
mRNAs through mRNA cleavage, translational repression or deadenylation, 
whereas the passenger strand (black) is degraded. In this review we discuss 
the many branches, crossroads and detours in miRNA processing that lead to 
the conclusion that many different ways exist to generate a mature miRNA.
Editing is defined as a post-transcriptional change of RNA sequences 
by deamination of adenosine (A) to inosine (I), altering the base-
pairing and structural properties of the transcript. Editing of miRNA 
transcripts by ADAR1 and ADAR2 was first described for miR-22 
(ref. 116) followed by miR-151, miR-197, miR-223, miR-376a, miR-
379 and miR-99a (ref. 117), as well as miR-142, miR-223, miR-1-1 
and miR-143 (ref. 118). In pri-miR-142, A-to-I editing inhibits its 
cleavage by the endonuclease Drosha and results in its degradation 
by the ribonuclease Tudor-SN, which preferentially cleaves double-
stranded RNA containing inosine–uracil pairs118,119. However, edit-
ing of other pri-miRNAs was shown to enhance their processing by 
Drosha120. Editing can also influence further downstream processing 
steps: pri-miR-151 editing abolishes its cleavage by Dicer in the cyto-
plasm. It remains to be established whether miRNA editing events 
are predominantly nuclear or cytoplasmic and whether they occur 
on the pri-miRNA or on the precursor miRNA (pre-miRNA)121. In 
addition to altering miRNA processing, miRNA editing can have 
an impact on miRNA target specificity. For example, a single A-to-I 
change in the miR-376 precursor redirects the mature miRNA to 
a new target, resulting in altered protein expression in mice122. In 
summary, miRNA editing can influence processing at multiple steps 
or can change the miRNA complementarity to target sequences, 
increasing the diversity of the cellular miRNA pool.
BOX 1 microRNA editing
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MicroRNAs are expressed in a tissue-specific and developmental stage-specific 
manner, providing an additional layer of complexity in the regulation of gene 
expression. Through the parallel modulation of the expression of target transcripts, 
miRNAs can coordinately alter many different signaling pathways and cellular 
processes such as proliferation, differentiation, or apoptosis. Accordingly, the control 
of critical targets by miRNAs has multiple implications in development and 
tumorigenesis (He and Hannon, 2004; Ventura and Jacks, 2009). 
In this context it was been observed that miRNAs can regulate also Rb family 
proteins. In mouse embryonic stem cells, a cluster of six miRNAs (miR-290 cluster) 
targets the Rb family member Rbl2, a repressor of DNA methyl transferase 
(DNMTs). Moreover it was observed that this cluster of miRNAs, targeting Rbl2, can 
control also mESC properties promoting self-renewal by establishing the cell cycle 
program of pluripotent mESCs (Benetti et al., 2008; Sinkkonen et al., 2008). 
These evidences suggest the existence of a miRNA network able to control Rb 
proteins and pRb pathway activity. 
 
 
1.1.3 Retinoblastoma protein in cancer initiation and progression 
 
The variety of human cancers in which the retinoblastoma protein pRb is inactivated 
reflects both its importance for tumor suppression and its multiplicity of protein 
interactions and cellular functions. Based on the analyses of human tumors, it is 
evident that Rb pathway is inactivated by different mechanisms that include both 
RB1 mutation/deletion and enzymatic inactivation of retinoblastoma proteins. 
In addition to their well-documented roles in retinoblastoma, inherited RB1 mutations 
are thought to cause a number of different tumors. Osteosarcoma, for example, is 
commonly observed in retinoblastoma survivors (Chauveinc et al., 2001). 
Susceptibility to small cell lung carcinoma (SCLC) has also been attributed to 
germline RB1 mutation and retinoblastoma survivors are also at increased risk for 
this and several other cancers (Kaye and Harbour, 2004). The frequency of RB1 loss 
in SCLC is extremely high (>80%), but is much less common in non-small cell lung 
cancer (NSCLC) (Wikenheiser-Brokamp, 2006). Other cancers display somatic loss 
of RB1 less frequently than SCLC but still in significant proportions, including 
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bladder, espophageal, liver, brain, breast, and prostate cancers, as well as chronic 
myelogenous leukemia (CML). RB1 loss is perhaps involved in disease progression 
in some cancers rather than initiation, which has been suggested for retinoblastoma 
and SCLC (Burkhart and Sage, 2008), as the majority of these diseases are not 
associated with inheritance but rather have lost RB1 sporadically and at lower 
frequency.  
 
Importantly the deletion of RB1 is not necessary for tumorigenesis in many cancers, 
as pRb function is affected by other genetic alterations. Studies have shown E2F 
transcription factors to be overexpressed or amplified in some tumor cells, such as 
prostate cancer (Foster et al., 2004) and bladder cancer (Feber et al., 2004), which 
likely overcome the regulatory activity of pRb. Additionally, functional inactivation 
of pRb due to loss of cooperating tumor suppressors such as p16 is also common. The 
molecular alterations in SCLC and NSCLC illustrate the cooperation between these 
genes, as the great majority of NSCLC tumors display either p16 loss or 
overexpression of Cyclin D (Wikenheiser-Brokamp, 2006). Further, the inverse 
correlation of p16 and RB1 loss is observed in a wide range of other tumors and 
suggests that inactivation of the pRb pathway is nearly universal in cancer (Sharr and 
McCormick, 2002). However this functional inactivation is unlikely to simply 
phenocopy the effect of RB1 loss. For example, cooperating mutations in Trp53 are 
more frequent in SCLC than in NSCLC (Miller et al., 1992). It is possible that cell 
types differ in the relative expression of pRb and p16, and these differences could 
affect how loss of function mutations in either tumor suppressor impact 
tumorigenesis. Consistent with this, it was shown that loss of RB1 but not p16 results 
in the accumulation of DNA double strand breaks induced by deregulated E2F1 
(Pickering and Kowalick, 2006).  
In addition, hyperphosphorylated pRb may have a function regulating apoptosis 
depending on the cellular context (Ianari et al., 2009). In addition, functional pRb 
inactivation could also cooperate with other alterations that affect p53 such as 
concomitant loss of p14 due to deficiency at the INK4 locus. 
 
We can therefore conclude that numerous studies on pRb protein have already been 
done to understand its complex biological functions, nevertheless further steps are 
still needed to reveal new insights into the functional details of upstream and 
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downstream targets and important signaling pathways that impinge on pRb functions 
during tumor development, such as reduced differentiation potential of cells (1.1.3.1), 
chromosomal instability (1.1.3.2) and impairment of cellular senescence (1.1.3.3).  
 
1.1.3.1 pRb and cellular differentiation 
 
The loss of pRb and corresponding changes in cell cycle control are critically linked 
to two additional processes that are associated with terminal proliferative arrest: 
differentiation and cellular senescence. 
Cellular differentiation is critical for tissue function and generally restricts subsequent 
cellular proliferation. As such, differentiation can function in specific cell types as a 
tumor suppressive mechanism. pRb action has been analyzed in a host of 
differentiation paradigms in both cell culture and animal models. For example, in 
myogenic differentiation pRb is required for the full spectrum of muscle markers to 
be expressed (Novitch et al., 1999).  
Cells lacking pRb function cannot exit the cell cycle and may continue to proliferate 
when they should be terminally differentiated (Burkhart and Sage, 2008). In addition, 
RB1-null hematopoietic cells cannot fully differentiate and this may result in 
myeloproliferative disorders, which could further lead to an increased number of 
precursor cells and increased tumor occurrance (Spike et al., 2004). RB1-null skin 
cells continue to divide despite expressing differentiation marker genes (Ruiz et al., 
2004), and sensory hair cells of the ear, null for pRb, are fully differentiated cells but 
continue to proliferate (Sage et al., 2005). Moreover, conditional knockout RB1 mice, 
together with altered cell cycle exit, display abnormal development and impaired 
osteogenesis (Berman et al., 2008). All these evidences suggest that pRb has an 
important role in coordinating or establishing cell cycle exit and the quiescent state of 
differentiated cells.  
In many of these processes not only does pRb loss modify cell cycle withdrawal 
associated with differentiation, but interestingly, pRb actually functions as a 
transcriptional activator for many differentiation associated transcription factors (e.g., 
MyoD in muscle differentiation or core binding factor A (CBFA) in osteogenic 
differentiation) (Gu et al., 1993). Moreover, in rat neural stem cells, overexpression 
of pRb or p130 affects the neuronal lineage specification, but does not inhibit cell 
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proliferation or apoptosis (Jori et al., 2007). This underlines the fact that pRb can 
regulate differentiation independent of its role in the cell cycle. 
The evidence that pRb plays a key role in regulating differentiation together with the 
observation that mouse and human RB1-deficient tumors are usually fairly 
differentiated, suggest that the combined capability of pRb to control cell cycle exit 
and to promote differentiation could be essential during tumorigenesis.  
Histopathological classification of human tumors includes degree of differentiation, 
as important factor for diagnosis, prognosis and treatment. The neoplastic grading is a 
measure of cell anaplasia (reversion of differentiation) in the sampled tumor and is 
based on the resemblance of the tumor to the tissue of origin. Simplifying, well-
differentiated tumors have the lowest grade, and poorly differentiated anaplastic 
tumors have the highest grade.  
In this context, altered pRb expression has been correlated with poorly differentiated 
gastrointestinal cancers (Sanseverino et al., 2006). Similar to its role in progenitor 
cells undergoing differentiation, the presence of pRb in tumor cells could promote 
differentiation status and limit their proliferative potential. Since some anticancer 
treatments, such as the use of all-trans retinoic acid (RA), histone deacetylase 
inhibitors (HDACI) and PPARγ agonists, induce some tumor cells to undergo 
differentiation (Cruz and Matushansky, 2012; Connoli et al., 2013; Jeong et al., 
2013), this aspect of pRb function might have important therapeutic implications. 
 
1.1.3.2 pRb and chromosomal instability 
 
An alternative means through which cell cycle deregulation can influence cancer is 
via a breakdown of genome integrity. Increased chromosomal instability (CIN) is one 
of the representative events observed during cancer progression. Gain and loss of 
whole chromosomes result in the generation of aneuploid cells and has important 
implications for cancer, facilitating, among other features, both the loss of 
heterozygosity (LOH) of tumour suppressor genes and the increased copy number of 
oncogenes (Manning and Dyson, 2012).  
The mechanism through which pRb loss leads to these changes in genome stability is 
postulated to arise from at least two discrete mechanisms (Sage and Straight, 2010) 
(Figure 2). First, specific target genes of pRb/E2F which are important players in 
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chromatin condensation, chromosome segregation, spindle checkpoint, and DNA 
damage and repair pathways (Ishida et al., 2001; Ren et al., 2002; Polager and 
Ginsberg, 2003) have the capacity to deregulate cell cycle transitions and in so doing 
compromise DNA ploidy control.  
Perhaps the strongest data supporting this model come from analyses of pRb and 
MAD-2. The expression of MAD-2, which negatively regulates mitosis, is E2F-
dependent. As a consequence, RB-deficient cells exhibited elevation of MAD2 
expression, and this event is causally associated with mitotic delay and corresponding 
failures in appropriate chromosomal segregation leading to aneuploidy (Hernando et 
al., 2004).  
Second, pRb loss has been associated with modifications of chromatin (McCabe et 
al., 2005; Siddiqui et al., 2007). In particular, pRb directly binds the histone H4 Lys 
20 (H4K20) methyltransferases SUV4-20H1 and SUV4-20H2, and recruits those 
enzymes to pericentric and telomeric heterochromatin (Gonzalo and Blasco, 2005; 
Isaac et al., 2006; Siddiqui et al., 2007). Altered SUV4-20H1-2 activity has been 
associated with increased frequencies of telomere recombination (Benetti et al., 
2007), while loss of H4K20 methylation has been connected to chromosome 
condensation defects, G2/M checkpoint arrest, and DNA damage (Heit et al., 2009; 
Oda et al., 2009). 
In addition, loss of pRb affects also the function of complexes involved in mitotic 
chromosome assembly, such as condensin II complexes (Coschi et al., 2010). 
Finally, under stress conditions, loss of pRb function causes DNA replication defects 
that lead to accumulation of double strand breaks (DSBs) that, if not resolved, 
interfere with mitotic progression and chromosome segregation (Cimini, 2008, 
Manning and Dyson, 2011). 
Altogether, these observations define a complex regulatory network of transcriptional 
and post-transcriptional elements by which the pRb pathway controls precise DNA 
replication, chromosomal stability and abnormal chromosomal segregation during 
different phases of the cell cycle. 
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Figure 2. Loss of pRb function triggers chromosomal instability by several mechanisms. Inactivation of 
pRb results in deregulated activation of E2F transcription factors that promote the expression of critical 
regulators of chromatin condensation, chromosome segregation and spindle checkpoint. In addition, loss of 
pRb function may alter the activity of some of its binding partners involved in the control of chromatin 
structure, such as SUV4-20H. Similarly, loss of pRb affects the function of complexes involved in mitotic 
chromosome assembly, such as condensin II, and finally, pRb inactivation may lead to the accumulation of 
DSBs due to defects during DNA replication.  (Sage and Straight, 2010) 
 
1.1.3.3 pRb and cellular senescence 
 
Cellular senescence is an extremely stable form of cell cycle arrest that limits the 
proliferation of damaged cells and may act as a natural barrier to cancer progression 
(Chicas et al., 2011). Senescent cells exit the cell cycle irreversibly, acquire a large 
and flat morphology, accumulate a senescence-associated β-galactosidase (SA-β-gal) 
and undergo changes in gene expression linked to cell cycle inhibition and 
inflammation (Campisi and d’Adda di Fagagna, 2007). Moreover cellular senescence 
is associated with dramatic changes in chromatin structure, and in particular with 
accumulation of distinct heterochromatin structures, called senescence associated 
heterochromatin foci (SAHF) (Narita and Lowe, 2005).  
Cellular senescence can be triggered by telomere erosion, by response to activated 
oncogenes, DNA damage, or oxidative stress (Courtois-Cox et al., 2008). Therefore 
senescence program acts as a general anti-proliferative stress response and is 
considered a potent tumor suppressive mechanism in vivo (Narita and Lowe, 2005; 
Prieur and Peeper, 2008).  
In the context of induced senescence programs, pRb has been shown to play a pivotal 
role downstream of both oncogene activation and DNA damage stresses (Munger et 
blocking activation of the key E3 ubiquitin ligase, the
anaphase-promoting complex (APC), which ubiquitylates
Cyclin proteins and the chromosome cohesion regulator
Securin. In the absence of APC activity, Cyclins and
Securin remain stable, and cells arrest in metaphase until
the mitotic checkpoint is satisfied. Overexpression of
MAD2 is sufficient to induce CIN and cancer in mice
(Sotillo et al. 2007). Related to the transcriptional control
of Mad2 levels by RB/E2F complexes, the control of the
expression of other negative regulators of APC activity,
Emi1 and BubR1, by E2F (Hsu et al. 2002; Lehman et al.
2007) indicates that both increased E2F-mediated tran-
scription and inappropriate protein stability may cooper-
ate in the genomic instability downstream from loss of
RB function.
In addition to its role in regulating the transcription of
specific genes important for G2 and M, RB may prevent
genomic instability by controlling the expression of
chromatin- and DNA-modifying enzymes themselves
(McCabe et al. 2005; Siddiqui et al. 2007), and by directly
influencing chromatin structure, including in centro-
meric and telomeric regions; for instance, RB directly
binds the histone H4 Lys 20 (H4K20) methyltransferases
SUV4-20H1 and SUV4-20H2, and is thought to recruit
those enzymes to pericentric heterochromatin to main-
tain pericentric histone H4 methylation (Gonzalo and
Blasco 2005; Isaac et al. 2006; Siddiqui et al. 2007). Loss of
SUV4-20H1,2 activity has been associated with increased
frequencies of telomere recombination (Benetti et al.
2007), and loss of H4K20 methylation in general has been
connected to chromosome condensation defects, G2/M
checkpoint arrest, and DNA damage (Heit et al. 2009;
Oda et al. 2009), but a direct link between RB loss, loss of
these methylation marks, and CIN is still missing.
While these observations have provided strong sup-
port for a role of the RB pathway in the maintenance of
chromosomal stability, the exact mechanisms underlying
this role are still poorly understood, and a direct link be-
tween loss of RB function, increased instability, and can-
cer has not been clearly demonstrated. Three studies
published in this issue of Genes & Development (Coschi
et al. 2010; Manning et al. 2010; van Harn et al. 2010) now
provide novel mechanistic advances regarding the role of
RB in the maintenance of chromosomal stability and can-
cer prevention.
Accumulation of DNA damage and CIN in RB family
mutant cells under stress conditions
In mammalian cells, RB belongs to a family of structur-
ally and functionally related proteins with p107 and p130.
Combined deletion of the three RB family genes in MEFs
blocks the ability of these triple-knockout (TKO) cells to
arrest in G1 (Dannenberg et al. 2000; Sage et al. 2000).
Hein te Riele and colleagues (van Harn et al. 2010) had
already shown that TKO MEFs expressing Bcl2 (to pre-
vent apoptotic cell death) arrest in G2 after serum dep-
rivation; this arrest is transient, and the cells can com-
plete their cell cycle upon serum stimulation (Foijer et al.
2005). van Harn et al. (2010) took this observation one
step further, and found that inhibition of the sensor of
DNA damage, ATM, accelerated mitotic entry of serum-
stimulated TKO-Bcl2 MEFs that were arrested in G2,
suggesting that a DNA damage response was slowing cell
cycle re-entry in G2. Indeed, G2-arrested TKO-Bcl2 MEFs
displayed an increase in the presence of DNA double-
strand breaks (DSBs) compared with cycling controls.
Furthermore, some DSBs persisted after mitosis, indi-
cating that TKO cells did not fully repair the damage to
their DNA before re-entering the cell cycle. van Harn
et al. (2010) then analyzed the chromosomes of TKO-Bcl2
MEFs that had been arrested in G2 in low serum and
then had resumed proliferation in full serum. They found
that these mutant cells displayed chromatid breaks,
railroad chromosomes, and loss of tight centromeric co-
hesion. Clones derived from these cells were analyzed by
Figure 1. Loss of RB function triggers CIN
by several mechanisms. Inactivation of RB
and its family members, p107 and p130, re-
sults in deregulated activation of E2F tran-
scription factors. Targets of E2F include
MAD2, a critical regulator of the spindle as-
sembly checkpoint in mitosis, as well as
enzymes that modify the structure of the
DNA, such as the DNMT1 methyltransfer-
ase. In addition, loss of RB function may
alter the activity of some of its binding
partners involved in the control of chro-
matin structure, such as SUV4-20H. Simi-
larly, loss of RB affects the function of
complexes, such as condensin II complexes,
involved in mitotic chromosome assembly.
Finally, loss of RB family function may lead
to the accumulation of DSBs due to defects
during DNA replication, including under
stress conditions. Altogether, this defines
a complex regulatory network of transcriptional and post-transcriptional elements by which the RB pathway controls chromosomal
stability at the G2/M transition of the cell cycle.
Sage and Straight
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al., 1989; Sage et al., 2003; Narita et al., 2003; Serrano et al., 1997). For example, 
oncogenic Ras induces a senescent phenotype in primary human fibroblasts, and this 
senescence phenotype is partially reversed via disruption of the pRb pathway (Narita 
et al., 2003). Therefore, loss of pRb is proposed to represent one means for such 
challenged cells to progress to tumor development. 
In addition, different studies place pRb-E2F activity and associated chromatin-
regulating complexes, such as SUV39H1, as important regulators of senescence in 
cultured cells (Sage, 2005; Collado et al., 2007; Courtois-Cox et al., 2008). This 
seems to be mediated, at least in part, through the formation of senescence associated 
heterochromatin foci (SAHF). SAHF accumulation coincides with the recruitment of 
pRb and heterochromatin proteins to E2F-responsive promoters and is associated 
with the stable repression of E2F target genes to promote permanent cell cycle arrest. 
Importantly, both SAHF formation and the silencing of E2F target genes depend on 
the integrity of the pRb pathway (Narita et al., 2003).  
Cellular senescence can be also promoted by telomere shortening. Telomere erosion, 
upon continuous rounds of replication, leads to the accumulation of dysfunctional 
telomeres, inducing a permanent cell cycle arrest, known as replicative senescence 
(d’Adda di Fagagna et al., 2003; Takai et al., 2003). In this context, it was shown that 
pRb controls the length of telomeres and that, in association with p21 and p53, 
regulates cell entry into replicative senescence (Garcia-Cao et al., 2002; Wei et al., 
2003). 
In conclusion, these evidences strongly suggest that, during cancer progression, loss 
of pRb function allows tumor cell to bypass the cell cycle arrest associated with 
replication and oncogene-induced senescence (Alexander and Hinds, 2001). 
 
1.1.4 Retinoblastoma protein and stem cell biology 
 
Stem cells play a critical role during embryonic development and contribute to tissue 
homeostasis in adult individuals. Developmental defects cause many different 
diseases, therefore a better understanding of stem cell biology could facilitate the 
comprehension of a number of pathologies and open the possibility to improve 
therapies for such diseases. 
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Increasing number of evidences suggests now an important role for pRb also in the 
biology of stem cells, including embryonic and adult stem cells. 
 
1.1.4.1 Embryonic stem cells 
 
Mouse embryonic stem cells are derived from the inner cell mass of the pre-
implantation embryo, while human embryonic stem cells correspond to a more 
advanced stage of development (Tesar et al., 2007). Embryonic stem cells (ESC) are 
characterized by their unlimited capacity for self-renewal and their ability to 
contribute to all cell lineages (pluripotency). These features are controlled by a 
complex network of transcription factors, molecular signalling pathways, and also by 
an atypical cell cycle structure composed of a truncated G1 phase and high proportion 
of cells in S-Phase (Young, 2011; Galderisi et al., 2006). 
The major signaling pathways that are involved in the external regulation of 
pluripotency include LIF/JAK/STAT, BMP, WNT, PI3K, MAPK/ERK, TGFβ and 
Notch (Boiani and Scholer, 2005), while the core of the transcriptional regulatory 
circuits controlling self-renewal is composed by the transcription factors Oct4, Nanog 
and Sox2, which maintain self-renewal through coordination of a series of feedback, 
and feedforward loops (Chambers and Smith, 2004; Niwa, 2007; Silva and Smith, 
2008; Boyer et al., 2005; Loh et al., 2006). 
In particular, Oct4 (octamer-binding trascription factor 4) also kown as POU5F1 
(POU domain, class 5, transcription factor 1) is a homeodomain transcription factor 
of POU family which functions as a heterodimer with Sox2 protein (Ambrosetti et al., 
2000; Avilion et al., 2003; Masui et al., 2007). 
Oct4 plays a crucial role in self-renewal, pluripotency, and lineage commitment being 
highly expressed in mouse and human embryonic stem cells and decreasing its 
expression during differentiation. Strict control of Oct4 expression is therefore 
necessary to maintain ESC identity. It has been shown that alterations in Oct4 
expression promote differentiation and leads to the specification of ectodermal 
(Shimozaki et al., 2003), endodermal (Reim et al., 2004), or mesodermal (Niwa et al., 
2000) primitive progenitors. Mouse embryos that are Oct4-deficient or have low 
expression levels of Oct4 fail to form the inner cell mass, lose pluripotency and 
differentiate into trophectoderm (Nichols et al., 1998).  
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In addition to the well characterized role for Oct4 in controlling ES cell fate, 
increasing evidences point out Oct4 as important player in cancer biology. In fact, it 
has been shown that Oct4 promotes tumor growth in a dose dependent manner 
(Gidekel et al., 2003), and interferes with progenitor cell differentiation 
(Hochediinger et al., 2005). In line with this, elevated levels of Oct4 have been 
detected in various cancer types (Schoenhals et al., 2009; Wang et al., 2010). 
Importantly, embryonic stem cells and cancer cells exhibit several common traits: 
ESCs give rise to teratomas after injection into immunocompromised mice (Thomson 
et al., 1998), embryonic stem cells show immortal cell growth with high proliferation 
rates under the appropriate culture conditions (Amit et al., 2000), high telomerase 
activity is detectable in both cancer and pluripotent cells (Hiyama and Hiyama, 
2007). Similarly, genomic instability, which leads to numerical and structural 
aberrations, is frequently observed in cancer and pluripotent stem cells (Baker et al., 
2007).  
The unlimited proliferative potential and pluripotency of embryonic stem cells are not 
only characterized by a specific transcriptional network but also by an atypical cell 
cycle (Figure 3). In particular, ES cells display a rapid proliferation and a short cell 
cycle (11–16 hours), principally due to a reduction in the duration of G1 phase (Stead 
et al., 2002; Orford and Scadden, 2008). At the molecular level, it was shown that 
CDK inhibitors, such as p27, p21 and p16, are expressed at very low levels in ESCs, 
leading to a cell cycle-independent activity of Cyclin/Cdk complexes and to a 
constitutive pRb hyperphosphorylation and biochemical inactivation (Stead et al., 
2002; White et al., 2005). Moreover, E2F activity stimulates the constitutive 
expression of cyclin A and cyclin E, which, in complexes with Cdk2, further enforce 
pRb hyperphosphorylation, allowing stem cells to bypass cell cycle exit (Stead et al., 
2002; White and Dalton, 2005; Galderisi et al., 2006; Conklin and Sage, 2009) 
(Figure 3).  
This unusual regulation of cell cycle is fundamental for self-renewal and to avoid cell 
specification and differentiation (White and Dalton, 2005).  
Recent studies in human embryonic stem cells have shown that stemness associated-
inhibition of Cdk2 activity, which mostly results in hyperphosphorylation of Rb 
family proteins, arrests ES cells growth (Barta et al., 2010; Neganova et al., 2011). 
Other recent observations indicate also that, increased pRb activity in G1 lengthens 
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this phase of the cell cycle and increases the probability of differentiation (Orford and 
Scadden, 2008; Ying et al., 2008; Sela et al., 2012), suggesting that pRb activity is 
associated with the loss of stemness. 
All these evidences indicate that there is a strong connection between cell cycle 
regulation and self-renewal in embryonic stem cells, and that, in this context, the 
regulation of pRb activity and its phosphorylation must be tightly controlled.  
 
 
 
 
Figure 3. The cell cycle in embryonic stem cells. Embryonic stem (ES) cells display a short cell cycle, 
principally due to a reduced G1 phase. For most cells, the transition through early G1 phase requires the 
mitogen-induced accumulation of cyclin D, resulting in the hyperphosphorylation of pRb by cyclin D-Cdk4 
or cyclin D-Cdk6 complexes. Inactivation of pRb by hyperphosphorylation results in the mitogen-
independent activity of cyclin E-Cdk2 complexes, characteristic of late G1 phase. In ES cells, cyclin E-
Cdk2 is constitutively active throughout the cell cycle, allowing the transition of ES cells from M phase 
directly to late G1. The resulting absence of the cyclin D-dependent early G1 phase shortens the G1 phase 
and the entire cell cycle. (Orford and Scadden, 2008) 
 
 
1.1.4.2 Adult stem cells 
 
Adult and progenitor stem cells exhibit many common characteristics with embryonic 
stem cells, including their strong regenerative potential. However, although these 
stem cells have the ability to proliferate and renew, they are more often held in a 
quiescent state and, unlike ES cells, only cycle rarely. 
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for MAPK-induced cyclin D expression, ES cells uncou-
ple cell-cycle traversal from differentiation, allowing for 
efficient in vitro self-renewal.
Comparison to human ES cells. Although less is known 
about the cell-cycle regulation of human ES (hES) than 
mES cells, some similarities and differences have been 
identified. Even though hES cells are grown under dif-
ferent conditions than mES cells (because hES cells do 
not respond to LIF), both hES cells and mES cells have 
a shortened cell cycle owing to the truncation of G1 
(REF. 10). The molecular regulation of the transition 
through G1 is less well defined in hES and primate ES 
(pES) than it is in mES cells. The expression of cyclin 
D2 and CDK4 seem to be upregulated upon entry into 
G1, suggesting that these cells might be dependent on 
D-type cyclins; however, no functional dependence 
on this activity has been shown and the expression of 
cyclin E was not assessed throughout the cell cycle10. 
Conversely, pES cells are similar to mES cells in terms 
of having cell-cycle-independent expression of cyclin E, 
constitutive hyperphosphorylation of RB and serum and 
MAPK-independent cell-cycle progression9. Although 
there are some differences in the regulation of the cell 
cycle between hES, pES and mES cells, self-renewal of 
the three cell lines is characterized by a shortened early 
G1 phase.
Cell-cycle regulation in adult stem cells
Adult stem cell quiescence. In contrast to ES cells, a 
hallmark feature of adult stem cells is their relative pro-
liferative quiescence. Haematopoietic stem cells (HSCs), 
which are the most extensively studied adult stem cell 
population in both humans and mice (BOX 2), are largely 
in the G0 or G1 phase of the cell cycle and, of these cells, 
the large majority have exited the cell cycle completely. 
Approximately 75% of the most primitive long-term 
repopulating haematopoietic stem cells (LT-HSCs) are 
resting in G0 (REF. 22). Interestingly, primate HSCs seem 
to be even more quiescent than murine HSCs23.
It is widely accepted that the quiescent state is a 
functionally important characteristic of adult stem 
cells. This view has developed largely from experience 
with the haematopoietic system. Although these cells 
are often considered immortal, HSC function clearly 
has limitations and these limitations are frequently 
hastened by proliferative stress24,25. For example, HSCs 
are capable of reconstituting the haematopoietic system 
following transplantation. However, after serial trans-
plantation, HSCs gradually decline and are eventually 
exhausted26–29 (BOX 2).
The link between proliferation and self-renewal of 
HSCs has been further explored using mouse strains 
that have intrinsically different life spans. The prolif-
erative rate of HSCs in these various mouse strains was 
strongly anti-correlated with the maximum longevity of 
the strain30,31. Furthermore, HSCs that are derived from 
young animals from shorter-lived mouse strains with 
more proliferative HSCs (for example, the DBA/2 strain) 
reconstituted the haematopoietic system more efficiently 
than HSCs that are derived from young animals from 
longer-lived strains with less proliferative HSCs (for 
example, the C57B6 strain). However, HSCs from old 
animals of these strains showed the opposite result, sug-
gesting that the HSCs from faster cycling animals might 
become functionally exhausted more rapidly than those 
in animals with slower cycling HSCs.
Proliferation results in stem cell exhaustion. Support 
for the suggestion that proliferation can lead to the 
exhaustion of stem cell function comes from a number 
of genetic models in which there is increased prolifera-
tion of stem cells or a stem cell-containing primitive cell 
population (TABLE 1). In most of these models, the result is 
long-term loss of stem cells and increased susceptibility 
to stress-induced exhaustion. One of the first publica-
tions to suggest that stem cell proliferation itself results in 
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Figure 1 | The cell cycle in embryonic stem cells. The cell cycle of embryonic stem 
(ES) cells is shortened relative to that of most other cells (~11–16 hours as opposed 
to ~24 hours). An abbreviated G1 phase is responsible for the difference in cell-cycle 
length. For most cells, the transition through early G1 phase requires the mitogen-
induced accumulation of cy lin D, resulting in the hyperphosphorylation of the 
retinoblastoma tumour suppressor protein (RB) by cyclin D–CDK4 or cyclin D–CDK6 
complexes (D/4,6). Inactivation of RB by hyperphosphorylation results in the 
mitogen-independent activity of cyclin E–CDK2 complexes, the defining 
characteristic of late G1 phase. In ES cells, cyclin E–CDK2 (E/2) is constitutively 
active throughout the cell cycle, which allows the transition of ES cells from M phase 
directly to late G1. The resulting absence of the cyclin D-dependent early G1  
phase shortens the G1 phase and the e tire cell cycle. Upon commitment of ES cells,  
the cell-cycle length is extended as cyclin E–CDK2 activity comes under the  
control of cyclin D–CDK4 and phosphorylated RB. + refers to cyclin–CDK activity:  
+/-, negligible; +, low; ++, intermediate; +++, high.
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for MAPK-induced cyclin D expression, ES cells uncou-
ple cell-cycle traversal from differentiation, allowing for 
efficient in vitro self-renewal.
Comparison to human ES cells. Although less is known 
about the cell- ycle regulation of human ES (hES) than 
mES cells, some similarities and differences have been 
identified. Even though hES cells are grown under dif-
ferent conditions than mES cells (because hES  do 
not respon  to LIF), both hES cells and mES cells have 
a shortened cell cycle owing to the truncation of G1 
(REF. 10). The molecular regulation of the transition 
through G1 is less well defined in hES and primate ES 
(pES) than it is in mES cells. The expression of cyclin 
D2 and CDK4 seem to be upregulated upon entry into 
G1, suggesting that these cells might be dependent on 
D-type cyclins; however, no functional dependence 
on this activity has been shown and the expression of 
cyclin E was ot ass ss d throughout the cell cycle10. 
Conversely, pES cells are similar to mES cells in terms 
of having cell-cycle-independent expression of cyclin E, 
constitutive hyperphosphorylation of RB and serum and 
MAPK-independent cell-cycle progression9. Although 
there are some differences in the regulation of the cell 
cycle between hES, pES and mES cells, self-renewal of 
the three cell lines is characterized by a shortened early 
G1 phase.
Cell-cycle regulation in adult stem cells
Adult stem cell quiescence. In contrast to ES cells, a 
hallmark feature of adult stem cells is their relative pro-
liferative quiescence. Haematopoietic stem cells (HSCs), 
which are the most extensively studied adult stem cell 
population in both humans and mice (BOX 2), are largely 
in the G0 or G1 phase of the cell cycle and, of these cells, 
the large majority have exited the cell cycle completely. 
Approximately 75% of the most primitive long-term 
repopulating haematopoietic stem cells (LT-HSCs) are 
r sting in G0 (REF. 22). Int restingly, primate HSCs seem 
to be even more quiescent than murine HSCs23.
It is widely accepted that the quiescent state is a 
functionally important characteristic of adult stem 
cells. This view has developed largely from experience 
with the haematopoietic system. Although these cells 
are often considered immortal, HSC function clearly 
has limitations and these limitations are frequently 
hastened by proliferative stress24,25. For example, HSCs 
are capable of r constituti g the haematopoietic system 
fo lowing transplantation. However, after serial trans-
plantation, HSCs gradually decline and are eventually 
exhausted26–29 (BOX 2).
The link between proliferation and self-renewal of 
HSCs has been further explored using mouse strains 
that have intrinsically different life spans. The prolif-
erative rate of HSCs in these various mouse strains was 
strongly anti-correlated with the maximum longevity of 
the strain30,31. Furthermore, HSCs that are derived from 
young animals from shorter-lived mouse strains with 
more proliferative HSCs (f r example, the DBA/2 strain) 
reconstituted the haematop ietic system more efficiently 
than SCs that are derived from young animals from 
longer-lived strains with less proliferative HSCs (for 
example, the C57B6 strain). However, HSCs from old 
animals of these strains showed the opposite result, sug-
gesting that the HSCs from faster cycling animals might 
become functionally exhausted more rapidly than those 
in animals with slower cycling HSCs.
Proliferation re ults in stem cell exhaustion. Support 
for the suggestion that proliferation can lead to the 
exhaustion of stem cell f nction comes from a number 
of genetic models in which there is increased prolifera-
tion of stem cells or a stem cell-containing primitive cell 
population (TABLE 1). In most of these models, the result is 
long-term loss of stem cells and increased susceptibility 
to stress-induced exhaustion. One of the first publica-
tions to suggest that stem cell proliferation itself results in 
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characteristic of late G1 phase. In ES cells, cyclin E–CDK2 (E/2) is constitutively 
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Several evidences in mice suggest that their relative proliferative quiescence is 
regulated via pRb, often with the help of its two family members, p107 and p130 
(Burkhart and Sage, 2008). In line with this, recent studies have shown that 
quiescence in postnatal skeletal muscle stem cell is controlled by pRb and its deletion 
leads to cell cycle re-entry and the expansion of myoblast (Hosoyama et al., 2011). 
Most importantly, loss of pRb in mouse liver and neural stem cells determines the 
exit from quiescence and the expansion of stem cells populations, promoting the 
development of tumors (Viatour et Sage, 2011; Sutter et al., 2010).  
Although these evidences clearly shown that pRb have a key role in maintaining 
quiescence in adult and progenitor cells, the molecular basis that regulates this 
function is largely unknown and could be extremely dependent on specific tissue or 
organ (Sage, 2012). 
In conclusion, pRb plays a key role in restricting the expansion of progenitor cell 
populations maintaining the quiescence status of stem cells. Consequently, pRb 
pathway inactivation could promote cell cycle re-entry, expansion of stem cells 
population and ultimately lead to the development of cancer. 
 
These considerations open new interesting avenue for pRb biology pointing an 
important role for this protein in the modern theories related to the origin of cancer, 
where the stemness properties of particular cells could play a decisive role. 
 
 
 
In conclusion, research over the last ten years find that pRb functions in multiple 
pathways and biological processes are deregulated during tumor initiation and 
progression. However, although many efforts have been made to dissect these 
different and complex roles of pRb, further steps are still needed to fully characterize 
some of these functions and better understand the molecular basis that regulate pRb 
activity in these processes. Moreover, the identification of functionally relevant 
regulatory connections between different pRb functions will be crucial to understand 
new aspects of tumor biology, and in particular could provide novel and fundamental 
insights to better characterize functions and dysfunctions of the pRb pathway in 
cancer. 
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2. AIM OF THE THESIS 
 
A vast body of evidence from clinical and basic research studies demonstrates that the 
pRb tumor suppressor pathway acts as an essential barrier in preventing cancer 
formation and progression.  
A hallmark of the pRb pathway is its ability to control G1-S transition of the cell 
cycle in response to a variety of extracellular and intracellular signals to prevent 
uncontrolled cell proliferation (Burkhart and Sage, 2008). Nevertheless, pRb is 
involved in several other processes, such as cellular differentiation, cell death, 
senescence, genomic stability and stem cell biology, that in contrast to its role in cell 
cycle control, remain still not fully understood (Viatour and Sage, 2011). pRb exerts 
its function mainly at the transcriptional level, controlling the activity of E2F 
transcription factors, but also through the interaction with a diverse  set of proteins 
directly involved in each specific cellular process or in chromatin remodelling.  
A more complex picture is defined by the regulation of its expression and function: 
pRb is timely activated/inactivated in response to a complex repertoire of post-
translational modifications and protein interactions (Munro et al., 2012).  
An aspect of pRb modulation that is largely unknown regards its post-transcriptional 
regulation by miRNAs, which modulate critical cellular processes deregulated in 
cancer by their capability to control gene expression at post-transcriptional level. 
Taking advantage of bioinformatic analysis we focused our attention on the 
characterization of a particular miRNA, miR-335, predicted to target RB1 in a 
conserved manner.  
 
Therefore, the first aim of this thesis work was the study of the functional 
relevance of miR-335 dependent regulation of pRb. 
  
Cancer cells and pluripotent embryonic stem cells share some common properties 
(Kim and Orkin, 2011), which give rise to the idea that the acquisition of stemness 
properties by particular cells could be decisive for tumor initiation and progression. 
pRb plays an important role also in the biology of stem cells: there is a strong 
connection between cell cycle regulation and self-renewal characteristics, and in this 
context, the regulation of pRb activity and its phosphorylation must be tightly 
controlled. 
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Using mouse embryonic stem cells as model system, our second aim was to clarify 
the role of pRb in stem cells context focusing on the relationship between the 
control of cell-cycle progression and the maintenance of self-renewal features. 
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3. RESULTS 
 
Tumourigenesis is a multistep process characterized by sequential alterations in 
pathways that regulate biological processes such as cell proliferation and cell survival 
(Hahn and Weinberg, 2002; Vogelstein and Kinzler, 2004). 
In mammals, a major tumor suppressor pathway is centred on the family of 
retinoblastoma (Rb) proteins, consisting of Rb1 (pRb/p115), Rbl1 (p107), and Rbl2 
(p130) (Classon and Harlow, 2002; Lipinski and Jacks, 1999; Weinberg, 1995). The 
best-known function of Rb family proteins is the ability to restrict cell cycle 
progression at the G1/S transition of the cell cycle through inhibition of E2F 
transcription factors and the transcriptional repression of genes encoding cell cycle 
regulators (Burkhart and Sage, 2008). For its tumour suppressor function, mutation of 
RB1 gene occurs in one third of all human tumours (Calo et al., 2010). The pRb 
pathway is essential for cell cycle control, but was also been shown to control many 
other cellular processes including cellular differentiation, chromatin remodelling, 
genome stability and also several aspects of stem cell biology (Manning and Dyson, 
2012; Sage, 2012). This identifies pRb as a molecular adaptor at the crossroads of 
multiple pathways, depending on cellular context (Viatour and Sage, 2011). 
  
The work presented in this thesis aimed to investigate the post-transcriptional 
regulation of pRb expression and pRb function in the context of human cancer and 
stem cell biology. 
 
miR-335 orchestrates the pRb and p53 pathway 
 
Scarola M, Schoeftner S, Schneider C, Benetti R. miR-335 directly targets Rb1 
(pRb/p105) in a proximal connection to p53-dependent stress response. Cancer 
Res 2010;70:6925–6933. 
 
  
3.1 Identification of miR-335 as a novel regulator of the tumor suppressor pRb 
 
MicroRNAs are a class of non-protein-coding RNAs, which are involved in the post-
transcriptional control of gene expression and critically impact on cancer. Although 
Rb proteins have a critical role in many cellular processes, information on 
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microRNAs that control Rb family proteins at post-transcriptional levels are still very 
limited (Benetti et al., 2008; Sinkkonen at al., 2008). 
The discovery of a cluster of six miRNAs (miR-290 cluster) targeting Rbl2 in mice 
suggested the existence of a miRNA network controlling Rb proteins and pRb 
pathway activity (Benetti et al., 2008; Sinkkonen et al., 2008). Interestingly, whereas 
the mouse miR-290 cluster lacks conservation in humans, a computational analysis 
performed in our laboratory, showed that an additional microRNA, miR-335, is 
identical in a series of placental mammalian species and was predicted to target RB1 
in a highly conserved manner (Figure 1). 
 
 
 
 
 
 
 
 
 
Figure 1. miR-335 is highly conserved in placental mammals. (A) miR-335 sequence is identical in 
placental mammals. Sequence of mature miR-335 in the listed mammalian species is shown. Accession 
numbers, sequence and location to chromosomes are indicated. (B) Alignment of miR-335 with the 
predicted target region in the RB1 3’UTR of placental mammals. 
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Based on these bioinformatic data, we decided to focus our attention on the 
characterization and functional verification of miR-335 as regulator of the tumor 
suppressor pRb.  
To verify whether miR-335 controls human pRb expression, we adopted an in vitro 
approach based on the generation of constructs containing the 3’UTR of human RB1 
or, as negative control, a RB1 3’UTR carrying a deletion for the predicted miR-335 
target sequence downstream the firefly-luciferase reporter cDNA.  
These reporter constructs were transfected together with mimic miR-335 miRNAs (or 
miR-control, as control) in U2OS osteosarcoma cells, which showed very low levels 
of endogenous miR-335 (Figure 2B). As reported in figure 2A, miR-335 
overexpression efficiently reduced the expression of a luciferase reporter fused to the 
entire RB1 3’UTR, but did not have any effect when the target region was deleted, 
thus indicating the specificity of the effect of miR-335 on the 3’UTR of human RB1. 
 
 
 
 
 
 
 
Figure 2. miR-335 directly targets RB1 3’UTR (A) RB1 3′ UTR luciferase reporter assay in U2OS cells. 
miR-335 suppresses the expression of a firefly-luciferase reporter fused to the 3′UTR of human RB1. No 
change on deletion of the miR-335 target sequence in the RB1 3′UTR (3′UTR Δ). Luciferase activity was 
assayed 72 h after transient cotransfection. (B) Determination of miR-335 expression levels in human cancer 
cell lines by quantitative stem-loop RT-PCR. miR-335 levels were normalized with the RNU48 snoRNA. 
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We used real time PCR to quantify miR-335 levels in various cancer cell lines. We 
found that miR-335 are highly expressed in lines derived from human tumors except 
U2OS and MG63 osteosarcoma cell lines (Figure 2B). Due to the fact that U2OS 
cells carry RB1 and p53 wild type alleles, we used this cell line as a gain of function 
model system to study the role of miR-335 in controlling the pRb pathway.  
In order to verify the direct control of RB1 by miR-335 and to validate in vitro the 
effect of miR-335 on pRb protein levels, we transiently transfected a control miRNA 
or miR-335 into U2OS cells and performed immunoblotting and immunofluorescence 
analyses.  
 
 
 
 
Figure 3. miR-335 directly controls pRb expression. (A) Western blotting analysis showing pRb levels 3 
days after transfection of the indicated miRNAs. (B) Immunofluorescence analysis showing a reduction in 
pRb protein levels after transfection of miR-335. 
 
In both of these assays, ectopic introduction of miR-335 efficiently reduced pRb 
protein levels (Figure 3A, 3B). Importantly co-transfection of miR-335 with antago-
miR-335 molecules (antagomiR-335) rescued pRb protein levels (Figure 3A), 
indicating that the reduction of pRb is specific due to the effect of miR-335. 
Altogether these experiments demonstrate that miR-335 controls pRb protein levels 
by direct targeting the RB1 3’UTR in a conserved manner. 
 
3.2 miR-335 impairs cell proliferation and neoplastic transformation  
 
One of the major pRb functions is the regulation of cell proliferation (Manning and 
Dyson, 2012). To establish whether the downregulation of pRb by miR-335 could 
directly affect cell cycle progression, we performed experiments of growth curve and 
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Bromodeoxyuridine (BrdU) incorporation assays in conditions of miR-335 
overexpression. Although loss of pRb is expected to be associated with increased cell 
proliferation, we observed that U2OS cells display significantly reduced cell 
proliferation rates and number of BrdU positive cells when transiently transfected 
with miR-335 (Figure 4A, 4B).  
 
 
            
 
  
 
Figure 4. pRb downregulation by miR-335 impairs cell proliferation. Proliferation and cell cycle of 
U2OS cells transiently transfected with miR-335 or miR-control. (A): growth curve; (B), percentage of 
BrdU-positive cells. (C): cell cycle profile as determined by FACS. 
 
In line with these data, cell cycle profiles of U2OS cells transiently transfected with 
miR-335 revealed an accumulation of cells in G0-G1 phase and a reduction of 
percentage of cell in S phase compared to control cells (Figure 4C).  
To understand whether antagonizing pRb downregulation could rescue the effect on 
proliferation by miR-335, we co-transfected U2OS cells with miR-control or miR-
335 together with a pRb expression vector lacking its 3’UTR. 
As shown in figure 5, transient overexpression of pRb rescues impaired proliferation, 
BrdU incorporation, and cell cycle regulation in the context of ectopically increased 
miR-335 levels. Altogether these data suggest that reduced cell proliferation and 
delayed S-phase entry are a direct consequence of the decrease of pRb levels due to 
miR-335 targeting. 
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Figure 5. pRb overexpression rescues proliferation defects driven by miR-335. (A), (B), (C): U2OS 
cells transiently co-transfected with miR-335 and pRb expression vector lacking the RB1 3’UTR. (A) 
Transient overexpression of pRb as detected by western blotting; (B) Growth curve; (C) Percentage of 
BrdU-positive cells; (D) Cell cycle profile of U2OS cells transiently co-transfected with miR-335 and pRb 
expression vector lacking the RB1 3’UTR, as determined by FACS. 
 
To study the impact of miR-335 in the context of neoplastic transformation, we 
generated U2OS cells stably expressing a control miRNA and a miR-335 construct 
(Figure 6A) and performed a soft agar colony formation assay, the most commonly 
used in vitro assays to determine anchorage independent-growth.  
U2OS cells stably expressing miR-control or miR-335 were plated on soft agar and 
the number of cell colonies was analyzed 14 days later. Results indicate that high 
levels of miR-335 are associated with a significant decrease of colony formation 
(Figure 6B). 
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Figure 6. Neoplastic transformation of U2OS cells stably expressing miR-control or miR-335 in soft 
agar assay. (A) Verification of stable miR-335 overexpression by quantitative RT-PCR. miR-335 levels 
were normalized with the RNU48 snoRNA. (B) Representative images of soft-agar plates and quantification 
of total colony number. 
 
Together these data demonstrate that increased miR-335 levels activate a cellular 
response that compensate the growth advantage of impaired pRb activity, resulting in 
reduced proliferation and neoplastic transformation in vitro. 
 
3.3 miR-335 controls cell proliferation in a p53-dependent manner 
 
The inactivation of the pRb pathway in the developing mouse or human retina was 
reported to be associated with the activation of the Arf–MDM2/MDMX–p53 tumour 
surveillance pathway (Laurie et al., 2006). In particular it was shown that when pRb 
activity is lost, the transcription factor E2F activates transcription of p14ARF (Aslanian 
et al., 2004); p14ARF then inactivates MDM2 (Lowe and Sherr, 2003), leading to p53 
activation and exit from the cell cycle. 
To verify whether miR-335 can also contribute to the activation of p53 pathway, we 
decided to study the pRb and p53 tumor suppressor pathways in the context of altered 
miR-335 levels.  
After transient transfection of miR-335 into U2OS cells, we found that miR-335 
overexpression is linked to a significant increase in p53 protein levels (Figure 7).    
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Figure 7. Transient transfection of miR-335 decreases pRb and increases p53 expression in U2OS 
cells. miR-control and mouse miR-290 cluster were used as negative control. Left panel: representative 
western blotting analysis of pRb and p53 protein levels. Right panel: quantification of p53 protein levels 
against actin. 
 
In functional analogy, siRNA-mediated knockdown of RB1 in U2OS cells was found 
to drive a marked increase of p53 levels (Figure 8A) whereas the transient 
overexpression of an expression vector encoding for human pRb readily reduces the 
expression of p53 (Figure 8B) thus confirming a functional link between pRb and p53 
tumor suppressor pathways in our model system. 
Based on these results, we also investigated whether p53, stabilized by miR-335 
dependent depletion of pRb, is functionally active. For this purpose, we used an 
approach based on luciferase reporter constructs regulated by p53 responsive 
promoters. The assay was performed by transiently transfecting U2OS cells stably 
expressing miR-335 or miR-control with the luciferase reporter constructs under the 
control of promoters of the p53 target genes MDM2, PG13, PIG3, P21 and Bax 
(Monte et al., 2006). As shown in figure 8C, the increase of luciferase reporter 
expression in U2OS cells with increased miR-335 levels clearly demonstrates an 
activation of the p53 pathway. 
Altogether, these results suggest that the reduction of pRb levels by miR-335 
stimulates a compensatory activation of the p53 pathway, probably aiming to protect 
cells from the loss of pRb-dependent cell cycle regulation and uncontrolled cell 
proliferation. 
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Figure 8. Reduction of pRb pathway activity causes an increased expression of p53. (A) Representative 
western blotting analysis (Left panel) and relative quantification (Right panel) of U2OS cells transiently 
transfected with siRNAs specific for human RB1. A reduction of pRb levels causes a concomitant increase 
in p53 protein levels. (B) Representative western blotting analysis (Left panel) and relative quantification 
(Right panel) of U2OS cells transiently transfected with an expression vector encoding human pRb. 
Increased pRb levels drive a concomitant decrease in p53 protein levels. (C) Reporter assay for p53 activity 
in U2OS cells stably expressing miR-335 or miR-control. Increased p53 reporter gene expression was 
detected 3 days after transfection. In luciferase assay p53 target genes are upregulated in U2OS with 
elevated miR-335 levels. 
 
 
We next addressed whether the activation of p53 pathway was responsible for 
reduced cell proliferation in the context of elevated miR-335 levels. To this aim, we 
used U2OS cells stably expressing shRNAs targeting p53 (U2OS shp53, Figure 9A) 
or control shRNAs (U2OS sh Control, Figure 9A) and performed proliferation assays. 
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Figure 9. p53 protein is crucial for miR-335 control on proliferation and transformation. (A) 
Verification of stable p53 knockdown in U2OS cells by western blotting. Stable expression of shRNAs 
targeting p53 causes an efficient reduction of p53 protein levels (U2OS shp53, clone1, 2) compared to 
U2OS cells stably expressing control shRNAs (U2OS sh Control, clone 1, 2). (B) Growth curve of U2OS sh 
Control or sh p53 cells stably expressing miR-335 or miR-Control. (C) Quantification of soft-agar assay of 
cells described in C. Left, U2OS sh Control cells stably overexpressing miR-Control or miR-335. Right, 
U2OS sh p53 cells stably overexpressing miR-Control or miR-335. 
 
We found that the stable overexpression of miR-335 in U2OS sh Control cells 
resulted in significantly reduced proliferation compared with U2OS cells that stably 
expressing a control miRNA (Figure 9B, left panel). On the contrary, stable 
expression of miR-335 in U2OS cells with reduced p53 levels (U2OS shp53) 
significantly accelerates cell proliferation (Figure 9B, right panel). Consistent with 
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this, we found that reduced soft-agar colony formation of sh Control U2OS cells 
overexpressing miR-335 (U2OS sh Control; Figure 9C, left panel) was compensated 
by stably reducing p53 levels (U2OS sh p53; Figure 9C, right panel).  
Together, these evidences shown that miR-335 activates p53 tumor suppressor 
pathway to compensate the growth advantage of impaired pRb, limiting cell 
proliferation and in vitro transformation. 
To confirm that cell proliferation is controlled by miR-335 in a p53-dependent 
manner, we used human p53-deficient non-small lung carcinoma cell line H1299. 
As shown in figure 10A, transient transfection of H1299 cells with miR-335 resulted 
in a significant reduction of pRb protein levels confirming the data obtained in U2OS 
cells.  
 
  
 
 
             
 
Figure 10. Cells lacking p53 respond to miR-335 by increasing proliferation. (A) pRb protein levels in 
H1299 cells transiently transfected with miR-335 or miR-Control 3 days after transfection. (B), (C) miR-
335 promotes cell proliferation in p53-deficient cells. (B) Growth curve of H1299 transiently transfected 
with miR-335 or miR-Control. (C) Soft-agar assay of H1299 cells overexpressing miR-335.  
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Importantly, we demonstrated that the reduction of pRb protein levels by miR-335, in 
the absence of the p53 tumor suppressor pathway, accelerates cell proliferation and 
neoplastic cell transformation in soft agar colony formation assay (Figure 10B, 10C).  
Our data shown that miR-335 could has an important role in balancing the pRb and 
p53 tumor suppressor pathways, impacting on the control of proliferation and 
immortalization.  
 
3.4 miR-335 is upregulated upon DNA damage and cooperates with p53 in a 
positive feedback loop to induce cell cycle arrest 
 
The activation of the p53 pathway is promoted by a wide range of stress signals 
potentially affecting genome integrity and proper cell proliferation, such as DNA 
damage, oncogene signalling and replication stresses (Sperka et al., 2012).  
Activation of the p53 pathway leads to the inhibition of cell growth, either through 
cell cycle arrest or induction of apoptosis, therefore preventing tumour development 
(Vousden and Lu, 2002). In this pathway, ARF inhibits MDM2 activity, leading to 
p53 stabilization and transcriptional activation of p21-mediated cell cycle arrest (de 
Stanchina et al., 1998; Palmero et al., 1998; Stott et al., 1998; Stein et al., 1999). The 
inhibition of cyclin-dependent kinases (CDK) by p21 and p16 keeps pRb in the 
hypophosphorilated form, thereby preventing E2F from transcribing S-phase genes 
(Sherr and McCormick, 2002).  
To evaluate whether a functional link exists between miR-335 and p53, that could 
explain the p53-dependent effect on cell proliferation by miR-335, we analyzed the 
effects of the DNA damage induction on miR-335 levels in U2OS cells. We treated 
cells for 24 hours with DNA-damaging agents etoposide or actinomycin D, and with 
microtubule-damaging agent nocodazole. Etoposide is a DNA damaging agent able to 
inhibit the topoisomerase II, while actinomycin D binds DNA by intercalating double 
helix and causing DNA breaks.  
As shown in figure 11, treatment with etoposide or with the actinomycin D causes 
cell cycle arrest respectively in G1 or G2-M phase that is paralleled by an efficient 
increase in p53 protein levels and miR-335 expression (Figure 11A). In contrast, the 
microtubule-damaging agent nocodazole causes a modest upregulation of p53 without 
significantly affecting miR-335 expression (Figure 11A).  
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To verify whether the upregulation of miR-335 upon DNA damage was due to a 
direct effect of p53 activation, we treated U2OS cells with reduced p53 levels (U2OS 
sh p53) with actinomycin D, etoposide and nocodazole, and analyzed miR-335 
expression levels. 
 
 
 
 
 
 
 
Figure 11. miR-335 is upregulated upon DNA damage. (A) Left, p53 protein levels in U2OS sh Control 
cells on induction of DNA damage, as determined by Western blotting. The DNA-damaging agents 
etoposide and actinomycin D cause efficient p53 upregulation. Induction of microtubule damage by 
nocodazole results in a modest p53 upregulation. Actin was used as a loading control. Right, miR-335 levels 
on induction of DNA damage as determined by quantitative stem-loop RT-PCR. Representative pictures of 
agarose gels after PCR are shown. Human snoRNA RNU48 was used as a loading control. (B) Left, reduced 
activation of p53 in U2OS sh p53 cells on DNA damage, as determined by Western blotting. Actin was used 
as a loading control. Right, reduced p53 levels in U2OS sh p53 cells impair the upregulation of miR-335 on 
DNA damage. miR-335 levels were determined by quantitative stem-loop RT-PCR. Representative agarose 
gels of PCR products are shown. Human snoRNA RNU48 was used as a loading control.  
 
As shown in figure 11B, actinomycin D or etoposide treatment does not result in 
increased miR-335 levels in the context of reduced p53 levels. This data is supported 
by identical results obtained with p53-deficient MG-63 osteosarcoma cells. This 
indicates that miR-335 levels are increased during DNA damage in a p53-dependent 
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manner.  
Since downregulation of pRb by miR-335 mediates the activation of p53 tumor 
suppressor pathway, we hypothesized that upregulation of miR-335 could be required 
for DNA damage–mediated cell cycle arrest. To test this hypothesis, we assessed cell 
cycle profiles and BrdU incorporation assays of U2OS cells stably overexpressing 
miR-335 or antago-miR-335 after treatment with etoposide. As expected, 
overexpression of miR-335 results in a significantly reduced S-phase entry and BrdU 
incorporation in untreated U2OS cells. Introduction of antago-miR-335 does not 
affect cell cycle regulation, as miR-335 is expressed at very low levels in U2OS cells 
(Figure 12A and 12B, top). In contrast, antagonizing the upregulation of miR-335 by 
stable overexpression of antago-miR-335 in etoposide-treated cells causes a 
significant increase in the number of cells in S phase, with a concomitant reduction of 
cell number in G1 phase, and a higher number of BrdU-positive cells, when 
compared with control cells or miR-335 overexpressing U2OS cells (Figure 12A and 
12B, bottom).  
 
 
            
 
Figure 12. miR-335 is important for p53 dependent DNA stress response. (A) Reduced miR-335 
expression during DNA damage impairs p53-mediated cell cycle arrest. FACS cell cycle profiles of U2OS 
cells stably overexpressing miR-335, antagomiR-335, or miR-Control, untreated (top) or treated with 
etoposide for 24 h (bottom). miR-335 overexpression causes reduced S-phase entry in untreated cells. 
Antagonizing miR-335 upregulation during DNA damage by overexpression of antagomiR-335 in U2OS 
cells impairs cell cycle arrest. Percentages of cells in different cell cycle phases are indicated. (B) BrdU 
incorporation in untreated (top) and etoposide-treated (bottom) cells with stably altered miR-335 levels. 
Increased miR-335 levels in control cells impair S-phase entry; antagomiR-335 overexpression promotes S-
phase entry.  
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Together, these data identify miR-335 as a potent regulator of pRb at post-
trascriptional level connecting the pRb and p53 tumor suppressor pathway activities, 
and underline its critical role in the execution of a p53-mediated cell cycle arrest 
during DNA damage response.  
To summarize, miR-335 controls pRb protein levels by direct targeting the RB1 
3’UTR in a conserved manner. The reduction of pRb protein levels stimulates a 
compensatory activation of p53 tumor suppressor pathway, impairing cell 
proliferation. Upon DNA damage the activation of the p53 pathway drives the 
upregulation of miR-335 that, in a positive feedback loop, represses pRb at the post-
transcriptional level, enforcing the activation of the p53 tumor suppressor pathway 
and ensuring an efficient cell cycle arrest (Figure 13). 
 
  
Figure 13. Model for miR-335 function during cell proliferation and DNA damage response. miR-335 
controls pRb by targeting a conserved region in the RB1 3′UTR. Reduced pRb protein levels activate the 
p53 tumor suppressor pathway, limiting cell proliferation. DNA damage activates p53 (p53*) and induces 
cell cycle arrest and/or apoptosis. Increased p53 levels upregulate miR-335, further enhancing the activation 
of the p53 tumor suppressor pathway in a positive feedback loop. 
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miR-335-Oct4-pRb axis controls stem cell self-renewal and 
proliferation 
 
Schoeftner S*, Scarola M*, Comisso E, Schneider C, Benetti R. An Oct4-pRb axis, 
controlled by miR-335, integrates stem cell self-renewal and cell cycle control. 
Stem Cells 2013; doi: 10.1002/stem.1315. 
* Equal contribution 
 
3.5 pRb promotes mouse embryonic stem cell (mESC) self-renewal 
 
The identification of the origin of cancer represents an important issue in the modern 
cancer research. An attractive view is that tumors are derived from stem cells or 
progenitors cells (Viatour and Sage, 2011). In fact, self-renewing stem cells and 
progenitor cells have an intrinsic proliferation potential that can become unlimited if 
these cells acquire new genetic or epigenetic mutations required for oncogenesis 
(Visvader, 2011). 
For a long time, retinoblastoma tumor suppressor pRb has been investigated in the 
context of cell cycle regulation. However, recent observations indicate that pRb 
functions in multiple pathways and biological processes that are deregulated during 
tumor initiation and progression (Viatour and Sage, 2011), and also controls several 
aspects of stem cell renewal and biology (Sage, 2012). Recent studies suggest that 
loss of pRb function in stem or progenitor cells is a key event in the initiation of 
cancer and determines the subtype of cancer arising from these pluripotent cells by 
altering their fate (Jacques et al., 2010; Sutter et al., 2010; MacPherson et al., 2004; 
Chen et al., 2010). In other case, pRb inactivation is often not sufficient to initiate 
cancer but may still lead to some stem cell expansion (Viatour et al., 2008; Viatour 
and Sage, 2011).  
In this context and supported by the evidence that key aspect of the ESC gene 
expression program are recapitulated in cancer cells (Ben-Porath et al., 2008), we 
decided to investigate how pRb and pRb pathway control stem cell’s decisions to 
divide, self renew, or give rise to differentiated progeny using mouse embryonic stem 
cells (mESCs) as model system. Self-renewing mESCs are characterized by the 
coordinated expression of core pluripotency transcription factors, comprising Oct4, 
Sox2 and Nanog, and by the establishment of a specific cell cycle program that 
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allows rapid cell proliferation maintaining Rb family proteins in the 
hyperphosphorylated and biochemically inactivated form (White and Dalton, 2005; 
Ballabeni et al., 2011; Stead et al., 2002).  
To better characterize the relevance of the pRb pathway in the biology of stem cells, 
we studied self-renewal features in the context of pRb depletion in mouse embryonic 
stem cells (mESCs).  
mESC cells, growing under self-renewal condition, were transfected with double-
stranded small interfering RNA oligonucleotides targeting Oct4 (siOct4), Rb1 (siRb1) 
or control siRNA. As shown in figure 14A, the transient transfection of siOct4 and 
siRb1 oligonucleotides efficiently reduced Oct4 and pRb protein levels, respectively. 
Importantly, we observed that Oct4 depletion resulted in an efficient reduction of 
total and hyperphosphorylated pRb (pRb and p-pRb-T356, respectively), suggesting 
that pRb could interact with Oct4 in controlling mESC self-renewal. 
We next were interested in testing whether pRb has a role in controlling mESC self-
renewal and proliferation. 
Mouse ES cells express high levels of alkaline phosphatase (AP), an hydrolase 
enzyme responsible for dephosphorylating molecules such as nucleotides, proteins, 
and alkaloids under alkaline conditions. The enzyme is present within all tissues of 
the body but is expressed at high levels in embryonic stem cells and its activity is 
progressively downregulated during differentiation program (Pera et al., 2000). For 
this reason, AP activity provides an efficient indicator for ES cell differentiation 
status and is the most widely used stem cell marker.  
As expected, siRNA-mediated knockdown of Oct4 determined a strongly decrease in 
alkaline phosphatase activity. Importantly, depletion of pRb, by gene specific RNAi, 
also significantly reduced AP activity, suggesting a putative role for pRb in 
promoting mESC self-renewal (Figure 14B).  
To confirm this observation, we decided to analyze the effect of pRb depletion on the 
expression level of some genes necessary to maintain the ESC self-renewal. In 
particular, we analyzed the expression of pluripotency trascription factors Oct4, 
Nanog, Sox2, Klf4, and of another important self-renewal marker gene, such as the 
growth differentiation factor-3 (GDF3).  
As shown in figure 14C, gene expression analysis indicate that siRNA-mediated 
knockdown of pRb in mESCs provoked a reduction of self-renewal markers genes 
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Nanog, Sox2 and Gdf3. These data confirmed that pRb depletion cause an impaired 
self-renewal potential. 
 
 
 
 
   
Figure 14. pRb promotes mESC self-renewal. (A) Western blotting of mouse embryonic stem cells 
(mESCs) transfected with siRNAs targeting Oct4 or Rb1 using the indicated antibodies. Knockdown of 
Oct4 reduces total and phospho-pRb levels. Actin was used as a loading control. (B) siRNA-mediated 
reduction of Oct4 or pRb leads to reduced self-renewal potential as determined by AP activity 
measurements. (C) Real-time PCR expression analysis of pluripotency marker genes after depletion of Oct4 
or pRb from mESCs. Expression values were normalized against gapdh. 
 
pRb-depleted mESCs display altered cell morphology, appearing flattened and 
enlarged, similar to differentiated mESCs (Figure 15A). Similar effects were 
observed upon siRNA-mediated knockdown of Oct4 (Figure 15A). Loss of mESC 
self-renewal results in reduced cell proliferation potential. To test whether pRb is 
important for mESC proliferation we performed proliferation assays under self-
renewal culture conditions. Similar to differentiating mESCs we found that 
transfection with siRNAs targeting Rb1 or Oct4 result in reduced cell proliferation 
rate compared to control cells (Figure 15B). 
An additional feature of self-renewing mESCs is their atypical cell cycle structure 
characterized by a long S phase and very short G1 and G2 phases. The induction of 
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mESC differentiation is characterized by an extension of G1 and G2 phase of the cell 
cycle (White et al., 2005; Wang et al., 2008; Orford and Scadden, 2008). Consistent 
with reduced self-renewal potential and cell proliferation, propidium iodide staining 
revealed that pRb-depleted mESCs had significantly less S phase cells and an 
increased cell numbers in G1 and G2/M phase, when compared to control cells 
(Figure 15C). This effect of pRb depletion on mESCs cell cycle profile is similar to 
the effect of the siRNA-mediated knockdown of Oct4 and reflects a shift toward the 
cell cycle status of differentiated cells (Figure 15C).  
Altogether these results indicate that pRb has a relevant role in mESCs by enhancing 
mESC self-renewal potential. 
 
 
          
 
 
 
 
Figure 15. pRb depletion promotes the establishment of a cell cycle program of differentiated cells. 
(A) Morphology of mESCs and mESC colonies transfected with siRNAs targeting Oct4 or Rb1. Arrows 
indicate cells with differentiated morphology. Scale bars are indicated. (B) Growth curve of mESCs 
transfected with siRNAs targeting Oct4 or Rb1. Oct4 or Rb1 siRNA reduces cell proliferation. (C) Cell 
cycle FACS analysis of cells described in (A). 
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Figure 1. Oct4 and pRb cooperate to promote mESC self-renewal. (A): Western blotting of mouse embryonic stem cells (mESCs) transfected
with siRNAs targeting Oct4 or Rb using the indicated antibodies. Knockdown of Oct4 reduces total and phospho-pRb levels. Actin was used as a
loading control (left panel). Quantitative real-time polymerase chain reaction (PCR) analysis using mESCs transiently transfected with siRNAs
targeting Oct4 or Rb. Oct4 does not regulate Rb transcription; expression values were normalized against gapdh (right panel) (B): Western blot-
ting of mESCs stably transfected with a control or HA-Oct4 expression construct. Increased Oct4 levels augment total pRb and phospho-pRb
expression levels; Actin was used as a loading control. (C): siRNA-mediated reduction of Oct4 or Rb leads to reduced self-renewal potential as
determined by AP activity measurements. (D): Real-time PCR expression analysis of pluripotency marker genes after depletion of Oct4 or pRb
from mESCs. Expression values were normalized against gapdh. (E): Morphology of mESCs and mESC colonies described in (A). Arrows indi-
cate cells with differentiated morphology. Scale bars are indicated. (F): Growth curve of mESCs described in (A). Oct4 or Rb siRNA reduces
cell proliferation (G): Cell cycle FACS analysis of cells described in (A); knock down of Oct4 or Rb promotes the establishment of a cell cycle
program of differentiated cells (n ¼ 3). n, refers to the number of independent experiments carried out; error bars indicate SD; a Student’s t-test
was used for statistical analysis: *, p < .05; **, p < .01; ***, p < .001. In Western blots, actin was used as a loading control. Abbreviations:
AP, alkaline phosphatase; HA, l l l; LIF, l l l.AQ8
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3.6 miR-335 controls pRb and Oct4 expression on the post-transcriptional level 
in mESCs 
 
Recently, microRNAs (miRNAs) have been identified to play a key role in 
controlling pluripotency and differentiation of mESCs. In particular, works with 
mESCs carrying homozygous mutations of the central miRNA maturation machinery 
components revealed a central role for miRNAs in controlling the cell cycle and self-
renewal program of mESCs (Wang et al., 2007; Wang et al., 2008; Kanellopoulou et 
al., 2005). miRNAs were demonstrated to directly target pluripotency transcription 
factors or interfere with regulators of cycle progression or cell differentiation (Melton 
et al., 2010; Mallanna and Rizzino, 2010; Tay et al., 2008a; Tay et al., 2008b; Xu et 
al., 2009; Wang et al., 2008). In line with this, recent studies have demonstrated that 
post-transcriptional repression of the Retinoblastoma family protein Rbl2 by miR-290 
cluster miRNAs promotes mESCs self-renewal by establishing the mESC cell cycle 
program and also impacts on gene expression by modulating Rbl2 dependent 
repression of DNMT1 (Wang et al., 2008; Benetti et al., 2008; Sinkkonen et al., 
2008).  
We previously demonstrated that miR-335 tightly controls the expression of pRb in 
human cancer (Figure 2, 3). Target prediction analysis performed in our laboratories, 
revealed that also the 3’UTR of Oct4 contains a conserved target site for the seed 
region of miR-335 (Figure 16). Based on the presence of conserved target sites for 
miR-335 in the 3’UTRs of Rb1 and Oct4, we hypothesized that miR-335 could link 
Oct4 and pRb pathway in mESCs. 
 
 
 
Figure 16. Alignment of miR-335 with the predicted target region in the 3’UTRs of H. sapiens and M. 
musculus Rb1 and Oct4. The target site for the seed region of miR-335 is identical in the 3’UTRs of Rb1 
and Oct4.  
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miRNAs controlling mESC function are tightly regulated during in vitro 
differentiation (Houbavity et al., 2003; Suh et al., 2004). In line with this, we found 
that miR-335 is efficiently upregulated when mESCs were differentiated using 
various differentiation schemes such as LIF withdrawal, retinoic acid treatment or 
embryoid body formation, that is an in vitro technique used to mimic early stages of 
embryo development (Figure 17A).  
Of interest, studying the regulation of Oct4 and pRb expression in mESCs, we found 
that Oct4 and pRb protein levels are rapidly reduced upon induction of 
differentiation, although the respective mRNAs are detectable at considerable 
amounts at the same time points (Figure 17B). These results suggested that miR-335 
could have an important role in controlling the expression of pRb and Oct4 at the exit 
from mESC self-renewal.  
 
 
 
 
 
Figure 17. Post-transcriptional regulatory mechanisms control the expression of pRb and Oct4 at the 
exit from mESC self-renewal. (A) Robust upregulation of miR-335 levels upon the induction of mESC 
differentiation during embryoid body differentiation (left panel), withdrawal of LIF from the cell culture 
medium (central panel) or retinoic acid treatment (right panel). miR-335 levels were measured by 
quantitative real-time PCR. Expression levels were normalized to sno-135. (B) Oct4 and pRb expression in 
self-renewing mESCs at Day 0 and upon induction of differentiation (Day 3, 6). Left panel, Western blotting 
using the indicated antibodies; actin was used as a loading control. Right panels, Quantitative real-time 
polymerase chain reaction (PCR) analysis for Oct4 and Rb1; gapdh was used as a loading control. 
A 
B 
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To investigate whether miR-335 could impact on mESC self-renewal by connecting 
Oct4 and pRb, we transiently transfected miR-control, mimic-miR-335 or antagomiR-
335 molecules in mouse embryonic stem cells and measured pRb and Oct4 protein 
levels by immunoblotting and immunofluorescence analyses. As shown in figure 
18A, ectopic introduction of miR-335 efficiently downregulated pRb and Oct4 under 
self-renewal conditions whereas antagomiR-335 were found to increase Oct4 and 
pRb protein levels. 
In order to verify whether miR-335 directly control mouse pRb and Oct4 expression 
through the interaction with its predicted target sites in their 3’UTR, we performed 
classic luciferase reporter assays. We generated constructs containing the firefly-
luciferase reporter cDNA fused to the entire 3’UTR of mouse Oct4 or Rb1 (Rb1-
3’UTR; Oct4-3’UTR) and as negative control the same 3’UTRs carrying a deletion 
for miR-335 target sites (Rb1-3’UTRΔ; Oct4-3’UTRΔ) (Figure 18B). These reporter 
constructs were transfected together with mimic miR-335 miRNAs in U2OS cells 
and, as reported in figure 18B, miR-335 overexpression efficiently reduced the 
expression of luciferase reporter fused to the 3’UTR of Oct4 or Rb1. However, when 
miR-335 was co-transfected with the reporters lacking the miR-335 target sites in the 
3’UTRs no changes on the luciferase expression were detected (Figure 18B). This 
demonstrates the specificity of miR-335 for the 3’UTR of Rb1 and Oct4. 
Together these experiments show that miR-335 targets conserved sequence motifs in 
the 3’UTR of Oct4 and Rb1 to control Oct4 and pRb expression in mESCs. 
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Figure 18. miR-335 controls pRb and Oct4 expression in mouse embryonic stem cells (mESCs). (A) 
Immunostaining and western blotting for pRb and Oct4 in mESCs 3 days after transfection with synthetic 
miR-335, antago-miR-335, or control oligonucleotides. (B) Luciferase reporter assays demonstrating miR-
335 target specificity for the 3’UTR of Rb1 and Oct4 (Rb1-3’UTR; Oct4-3’UTR) in U2OS cells. Rb1-
3’UTRΔ; Oct4-3’UTRΔ are control reporter vectors lacking the miR-335 target site. 
 
3.7 miR-335 antagonizes self-renewal and promotes differentiation in mESCs 
 
The strong upregulation of miR-335 during differentiation and co-targeting of Oct4 
and Rb1 anticipate an important role for miR-335 in regulating self-renewal and 
differentiation. To test this hypothesis, we transiently transfected mESCs with mimic-
miR-335 miRNAs or antago-miR-335 molecules under self-renewal condition and 
evaluated classic indicators of self-renewal potential, such as colony formation 
capacity, cell cycle profile, alkaline phosphatase activity and the expression of mESC 
self-renewal markers. Importantly, ectopic introduction of miR-335 into self-
renewing mESCs reduced cell proliferation rates and induced the formation of 
smaller colonies containing cells with a differentiated cell morphology (Figure 19A). 
Moreover when mESCs overexpressing miR-335 were replated 3 days post-
transfection, these cells displayed a severe impairment in the capacity to form 
colonies indicating an irreversible loss of self-renewal potential (Figure 19B). 
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Accordingly, we found that ectopically increased miR-335 levels reduced the number 
of cells in S-phase and increased the population in G1 phase of the cell cycle (Figure 
19C), indicating a shift toward the cell cycle profile of differentiated cells. As 
expected, reducing endogenous miR-335 levels by transfecting antago-miR-335 did 
not have an impact on cell morphology or cell cycle regulation when mESCs are 
cultivated under-self renewal conditions (Figure 19A, 19B, 19C).  
 
 
                
 
 
 
 
Figure 19. miR-335 reduces self-renewal potential. (A) mESC cell colonies 1, 2, and 3 days after 
transfection with the indicated RNAi oligonucleotides. miR-335 transfected mESCs form smaller colonies 
and show the morphology of differentiated cells. At day 3 two different magnifications are shown; scale 
bars are indicated. Arrows indicate cells with differentiated morphology. (B) Images of mESC cell colonies. 
mESCs described in (A, day 3) were trypsinized and replated in self-renewal medium for additional 3 days. 
Transient miR-335 transfection resulted in an irreversible loss of self-renewal potential. Two different 
magnifications are shown; scale bars are indicated. Arrows indicate cells with differentiated morphology. 
(C) FACS analysis of mESC 1, 2, or 3 days after transfection with the indicated mimic miRNA siRNAs. 
Ectopic miR-335 provokes a reduction of cells in S phase. 
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Figure 4. miR-335 antagonizes mESC self-renewal. (A): mESC cell colonies 1, 2, and 3 days after transfection with the indicated RNAi oligo-
nucleotides. miR-335 transfected mESCs form smaller colonies and show the morphology of differentiated cells. At day 3 two different magnifi-
cations are shown; scale bars are indicated. Arrows indicate cells with differentiated morphology. (B): Images of mESC cell colonies. mESCs
described in (A, day 3) were trypsinized and replated in self-renewal medium for addit onal 3 days. Transient miR-335 transfection resulted in an
irreversible loss of self-renewal potential. Two different magnifications are shown; scale bars are indicated. Arrows indicate cells with differenti-
ated morphology. (C): FACS analysis of mESC 1, 2, or 3 days after transfection with the indicated mimic miRNA siRNAs. Ectopic miR-335
provokes a reduction of cells in S phase (n ¼ 3). (D): AP mESC colony staining (left panel) and photospectrometric measurement (right panel)
of AP activity of mESCs transfected with the indicated mimic miRNA siRNAs. miR-335 reduces self-renewal potential. (E): Quantitative real-
time polymerase chain reaction measurement of self-renewal marker gene expression using mESCs transiently transfected with the indicated
mimic-miRNA siRNAs, 1, 2, or 3 days post-transfection. Ectopic miR-335 reduces self-renewal marker gene expression. Control mimic-miRNA
siRNA values were set ‘‘100.’’ Expression values were normalized against gapdh. (F): Spectrophotometric measurement of AP activity in mESC
transfected with the indicated mimic miRNA siRNAs. miR-335 reduces self-renewal potential. (G): Spectrophotometric measurement of AP ac-
tivity in mESC stably overexpressing miR-335 and Oct4/Rb. Expression of Oct4/Rb in the context of miR-335 overexpression rescues self-
renewal potential. Error bars indicates SD; a Student’s t test was used for statistical analysis: *, p < .05; **, p < .01; ***, p < .001. Abbrevia-
tions: AP, alkaline phosphatase; mESC, mouse embryonic stem cell;
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Figure 4. miR-335 antagonizes mESC self-renewal. (A): mESC cell colonies 1, 2, and 3 days after transfection with the indicated RNAi oligo-
nucleotides. miR-335 transfected mESCs form smaller colonies and show the morphology of differentiated cells. At day 3 two different magnifi-
cations are shown; scale bars are indicated. Arrows indicate cells with differentiated morphology. (B): Images of mESC cell colonies. mESCs
described in (A, day 3) were trypsinized and replated in self-renewal medium for additional 3 days. Transient miR-335 transfection resulted in an
irreversible loss of self-renewal potential. Two different magnifications are shown; scale bars are indicated. Arrows indicate cells with differenti-
ated morphology. (C): FACS analysis of mESC 1, 2, or 3 days after transfection with the indicated mimic miRNA siRNAs. Ectopic miR-335
provokes a reduction of cells in S phase (n ¼ 3). (D): AP mESC colony staining (left panel) and photospectrometric measurement (right panel)
of AP activity of mESCs transfected with the indicated mimic miRNA siRNAs. miR-335 reduces self-renewal potential. (E): Quantitative real-
time polymerase chain reaction measurement of self-renewal marker gene expression using mESCs transiently transfected with the indicated
mimic-miRNA siRNAs, 1, 2, or 3 days post-transfection. Ectopic miR-335 reduces self-renewal marker gene expression. Control mimic-miRNA
siRNA values were set ‘‘100.’’ Expression values were normalized against gapdh. (F): Spectrophotometric measurement of AP activity in mESC
transfected with the indicated mimic miRNA siRNAs. miR-335 reduces self-renewal potential. (G): Spectrophotometric measurement of AP ac-
tivity in mESC stably overexpressing miR-335 and Oct4/Rb. Expression of Oct4/Rb in the context of miR-335 overexpression rescues self-
renewal potential. Error bars indicates SD; a Student’s t test was used for statistical analysis: *, p < .05; **, p < .01; ***, p < .001. Abbrevia-
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Next, we decided to analyze the effect of miR-335 overexpression on alkaline 
phosphatase activity and on the expression of the self-renewal marker genes. 
As shown in figure 20, ectopic introduction of miR-335 into self-renewing mESCs 
efficiently reduced alkaline phoshatase activity (Figure 20A) and, in line with an 
impaired self-renewal potential, caused a strong reduction of the expression of the 
self-renewal marker genes Sox2, Oct4, Gdf3 and Klf4 (Figure 20B). As expected, 
antagonizing endogenous miR-335 by introducing antago-miR-335 molecules did not 
impact on mESC self-renewal potential under self-renewal conditions (Figure 20A, 
20B).  
Together these data indicate that miR-335 reduces self-renewal potential by 
antagonizing pluripotency gene expression program in mESCs.  
 
 
 
 
 
 
 
Figure 20. miR-335 antagonizes mESC self-renewal. (A) Photospectrometric measurement of AP activity 
of mESCs transfected with the indicated mimic miRNAs. miR-335 reduces self-renewal potential. (B) 
Quantitative real time polymerase chain reaction measurement of self-renewal marker gene expression using 
mESCs transiently transfected with the indicated mimic-miRNAs, 1, 2, or 3 days post-transfection. Ectopic 
miR-335 reduces self-renewal marker gene expression. Control mimic-miRNA values were set ‘‘100.’ 
Expression values were normalized against gapdh. 
 
After discovering a role of miR-335 in opposing mESC self-renewal, we evaluated 
the separate contribution of pRb and Oct4 pathways in miR-335 dependent alterations 
of mESC self-renewal potential. Accordingly to the data previously shown (Figure 
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14, 15), individual knockdown of Oct4 or pRb by gene specific RNAi reduced 
alkaline phosphatase activity. This effect was significantly augmented when si-Oct4 
and si-Rb1 oligonucleotides were co-transfected in mESCs (Figure 21A). Moreover, 
as shown in figure 21A, the reduction of alkaline phosphatase activity by the 
combined knockdown of pRb and Oct4 is similar to the effect due to ectopic 
introduction of miR-335. This suggests that the simultaneous repression of Oct4 and 
pRb by miR-335 is an important mechanism that impairs self-renewal potential. 
To exclude that alternative miR-335 targets could be responsible for the observed 
effect in self-renewal assays, we decided to perform rescue experiments by restoring 
Oct4 or pRb expression in miR-335 overexpressing mESCs.  
mESCs stably expressing a control miRNA or a miR-335 construct were stably 
transfected with vectors encoding for pRb or HA-tagged Oct4, and alkaline 
phosphatase activity was evaluated in these cell lines. As shown in figure 21B, 
ectopic expression of pRb or HA-tagged Oct4 in miR-335 expressing cells, rescued 
alkaline phosphatase activity, confirming that the effect of miR-335 on self-renewal 
is mediated by specific targeting of Rb1 and Oct4.  
Based on these results, we conclude that miR-335 antagonizes mESC self-renewal by 
directly repressing Oct4 and pRb expression. 
 
 
 
 
Figure 21. miR-335 antagonizes mESC self-renewal by directly repressing Oct4 and pRb expression. 
(A) Photospectrometric measurement of AP activity of mESCs transfected with the indicated mimic 
miRNAs. miR-335 reduces self-renewal potential. (B) Spectrophotometric measurement of AP activity in 
mESC stably overexpressing miR-335 and Oct4/pRb. Expression of Oct4/pRb in the context of miR-335 
overexpression rescues self-renewal potential. 
 
 
We next hypothesized that increased miR-335 levels during early stages of mESCs 
differentiation are important to repress Oct4 and pRb at the post-transcriptional level. 
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We speculated that this mechanism could allow the exit from self-renewal and to 
promote the establishment of cell differentiation programs. To test this hypothesis we 
altered miR-335 levels during mESC differentiation and analyzed various parameters 
such as cell cycle profile, alkaline phosphatase activity and differentiation marker 
genes.   
As shown in figure 22A, the ectopic expression of miR-335, in mESCs differentiated 
for 3 days in the absence of the LIF, reduced the numbers of cells in S phase 
increasing the G1 phase of the cell cycle. On the contrary, antagonizing the 
upregulation of endogenous miR-335 by introducing antago-miR-335 maintained a 
self-renewal cell cycle program even under differentiation conditions (Figure 22A). 
In line with these data, miR-335 strongly reduced alkaline phosphatase activity 
whereas antago-miR-335 delayed the reduction of AP activity during mESC 
differentiation (Figure 22B).  
To better investigate contribution of miR-335 to early cell differentiation events we 
used quantitative real-time PCR to study the expression of pluripotency and 
differentiation markers expressed in early stages of embryonic development. We 
found that mESCs overexpressing miR-335, differentiated for 3 days, showed a 
reduced expression of self-renewal markers Oct4, Sox2, Klf4 and Gdf3 and a 
significant increase of the expression of marker genes for primitive ectoderm (Fgf5, 
Otx2, Nestin) and mesoderm (Bmp4) compared to control cells (Figure 22C; 22D). 
On the contrary, antago-miR-335 caused an opposite effect. In particular reducing the 
upregulation of miR-335 during mESC differentiation significantly delayed the 
downregulation of self-renewal marker genes and impaired the induction of early 
differentiation marker genes (Figure 22C; 22D).  
Altogether, these data suggest that miR-335 represses the expression of Oct4 and 
pRb, to accelerate the exit from self-renewal and to promote early mESC 
differentiation events. 
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Figure 22. miR-335 drives mESC differentiation. (A) FACS analysis of mESC 3 days after transfection 
with the indicated mimic miRNAs. Cells were cultivated under differentiation conditions (LIF withdrawal). 
Reducing miR-335 levels block the acquisition of a cell cycle program of differentiated cells. (B) AP 
activity in differentiating mESCs after transfection with the indicated oligonucleotides. Ectopic miR-335 
accelerates the reduction of AP activity. (C, D) Expression of self-renewal marker genes (C) or early 
differentiation marker genes (D) in mESCs transfected with the indicated mimic-miRNAs. Quantitative 
polymerase chain reaction was performed 1, 2, or 3 days post-transfection; cells were grown under 
differentiation conditions (LIF withdrawal). Expression levels were normalized against gapdh. Gene 
expression levels from control mimic-miRNA transfected cells grown under self-renewal conditions were 
set ‘‘100’. Ectopically increased miR- 335 levels promote the exit from self-renewal and initiation of 
differentiation gene expression programs. 
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Figure 5. Collapse of the Oct4-Nipp1/Ccnf-PP1-pRb axis at the onset mouse embryonic stem cell (mESC) differentiation. (A): Cell colonies 3
days after transfection with the indicated RNAi oligonucleotides. Cells were grown under differentiation conditions (LIF withdrawal). Ectopic
miR-335 accelerated mESC differentiation. Two different magnifications are shown; scale bars are indicated. Arrows indicate cells with differen-
tiated morphology. (B): fluorescence-activated cell sorting (FACS) analysis of mESC 3 days after transfection with the indicated mimic miRNA
siRNAs (n ¼ 3). Cells were cultivated under differentiation conditions (LIF withdrawal). Reducing miR-335 levels block the acquisition of a cell
cycle program of differentiated cells. (C): AP activity in differentiating mESCs after transfection with the indicated oligonucleotides. Ectopic
miR-335 accelerates the reduction of AP activity. (D, E): Expression of self-renewal marker genes (D) or early differentiation marker genes (E)
in mESCs transfected with the indicated mimic-miRNA siRNAs. Quantitative polymerase chain reaction was performed 1, 2, or 3 days post-
transfection; cells were grown under differentiation conditions (LIF withdrawal). Expression levels were normalized against gapdh. Gene expres-
sion levels from control mimic-miRNA siRNA transfected cells grown under self-renewal conditions were set ‘‘100’’. Ectopically increased miR-
335 levels promote the exit from self-renewal and initiation of differentiation gene expression programs. (F): Formation of contractile structures
in embryoid body outgrowths derived from control, miR-335 overexpressing, or decoy-miR-335 mESCs. (G): Western blotting of Oct4, total pRb
and phospho-pRb (p-pRb), and Nipp1 in self-renewing mESCs (Day 0), embryoid bodies (Day 3, 6), or embryoid body outgrowths overexpress-
ing miR-335 or a decoy-miR-335 construct. For Western blots, actin was used as a loading control; *nonspecific band; > specific Oct4 band; n,
refers to the number of independent experiments carried out; error bars indicates SD; a Student’s t test was used for statistical analysis: *, p <
.05; **, p < .01; ***, p < .001. Abbreviations: AP, alkaline phosphatase; LIF, " " "; pRb, retinoblastoma protein; Nipp1, nuclear inhibitor of
PP1.
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3.8 A miR-335-Oct4-Nipp1/Ccnf-Pp1 axis controls the pRb pathway in mESCs 
 
mESCs display high Cdk2-Cyclin E complex activity resulting in the 
hyperphosphorylation and inactivation of pRb and its family members (Stead et al., 
2002; Orford and Scadden, 2008). Hyperphosphorylated pRb is unable to inhibit E2F 
trascription factors, thereby allowing a rapid progression through G1/S phase of cell 
cycle and rapid cell divisions (White and Dalton, 2005; Conklin and Sage, 2009). On 
the other hand, the induction of differentiation is characterized by the downregulation 
of Oct4 and pRb and the acquisition of a classic Retinoblastoma pathway-dependent 
cell cycle program (White and Dalton, 2005; Ballabeni, 2011; Stead et al., 2002; 
Ballabeni et al., 2011).  
Although we had already demonstrated that Oct4 and pRb pathways were 
functionally connected by the regulation of miR-335 in mESCs, we hypothesized that 
a more direct connection could exist between these two pathways and that could 
impact on the regulation of mESC self-renewal and differentiation.  
This hypothesis is supported by our finding that Oct4 depletion caused an important 
reduction of total and hyperphosphorylated pRb (Figure 14A). 
To exclude that the strong reduction of pRb and its hyperphosphorylated form was 
due only to a reduction of self-renewal potential in Oct4-depleted mESCs, we stably 
transfected mESCs with a control vector or HA-tagged Oct4 expression construct and 
evaluated total pRb levels and its phosphorylation status by western blotting analysis. 
Confirming our hypothesis, ectopic overexpression of HA-tagged Oct4 in self-
renewing mESCs increased not only total pRb levels but also pRb 
hyperphosphorylation (Figure 23). 
These results indicate that Oct4 has a role in controlling pRb levels in self-renewing 
mESCs.  
 
 52 
                                         
 
Figure 23. Oct4 control pRb levels in self-renewing mESC. Western blotting of mESCs stably transfected 
with a control or HA-Oct4 expression construct. Increased Oct4 levels augment total pRb and phospho-pRb 
expression levels; Actin was used as a loading control. 
 
We next focused our study on discovering the molecular mechanism Oct4 uses to 
regulate pRb in pluripotent mESC. After excluding that 1. Oct4 could control pRb 
levels through the regulation of miR-335 expression (Figure 24A), 2. Oct4 acts as 
transcriptional regulator of pRb (Figure 24B) and 3. pRb and Oct4 form a protein 
complex (Figure 24C), we hypothesized that Oct4 could regulate pRb function by 
modulating its phosphorylation status. 
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Figure 24. Oct4 regulates pRb phosphorylation. (A) Quantitative real-time PCR analysis to measure mir-
335 levels in mESC treated with siRNA targeting Oct4 or HA-Oct4 overexpressing mESCs. Altered Oct4 
expression does not impact on miR-335 levels. miR-335 levels were normalized to snoR-135. (B) 
Quantitative real-time PCR analysis using mESCs transiently transfected with siRNAs targeting Oct4 or 
Rb1. Oct4 does not regulate Rb1 transcription; expression values were normalized against gapdh. (C) 
Immunoprecipitation experiments using extracts from HA and HA-Oct4 overexpressing mESCs under self-
renewal conditions. Anti-HA and anti-Oct4 antibodies were used for immunoprecipitation. Precipitates were 
used for western blotting using pRb/Oct4 specific antibodies. Oct4 does not interact with pRb in 
undifferentiated mESCs. * indicates a non-specific band. 
 
 
In proliferating cells, such as mESCs, pRb is a substrate for the protein phosphatase 
complex 1 (Pp1) (Kolupaeva and Janssens, 2013). The Pp1 complex, that comprises 
three isoforms, α, γ1 and β, binds and activates pRb by mediating its 
dephosphorylation (Durfee et al., 1993; Nelson et al., 1997; Hirschi et al., 2010; 
Ludlow et al., 1993). The activity of Pp1 complex is negatively regulated by Nipp1 
(nuclear inhibitor of PP1) and Ccnf (cyclin F).  
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Nipp1 is an ubiquitously expressed nuclear scaffold protein and is known as the most 
potent and specific inhibitor of Pp1 (Beullens et al., 1992). Ccnf, a member of the F-
box family proteins, is associated with the SCF ubiquitin ligase complex and 
promotes the ubiquitination and the consequent degradation of its target substrates, 
such as Pp1 (Tamrakar et al., 2000). In addition, it has been shown that both proteins 
are associated with the maintenance of pRb in its hyperphosphorylated and inactived 
status. Finally, combined gene expression and chromatin immunoprecipitation 
analyses in somatic cells revealed that Nipp1 and Ccnf expression positively correlate 
with Oct4 expression (Campbell et al., 2007). 
In order to investigate whether Oct4 could regulate Ccnf and Nipp1 expression 
thereby modulating pRB phosphorylation status, we transiently transfected siOct4 
oligonucleotides in mESCs under self-renewal conditions. As shown in figure 25A, 
RT-PCR experiments demonstrated that Oct4 depletion caused a decrease of Nipp1 
and Ccnf mRNA expression. 
To support these data, we overexpressed a control vector and a construct encoding for 
HA-tagged Oct4 in mESCs, and induced differentiation for 5 days in absence of LIF. 
As shown in figure 25B, differentiated mESCs transfected with control vector do not 
express endogenous Oct4 and Nipp1 and Ccnf are expressed at very low levels. 
However in this context, forced expression of HA-Oct4 during mESC differentiation 
is able to rescue Ccnf and Nipp1 expression and, importantly, restores 
hyperphosphorylation of pRb leading to increased total pRb levels (Figure 25B, right 
panel). These data suggest that Oct4 regulates the expression of Nipp1 and Ccnf to 
modulate pRb phosphorylation status. 
In order to verify whether the pluripotency transcription factor Oct4 directly regulates 
the expression of Nipp1 and Ccnf by binding their relative promoter regions in 
mESCs, we performed a chromatin immunoprecipitation (ChIP) experiment under 
self-renewal conditions. As expected, we found an efficient enrichment of Oct4 at the 
Sox2 promoter (Figure 25C). Importantly, we also detected a significant Oct4 
enrichment at its consensus binding sites in the Ccnf and Nipp1 locus of mESCs 
(Figure 25C).  
Altogether, our results demonstrate that Oct4 promotes the expression of the Pp1 
inhibitors Nipp1 and Ccnf in self-renewing mESCs, by regulating their transcription. 
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Figure 25. Oct4 drives the expression of the Pp1 inhibitors Nipp1 and Ccnf in self-renewing mESCs 
(A) Quantitative real-time PCR after siRNA-mediated knockdown of Oct4. Expression values were 
normalized against gapdh. (B) Ectopic HA-Oct4 expression during mESC differentiation (5 days in the 
absence of LIF) augments the expression of Nipp1 and Ccnf; expression values were normalized against 
gapdh (quantitative real-time PCR, left panel) and rescues total and phospho-pRb levels; actin was used as a 
loading control (Western blotting, right panel). (C) Chromatin immunoprecipitation (ChIP) using specific 
Oct4 antibody. Left panel: ChIP PCR products visualized on an agarose gel; Right panel: quantification of 
real-time PCR results. An HA antibody was used as control. The Oct4 target gene Sox2 was used as a 
positive control, Dkk as negative control. 
 
 
To validate the relevance of Nipp1 and Ccnf in controlling the phosphorylation status 
of pRb and mESC self-renewal potential, we performed loss of function experiments 
in self-renewing mESCs. 
As shown in the representative western blotting in figure 26A, RNAi mediated 
depletion of Nipp1/Ccnf caused a specific reduction of total and hyper-
phopshorylated pRb. In contrast, knockdown of the Pp1 catalytic isoform Pp1β 
significantly increased the amount of total and hyperphosphorylated pRb (Figure 
26A).  
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Moreover, RNAi-mediated reduction of Nipp1/Ccnf in self-renewing mESCs resulted 
in the formation of colonies containing cells with differentiated morphology (Figure 
26B). In addition, siRNA-mediated knockdown of Nipp1/Ccnf reduced cell 
proliferation rates (Figure 26C). This phenotype is similar to that observed upon 
combined depletion of Oct4 and pRb (Figure 26B, 26C), thus indicating that Ccnf 
and Nipp1 play an important role in the maintenance of self-renewal features.  
Supporting these evidences, transient co-transfection of siCcnf and siNipp1 
oligonucleotides in mESCs reduced alkaline phosphatase activity and the expression 
of the self-renewal marker genes Nanog, Sox2, Gdf3 and Klf4 (Figure 26D, 26E). 
Together, our data suggest a model where Oct4 drives the expression of Nipp1/Ccnf 
to protect hyperphosphorylated pRb from dephosphorylation by Pp1 in self-renewing 
mESCs. The novel Oct4-Nipp1/Ccnf-Pp1-pRb axis promotes mESC self-renewal 
potential and establishes a direct link between self-renewal transcription circuits and 
the pRb pathway. 
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Figure 26. Oct4-Nipp1/Ccnf-Pp1-pRb axis promotes mESC self-renewal. (A) pRb and phospho-Rb 
levels in mESC transiently transfected with the indicated siRNA oligos, as determined by Western blotting 
using the indicated antibodies. Knockdown of Oct4 or Nipp1/Ccnf reduces total pRb and phospho-pRb 
protein levels. (B) Morphology of mESCs and mESC colonies transfected with the indicated siRNA 
oligonucleotides. Knockdown of Nipp1/Ccnf promotes cell differentiation. Arrows indicate cells with 
differentiated morphology. Scale bars are indicated. (C) Growth curve of mESCs described in (A). 
Nipp1/Ccnf siRNA reduces cell proliferation. (D) Spectrophotometric analysis of AP activity after siRNA 
mediated reduction of Nipp1/Ccnf. Depletion of Ccnf/Nipp1 results in reduced self-renewal potential. (E) 
Quantitative real-time PCR analysis of self-renewal marker genes in cells transfected with the indicated 
siRNA oligonucleotides. siRNA-mediated reduction of Nipp1/Ccnf in self-renewing mESCs causes a 
reduced expression of pluripotency marker genes; expression levels were normalized against gapdh. 
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To finally understand whether the upregulation of miR-335 is important in controlling 
the Oct4-Nipp1/Ccnf-Pp1-pRb axis at the exit from self-renewal we decided to use 
mESC lines stably overexpressing a miR-335 or a decoy-miR-335 constructs and 
evaluate the expression of Oct4, pRb, pRb-T356, and Nipp1 during embryoid bodies 
(EB) differentiation.  
Under self-renewal conditions, control mESCs (day 0) express high levels of total 
pRb (pRb) and hyperphosphorylated pRb (pRb-T356) (Figure 27). Reduction of Oct4 
protein levels is paralleled by a decrease of Nipp1 expression and a reduction of total 
and hyperphosphorylated pRb in miR-335 overexpressing cells. In contrast, stable 
transfection of decoy-miR-335 construct has an opposite effect: reducing miR-335 
levels increases Oct4, Nipp1, total and hyperphosphorylated pRb in self-renewing 
mESCs (Figure 27, lanes 1–3). Upon induction of differentiation, reduced expression 
of Oct4 by transcriptional repression and miR-335 targeting leads to decrease Nipp1 
expression permitting the dephosphorylation of pRb by Pp1. In this context, targeting 
the 3’UTR of Rb1 by endogenous miR-335 lead to a reduction of total pRb levels 
(Figure 27, lane 4). All these effects are accelerated upon miR-335 overexpression 
(Figure 27, lane 5). In contrast, antagonizing the upregulation of miR-335 by the 
stably transfection of the decoy-miR-335 construct, we observe a partial rescue of 
Oct4 and Nipp1 expression that causes an increased phosphorylation of pRb at day 3 
and day 6 of mESC differentiation, indicating an inefficient exit from mESC self-
renewal program (Figure 27, lanes 6,9).  
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Figure 27. miR-335 causes the collapse of the Oct4-Nipp1/Ccnf-Pp1-pRb axis promoting the exit from 
self-renewal. Western blotting of Oct4, total pRb and phospho-pRb (p-pRb), and Nipp1 in self-renewing 
mESCs (Day 0), embryoid bodies (Day 3, 6), or embryoid body outgrowths overexpressing miR-335 or a 
decoy-miR-335 construct. 
 
In conclusion, our data demonstrates that Oct4 in conjunction with miR-335 controls 
the activity of the pRb pathway in mESCs. In self-renewing mESCs, high Oct4 
expression drives the expression of Nipp1 and Ccnf, which antagonize the enzymatic 
activity of the PP1 complex, leading to pRb hyperphosphorylation as a hallmark 
feature of self-renewing mESCs (Figure 28, top).  
Upon induction of cell differentiation, transcriptional repression of Oct4 in 
conjunction with targeting of pRb and Oct4 by upregulated miR-335 causes the 
collapse of the Oct4-Nipp1/Ccnf-Pp1-pRb axis promoting the exit from self-renewal 
and establishment of a Retinoblastoma regulated cell cycle program (Figure 28, 
bottom). 
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Figure 28. Oct4 and miR-335 control the pRb pathway in mouse embryonic stem cells (mESCs). 
Schematic presentation of the Oct4-Nipp1/Ccnf-Pp1-pRb axis in (top) self-renewal conditions and (bottom) 
differentiating mESCs. 
 
 
3.9 First evidences of the relevance of Oct4-Nipp1/Ccnf-Pp1-pRb axis in cancer 
cells 
 
In the recent years it has become evident that stem cells and cancer cells share several 
common traits. In particular, self-renewal gene expression signatures, including 
pluripotency transcription regulators, were found in several types of human cancer 
and preferentially expressed in histologically poorly differentiated tumors (Ben-
Porath et al., 2008; Sanada et al., 2006). In particular, Oct4 was found associated with 
germ cells tumors and represents an important prognostic factor (Cheng et al., 2007; 
Santagata et al., 2007). These similarities have given rise to the theory that tumors 
could arise from undifferentiated stem/progenitor cells. However, although increasing 
evidences have indicated that the expression of several self-renewal regulators can 
contribute to stem cell-like phenotypes displayed by many tumors, there is scarce 
evidence for a direct link between self-renewal factors and tumor suppressor 
pathways.  
To verify whether Oct4 could have a role in controlling pRb pathway in the context 
of human cancer, we used ovarian cancer cell line OVCAR-3 as model system. We 
transiently transfected this cell line with siOCT4, siRB1 and the combination of 
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siNIPP1/siCCNF oligonucleotides and evaluate the pRb and phospho-pRb levels by 
western blotting. In line with data obtained in mouse embryonic stem cells, Oct4 
depletion, as well as RNAi-mediated knockdown of Ccnf/Nipp1, caused an important 
reduction of pRb and its hyperphosphorylated and inactive form (Figure 29A). 
Importantly, RNAi-mediated reduction of Oct4 and Ccnf/Nipp1 in OVCAR-3 cells 
reduced cell proliferation rates in growth curve experiments (Figure 29B). These data 
suggest that the Oct4-Nipp1/Ccnf-Pp1 axis controls pRb pathway in ovarian cancer 
cells and impacts on cell proliferation.  
We next linked the association of NIPP1/CCNF/RB1 expression with clinical 
outcome in ovarian cancer patients. Interestingly, linking gene expression data with 
patient survival, we discovered that increased NIPP1/CCNF/RB1 expression is 
associated with poor prognosis and significantly reduced survival of serous ovarian 
cancer patients (Figure 29C), suggesting also a clinical relevance for the Oct4-
Nipp1/Ccnf-Pp1 axis. 
In conclusion, our results demonstrate that Oct4-Nipp1/Ccnf-Pp1 axis controls pRb 
activity in human cancer cells linking pluripotency gene expression with tumor 
suppression by the pRb pathway. 
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Figure 29. Oct4-Nipp1/Ccnf-Pp1-pRb axis in ovarian cancer. (A) pRb and phospho-Rb levels in 
OVCAR-3 ovarian cancer cells transiently transfected with the indicated siRNA oligos, as determined by 
western blotting using the indicated antibodies. Knockdown of OCT4 or NIPP1/CCNF reduces total pRb 
and phospho-pRb protein levels. (B) Growth curve of OVCAR-3 cells transfected with siRNAs targeting 
OCT4, RB1 or CCNF/NIPP1. CCNF/NIPP1 and OCT4 siRNAs reduce cell proliferation. (C) Kaplan-Meyer 
curve indicates reduced survival of serous ovarian cancer patients with elevated expression of NIPP1, CCNF 
and RB1. 
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4. DISCUSSION AND CONCLUSIONS 
 
The retinoblastoma tumor suppressor protein (pRb) belongs to a cellular pathway that 
is deregulated in several human tumors (Harbour and Dean, 2000). 
pRb plays a crucial role in restricting the G1-S transition of the cell cycle by 
controlling E2F activity in response to a large number of extracellular and 
intracellular signals. Research in the last years unravelled complex regulatory 
networks that ensure proper cell cycle progression, and also identified multiple 
alternative cellular functions regulated by pRb. Several studies have demonstrated 
that pRb is involved in cellular differentiation, genome stability, and chromatin 
remodeling (Burkart and Sage, 2008; Chinnam and Goodrich, 2011; Van den Heuvel 
and Dyson, 2008; Viatour and Sage, 2011; Manning and Dyson, 2012). Importantly, 
recent evidence has underlined the importance of pRb pathway in stem cell function 
and cell fate decisions. In this context, pRb inactivation in stem or progenitor cells 
can lead to the expansion of stem cell population and promote cancer initiation 
(Viatour and Sage, 2011; Sutter et al., 2010; Sage, 2012), underlying the concept that 
specific molecular pathways could be strongly connected in cancer and stem cell 
biology. 
Our findings provide new insight into the control of different pRb functions in tumors 
and embryonic stem cells. Most importantly, we identified a novel axis that for the 
first time links pluripotency expression signature to pRb-related tumorsuppression. 
 
Although Rb proteins play key roles in several cellular processes, information on 
microRNAs that regulate their expression at post-transcriptional levels is limited 
(Benetti et al., 2008; Sinkkonen et al., 2008). 
The data presented in this thesis identify miR-335 as novel miRNA able to efficiently 
control pRb protein levels by directly targeting a conserved region in the 3′UTR of 
RB1 in placental mammals. We demonstrated that miR-335-mediated reduction of 
pRb protein results in the activation of the p53 pathway in human cells, impairing cell 
proliferation and neoplastic transformation in vitro. In line with this, impairing the 
p53 pathway is sufficient to drive hyperproliferation and increased transformation in 
the context of ectopically increased miR-335 levels. We therefore proposed that miR-
335 activates the p53 tumor suppressor pathway to compensate the growth advantage 
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of impaired pRb, limiting cell proliferation and neoplastic transformation in a p53 
wild type context. We therefore suggest that miR-335 has an important role in 
balancing the p53 and pRb tumor suppressor pathways in cancer cell lines. 
In normal cells, the pRb and p53 pathways are connected to integrate stimuli such as 
DNA damage and other stress signals. The DNA damage response (DDR) and the 
activation of the p53 pathway provide a primary defense system against DNA double 
stand breaks and propagation of oncogenic mutations (Bartkova et al., 2005; 
Gorgoulis et al., 2005), whereas activation of p16-pRb pathway usually occurs as 
secondary event (Jacobs and de Lange, 2004; Stein et al., 1999). However, the 
outcomes of activation of the p53 and pRb pathways are different: cells that activate 
the p53 pathway can resume growth after inactivation of p53, whereas cells that fully 
engage pRb pathway for several days cannot re-entry into cell cycle due to 
heterochromatic silencing of E2F target genes and the formation of senescence-
associated heterochromatic foci (Beausejour et al., 2003; Narita et al., 2003; d’Adda 
di Fagagna et al., 2003).  
In our study, we show that activation of p53 pathway, during DNA damage response, 
increases miR-335 levels in a positive feedback loop; antagonizing this upregulation 
significantly impairs cell cycle arrest upon DNA damage. 
miR-335 upregulation targets the pRb pathway to enforce p53-mediated cell cycle 
arrest. We propose that miR-335 antagonizes the establishment of an irreversible 
pRb-dependent growth arrest by promoting p53-mediated cell cycle arrest. 
An important question we had to answer was to identify the mechanism that cells use 
to activate p53 pathway when pRb was deregulated by miR-335. 
Several studies suggest that p53 and pRb pathways are functionally connected: loss of 
pRb function and high E2F activity promotes p14ARF expression, which in turn leads 
to MDM2 inactivation and p53 activation (Laurie et al., 2006; Bates et al., 1998; 
Zhang et al., 2006). In our U2OS model system, the p16INK4a and p14ARF promoters 
are silenced by DNA methylation (Cavanaugh et al., 1995). We hypothesized 
therefore that miR-335 could release transcriptional silencing of p14ARF or control 
E2F activity, however experiments done to evaluate these hypothesis excluded these 
possibilities (data not shown). These evidences together with the observation that 
miR-335 overexpression increases p53 protein without affecting its RNA levels, 
suggested that miR-335/Rb1 uses an alternative pathway to increase p53 stability in 
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U2OS cells. The functional link has still to be identified and opens interesting 
possibilities for new connections between these important tumor-suppressors.  
To summarize, our data identify miR-335 as a strong regulator of pRb at post-
transcriptional level connecting the pRb and p53 tumor suppressor pathway activities. 
Based on its critical role in the execution of a p53-mediated cell cycle arrest during 
DNA damage response, we propose also that miR-335 could be an important factor to 
increase cancer susceptibility under conditions of impaired p53 tumor suppressor 
activity by allowing cells to bypass the control of the pRb tumor suppressor pathway.  
In line with this, miR-335 has been shown to be upregulated in a set of human 
multiple myeloma cell lines (Ronchetti et al., 2008). Moreover miR-335 has been 
reported to be differential expressed in benign and malignant adrenocortical tumors 
(Schmitz et al., 2011) and to regulate growth and invasion of malignant astrocytoma 
cells and breast cancer cells (Shu et al., 2011; Tavazoie et al., 2008). 
 
Recently it has become evident that cancer cells share intrinsic properties with 
pluripotent embryonic stem cells (Kim and Orkin, 2011). In particular, the hallmark 
traits of stem cells, self-renewal and differentiation capacity, are mirrored by the high 
proliferative capacity and phenotypic plasticity of tumor cells, indicating that 
common pathway could be utilized both in the acquisition of pluripotency and in 
tumorigenesis (Kim et al., 2010; Ben-Porath et al., 2010). 
In addition to their tumor suppressor function for differentiated cells, pRb but also 
p53 play an important role in stem cell biology. In mESCs, p53 does not only ensure 
genomic integrity after genotoxic insults but also control their proliferation and 
differentiation (Marion et al., 2009; Quin et al., 2007; Lin et al., 2005). Additionally, 
p53 represents an effective barrier for the generation of pluripotent stem cell-like 
cells from terminally differentiated cells (Kawamura et al., 2009; Li et al., 2009; 
Solozobova and Blattner, 2011). Importantly, the constitutive hyperphosphorylation 
of pRb that ensures rapid and indefinite cell proliferation potential of ESCs 
recapitulates the impaired function of the pRb pathway present in virtually all tumors 
(White and Dalton, 2005). In addition, self-renewal expression signature including 
the pluripotency transcription factors Oct4, Nanog and Sox2 were also found in 
several types of human cancer and were associated with poorly differentiated and 
aggressive tumors (Ben-Porath et al., 2008; Chiou et al., 2008; Gu et al., 2007; 
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Sanada et al., 2006). Although these evidences support the idea that the acquisition of 
stem cell-like gene expression signature represent a key step in tumorigenesis, 
evidence for a functional link between pluripotency transcription modules and the 
control of aberrant function of tumor suppressor pathways is limited. Of notice, while 
p53 functions in stem cells context is well defined, very little is known about pRb 
deregulation in this context. 
Our work proposes a novel regulatory pathway that connects the pluripotency 
transcription factor Oct4 with the Retinoblastoma tumorsuppressor pathway to 
control self-renewal in mouse embryonic stem cells (mESCs), as well as in ovarian 
cancer cells. 
In self-renewing mESCs, cell cycle regulation is mainly controlled by Cdk2 that 
mediates the hyperphosphorylation and biochemical inactivation of Retinoblastoma 
family proteins. The induction of cell differentiation is paralleled by a strong 
downregulation of Oct4 and pRb levels and the acquisition of a Retinoblastoma 
pathway-regulated cell cycle program (White et al., 2005; Ballabeni et al. 2002; Stead 
et al., 2002). 
Our data show that RNAi-mediated knockdown of pRb reduces self-renewal 
potential, recapitulating therefore physiological effects normally observed upon Oct4 
depletion or the induction of mESC differentiation, suggesting that pRb has a putative 
role in promoting mESC self-renewal. In line with this, mESCs with high level of 
total and hyperphosphorylated pRb due to deregulated Cdk2 activity show a severely 
impaired differentiation potential (Kim et al., 2009). Together, these evidences 
indicate that pRb does not only impact on cell cycle regulations but also enhances the 
self-renewal potential of mESCs by limiting the initiation of cell differentiation 
programs. 
Most importantly we were able to show that Oct4 plays a crucial role in ensuring the 
hyperphosphorylation of pRb under self-renewal conditions by impairing pRb 
dephosphorylation by the protein phosphatase type 1 (PP1) complex. In particular, we 
provide evidence that, in self-renewing mESCs, high Oct4 levels drive the expression 
of the reported Pp1 inhibitors Nipp1 (nuclear inhibitor of Pp1) and Ccnf (Cyclin F), 
to inhibit the activity of the Pp1 complex, thereby establishing pRb 
hyperphosphorylation as a key feature of rapidly cycling, pluripotent mESC. 
In addition, we demonstrate that the activity of this novel self-renewal pathway is 
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modulated by miR-335, which is dramatically upregulated during mESC 
differentiation and is able to control Oct4 and pRb expression on the post-
transcriptional level at the exit from mESC self-renewal. We will integrate these 
observations with future work aimed to integrate p53 pathway in this scenario. 
 
On the basis of these data, we propose a model where high Oct4 expression promotes 
the expression of inhibitors of the major pRb phosphatase Pp1 to ensure the 
hyperphosphorylation of pRb as hallmark-feature of self-renewing mESCs. The 
induction of differentiation leads to a contemporary transcriptional repression and 
miR-335-dependent post-transcriptional repression of Oct4 and pRb, leading to the 
collapse of the self-renewal promoting Oct4-Nipp1/Ccnf-Pp1-pRb axis, the exit from 
self-renewal and the establishment of pRB-regulated cell cycle profile of 
differentiated cells. 
Given the overlapping gene expression signatures of mESC and human cancer cells, 
we proposed that Oct4 could have an important role in controlling the activity of pRb 
pathway in the context of human cancers with embryonic stem cell gene expression 
signatures. In germ cell tumors diagnostics, Oct4 represents the most informative 
marker. In fact, it is expressed in the precursor lesions in gonadoblastoma and 
carcinoma in situ, as well as in invasive embryonal carcinoma and seminomatous 
tumors (Cheng et al., 2007; Cheng et al., 2007; Santagata et al., 2007; Lin et al., 
2012; Ezhe et al., 2005).  
Using the human ovarian cancer cell line OVCAR-3 as cell model system, we were 
able to demonstrate that Oct4 depletion reduces the expression of Oct4 target genes 
CCNF and NIPP1, leading to a reduction of pRb and its hyperphosphorylated and 
inactive form. Disruption of the axis in cancer cell line strongly reduces cell 
proliferation and induces senescence. Importantly, increased NIPP1/CCNF/RB1 
expression is linked with poor prognosis and significantly reduced survival of serous 
ovarian cancer patients. 
These preliminary results suggest that the Oct4-Nipp1/Ccnf-Pp1 axis could act as a 
novel and potent pathway that controls the activity of the pRb in ovarian cancer cells. 
This open the interesting possibility that Oct4-Nipp1/Ccnf-PP1-pRb pathway is a new 
tumor-promoting axis with relevance for the cancer clinics.  
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5. MATERIALS AND METHODS 
 
Cell culture 
 
Human cell lines 
H1299 cells were cultured in RPMI medium, 10% fetal bovine serum (FBS), and 1% 
penicillin/streptomycin. U2OS cells were maintained in DMEM, 10% FBS, and 1% 
penicillin/streptomycin. OVCAR-3 cells were cultured in RPMI medium, 20% FBS, 
10 µg/mL insulin and 1% penicillin/streptomycin. Cell growth was measured in 
triplicate after plating 5 × 104 cells. Cell number was counted at the indicated time 
points using a hemocytometer. 
Soft agar assays were performed as following described: for each cell pool 100,000 
cells were resuspended in 0.35% (w/v) top agar (LONZA, SeaKem LE Agarose 
cat.5004) and plated onto 0.5% (w/v) basal agar. 14 days (U2OS) or 10 days (H1299) 
after plating, colony number was counted. 
Stable transfections of plasmids were performed using Fugene6 (Roche Applied 
Science); selection was done using blasticidin (10 µg/mL; U2OS-miR control and 
U20S-miR-335). Cells were treated with etoposide (5µmol/L), actinomycin D (5 
nmol/L), nocodazole (50 ng/mL) for the indicated duration. 
 
Mouse embryonic stem cells (mESCs) 
Feeder-independent mouse embryonic stem cells (mESCs) were cultured on 0.2% 
gelatin-coated plates in mESC self-renewal medium (Dulbecco’s modified Eagle’s 
medium supplemented with 15% knockout serum replacement), 1% nonessential 
amino acids (Gibco), 1 mM sodium pyruvate (Invitrogen), 1% L-glutamine 
(Invitrogen), 0.1 mM b-mercaptoethanol, 1% penicillin/streptomycin (Invitrogen), 
and 1,000 U/ml mouse leukemia inhibitory factor. 
ES cell differentiation schemes was performed using mESC differentiation medium 
(Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 15% ES cell 
certified serum (Invitrogen), 1% non-essential amino acids (Gibco), 1mM sodium 
pyruvate (Gibco), 1% L-glutamine (Invitrogen), 0.1 mM bmercaptoethanol and 1% 
penicillin/streptomycin (Invitrogen). Embryoid body (EB) differentiation was 
performed with the following protocol: 300 cells were cultured in hanging drops for 
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three days. After 3-4 days EBs were transferred to cell culture or low-attachment 24-
well plates (Euroclone) and grown in suspension for 7 days. 
Alternatively, mESCs were plated on cell culture dishes and differentiated in mESC 
differentiation medium, supplemented with all-trans-retinoic acid (Sigma, final 
concentration: 1nM), or in mESC medium deprived of LIF. 
For proliferation assays 2 × 104 cells were plated and cell number was counted at the 
indicated time points using a hemocytometer. 
Stable transfections of plasmids were performed using Fugene6 (Roche Applied 
Science). Selection medium contained blasticidin (2µg/mL; mESCs-miR-335), 
puromycin (3 µg/mL; mESCs-miR-control and mESCs-decoy-miR-335) or G418 
(300 µg/mL; mESCs-pCDNA3 empty, mESCs-pCDNA3 pRb, mESCs-pCDNA3 
HA-empty and mESCs-pCDNA3 HA-Oct4). 
 
Transient transfections of miRNAs or siRNA oligos 
 
Human cell lines transfections 
U2OS and H1299 cells were transiently transfected with hsa_miR-335 mimic (C-
300708-05, Thermo Scientific Dharmacon), antagomiR-335 hairpin miR-IDIAN 
inhibitor (IH-300708-07, Thermo ScientificDharmacon), or a mix of all miR-290 
cluster mimics (mmu_miR-290, mmu_miR-291-3b, mmu_miR-292-3b, mmu_miR-
293, mmu_miR-294, and mmu_miR-295; Thermo Scientific Dharmacon) according 
to the manufacturer’s suggestions. MiR-IDIAN miRNA mimic negative control 
miRNA (CN-00100-01-05, Thermo Scientific Dharmacon) was used as a negative 
control. Mimic miRNAs resemble siRNA molecules that recapitulate miRNA 
function. Total RNA and protein were prepared 72 hours after transfection. U2OS 
and OVCAR-3 cells were transiently transfected with a siRNA against human RB1 
(Thermo Scientific Dharmacon; sense sequence: 
GGAAGGACAUGUGAACUUAUU), with a siRNA against human OCT4 (Thermo 
Scientific Dharmacon; sense sequence: CAUCAAAGCUCUGCAGAAA), with a 
siRNA against human CCNF (Thermo Scientific Dharmacon; sense sequence: 
UCACAAAGCAUCCAUAUUG), with a siRNA against human NIPP1 (Thermo 
Scientific Dharmacon; sense sequence: GGACUUGACUCCUGUUGUG) or siRNA 
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control siGENOME Non-Targeting siRNA #1 (D-001210-01-20, Thermo Scientific 
Dharmacon) according to the manufacturer’s suggestions.  
 
mESCs transfections 
Mouse ES cells were transiently transfected with hsa_miR-335 mimic (C-300708-05, 
Thermo Scientific Dharmacon), antagomiR-335 hairpin miR-IDIAN inhibitor (IH-
300708-07, Thermo Scientific Dharmacon) according to the manufacturer’s 
suggestions. 
MiR-IDIAN miRNA mimic negative control siRNA (CN-00100-01-05, Thermo 
Scientific Dharmacon) was used as a negative control. Total RNA and protein were 
prepared 72 hours after transfection. ES cells were transiently transfected with a 
siRNA against mouse Rb1 (Thermo Scientific Dharmacon; sense sequence: 
GCUUAAAUCAGAAGAAGAAUU), with a siRNA against mouse Oct4 (Thermo 
Scientific Dharmacon; sense sequence: CGGAAGAGAAAGCGAACUAUU), with a 
siRNA against mouse Ccnf (Thermo Scientific Dharmacon; sense sequence: 
CCGCAGAGCUAUCGAAUCA), with a siRNA against mouse Nipp1 (Thermo 
Scientific Dharmacon; sense sequence: UCACAAGCCUCAACAGAUU), with a 
siRNA against mouse Pp1b (Thermo Scientific Dharmacon; sense sequence: 
GAAGAUUUGUGGAGACAUU), or siRNA control siGENOME Non-Targeting 
siRNA #1 (D-001210-01-20, Thermo Scientific Dharmacon) according to the 
manufacturer's suggestions. 
 
Flow cytometry 
 
For fluorescence-activated cell sorting (FACS) analysis, U2OS cells or self-renewing 
and differentiating mESCs were collected and fixed in ethanol. After rehydration, 
cells were resuspended in 1 × PBS, 0.1% Nonidet P40 and treated with 200 µg/ml 
RNase A for 10 minutes; propidium iodide was added to a final concentration of 50 
µg/ml. Cells were analyzed on a flow cytometer (FACSCalibur, Becton Dickinson). 
FACS data were analyzed using ModFit LT 3.1. 
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Analysis of miRNA expression 
 
Total RNA was extracted and purified using TRIzol reagent (Gibco/BRL) and reverse 
transcribed using the miR-335, RNU48 and sno-135 TaqMan MicroRNA Assay 
system (Applied Biosystems). The human snoRNA RNU48 and mouse snoRNA sno-
135 were used as a reference respectively for human and mouse cells. The 
quantitative stemloop real-time polymerase chain reaction (RT-PCR) was performed 
according to conditions suggested by Applied Biosystems. Quantitative miRNA 
expression data were analyzed using a StepOnePlus Sequence Detection System 
(Applied Biosystems). 
 
Analysis of mRNA expression 
 
Total RNA from indicated cell lines was purified using TRIzol reagent (Gibco/BRL). 
1.5 µg of total RNA was treated with DNAse (RQ1, Promega) and subjected to 
reverse transcription using random primers (Promega) and SuperScriptII Reverse 
Transcriptase (Invitrogen) according to the manufacturer’s suggestions. Quantitative 
PCR was performed using the SYBR Green Master Mix (Applied Biosystem) and 
analyzed with a StepOnePlus real-time PCR machine (Applied Biosystem). mRNA 
levels were normalized with actin for human samples and Gapdh for mESCs derived 
samples. 
Experiments were performed using the following qRT-PCR primer sequences 
(Eurofins MWG Operon): human ACTIN: CCAACCGCGAGAAGATGA, 
CCAGAGGCGTACAGGGATAG; human p53: CTCCTCTCCCCAGCCAAAGA, 
GGAACATCTCGAAGCGCTCA; mouse Gapdh: TTCACCACCATGGAGAAGGC, 
CCCTTTTGGCTCCAC; mouse Oct4: TGAGGCTACAGGACACCTTTC, 
GTGCCAAAGTGGGGACCT; mouse Nanog: TTCTTGCTTACAAGGGTCTGC, 
AGAGGAAGGGCGAGGAGA; mouse Sox2: TGCTGCCTCTTTAAGACTAGGG, 
TCGGGCTCCAAACTTCTCT; mouse Klf4: CCGGTCCCTAGAGGCCCATTT, 
AGTTCATCGGAGCGGGCGAA; mouse Gdf3: 
TCAGCTTCTCCCAGACCAGGGTTT, CACACGCCCCGGTCCTGAAC; mouse 
Bmp4: CGCTGCAACCCAGCCTGAGT, GGCACTACGGAATGGCTCCATTGG; 
mouse Nestin: CTGCAGGCCACTGAAAAGTT, GACCCTGCTTCTCCTGCTC; 
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mouse Otx2: AGCTGCTCCCTCCGAAGCAGTA, 
AGCCGGACGGTCTCGATTCG; mouse Fgf5: GTTTCCAGTGGAGCCCTT, 
GAGACACAGCAAATATTTCCAAAA; mouse Rb1: 
GCCTCTCCAGGGTAACCATA, TTCTTTGGAGATCTTAGAGGAGAAA; mouse 
Ccnf: GGAGCGGCGGTGTGATCCATT, ACTGACCACGGTGGGCGGAT; mouse 
Nipp1: CCCGACTTGGGCAGGTAAACCA, CCCTCGTGGACGCGCCAAAT. 
 
Immunoprecipitation, western blot analysis and antibodies 
 
mESCs lysates were prepared with ice-cold lysis buffer containing 10 mM Tris-HCl, 
pH 7.4, 100 mM NaCl, 1 mM PMSF, 20 mM b-glycerophosphate, 1 mM Na3VO4, 1 
mM Na2F, 5 mM EDTA, and protease inhibitor mixture (Sigma) plus 1% Triton X-
100. After centrifugation and preclearing, lysates were incubated at 4ºC for 4 hours 
with 25 µl of protein A-Sepharose CL-4B (Amersham Biosciences) plus specific 
antibodies. The resin was washed, and bound proteins were eluted in SDS-PAGE 
sample buffer. 
Western blot analysis was performed according to standard procedures using the 
following primary antibodies: purified mouse anti-human Rb1 (554136; BD 
Pharmingen), monoclonal anti-p53 (DO-1; Santa Cruz Biotechnology), rabbit 
monoclonal anti-Rb phospho (pT356) (EPR21553AY; Epitomics); rabbit polyclonal 
anti-Oct4 (#2750; Cell Signaling); rabbit polyclonal anti-Oct4 (ab19857; Abcam); 
mouse monoclonal antibody anti-Nipp1 (sc-136425; Santa Cruz Biotechnology); 
mouse monoclonal anti-HA (HA-7; Sigma); rabbit polyclonal HA-probe (Y-11; sc-
805; Santa Cruz Biotechnology) and anti-Actin (A2066; Sigma). Secondary 
antibodies coupled to horseradish peroxidase were obtained from Sigma (anti-rabbit 
IgG peroxidase conjugate A-6154; anti-mouse IgG peroxidase conjugate A-4416). 
 
Chromatin immunoprecipitation 
 
ES cells were grown to a final count of 1 × 108 cells for each chromatin 
immunoprecipitation (ChIP) analysis. ChIP was performed as previously described 
(Drost et al., 2010). A rabbit polyclonal anti-Oct4 (ab19857; Abcam) and a rabbit 
polyclonal HA-probe (Y-11; sc-805; Santa Cruz Biotechnology) were used in ChIP 
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experiments. The following oligos were used for quantitative real time PCR on 
chromatin immunoprecipitates: Ccnf: GGGGAACCCTCACACTGTCTCT, 
CTTCCAGAGGCTACCAAAAGCA; Nipp1: 
GGCCCCTTAGGATTTTTCTCTGTGG, GTGCTGCCACACCCTCCAACC; Sox2: 
ATTTATTCAGTTCCCAGTCCAAGC, CCCTCTCCCCCCACGC; Dkk: 
GGGAACCAGGGAAAGAGGA, GGGAAATAGGCACCCGATAA. Quantitative 
PCR was performed using the SYBR Green Master Mix (Applied Biosystem) and 
analyzed with a StepOnePlus real-time PCR machine (Applied Biosystem). 
 
Luciferase reporter constructs and dual luciferase assay 
 
To produce human pGL3_RB1_3’UTR construct, a region in the 3’UTR of human 
RB1 containing the miR-335 target sequence was amplified by PCR using oligos 
GGGAATTCGACGTCGGATTCATTGTCTCTCACAG and 
GGGAATTCCATATGGGTTATACTTTGCTTCCAGC and cloned into 
pGL3Control (Promega) via AatII and NdeI. To produce human 
pGL3_RB1_3’UTRΔ construct, a fragments of the 3’UTR of human RB1 lacking the 
target site for miR-335 was generated by PCR and cloned into pGL3Control 
(Promega). 
 
The 3’UTR of mouse Oct4 were PCR-amplified from mESC cDNA, using 
GGGAATTCGACGTCTCAGGAGATATGCAAATCGGAG and 
GGGAATTCCATATGCTGTGTGTCCCAGTCTTTATTT oligonucleotides, cloned 
into pGL3Control (Promega) via AatII and NdeI downstream of the firefly luciferase 
gene. A region in the 3’UTR of mouse Rb1 containing the miR-335 target sequence 
were PCR-amplified from mESC cDNA, using oligos 
GGGAATTCGACGTCCAGCCCTGGGGACACCAGAC and 
GGGAATTCCATATGTGTGAAACAAACACACGGCACA, cloned into 
pGL3Control (Promega) via AatII and NdeI at downstream of the firefly luciferase 
gene. The 3’UTR of Oct4 and Rb1 lacking the target site for miR-335 were generated 
by PCR and cloned into pGL3Control (Promega). 
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In luciferase reporter assay, 2 × 104 U2OS cells were transiently transfected with 200 
ng of UTR pGL3Control (Promega) and 20 ng of reference Renilla luciferase 
expression vector using FUGENE 6 (Roche) transfection reagent following the 
manufacturer’s protocol. The next day miRIDIAN miRNA mimics (Thermo 
Scientific Dharmacon) were transfected with Lipofectamine RNAiMAX Transfection 
Reagent (Invitrogen) following the manufacturer’s protocol at a concentration of 30 
nM. Firefly/renilla luciferase activity was assayed 72 hours after transfection using 
the Dual Luciferase Assay kit (Promega). 
 
Alkaline phosphatase assay 
 
For the photospectrometric measurement of alkaline phosphatase (AP) activity in 
mouse embryonic stem cells, p-nitrophenol levels were determined using StemTAG 
Alkaline Phosphatase Activity Assay Kit (CBA-302; Cell Biolabs) following the 
manufacturer’s protocol. 
 
Immunofluorescence analysis 
 
For immunofluorescence stainings, cells grown on coverslips were pre-treated with 
20µg/ml polylysine (Sigma). After 12 hours, cells were fixed with 4% PFA for 10 
minutes, washed with PBS, and incubated in PBS with 0.1% Triton X-100 for 5 
minutes. After washing, PBS with 5% BSA was used to block for 30 minutes before 
the addition of primary antibody against Rb1 (554136; BD Pharmingen) or Oct4 
(ab19857; Abcam). Cells were washed twice in PBS and incubated with FITC- or 
TRITC-conjugated secondary antibodies (Sigma) for 1 hour. Slides were analyzed on 
a Leica DM 4000B fluorescence microscope. 
5-bromo-2′-deoxyruridine (BrdU) incorporation assay in U2OS cells was performed 
as following described. 24 hours after transfection cells were pulsed with 50 µM 
BrdU for 1 hour and fixed with paraformaldehyde. To reveal incorporated BrdU, 
coverslips were treated with 50 mM NaOH for 30 seconds and immediately washed 
with phosphate-buffered saline. BrdU was revealed by anti-BrdU monoclonal 
antibody (GH Healthcare) followed by incubation with rhodamine isothiocyanate 
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(RITC)-conjugated anti-mouse IgG2a antibody (Sigma). Nuclei were counterstained 
with Hoechst 33342. 
 
Survival analysis 
 
To verify the correlation of the RB1 signature expression and ovarian cancer clinical 
data we analyzed several microarray datasets of serous ovarian cancer (GSE14764, 
GSE15622, GSE18520, GSE19829, GSE23554, GSE26712, GSE30161, GSE3149, 
GSE9891, TCGA), to our knowledge encompassing all publicly available SOC 
profiles based on the Affymetrix platform, collectively consisting of more than 900 
patients. Kaplan–Meier survival curve of progression free survival time (pfs, 70 
months follow-up treshold, ) of ovarian cancer patients classified according to the 
expression of the RB1 signature expression was obtained using KMplotter tool 
(Györffy et al, 2012). The signature is composed by 3 genes (RB1,CCNF,PPP1R8). 
 
Statistics 
 
A Student’s t-test was performed so that p values for the difference between the 
means of the experimental conditions and control could be calculated. Error bars 
represent standard deviation (SD). Soft agar colony assays were performed at least 
twice with three plating replicates. Each finding was confirmed by three independent 
biological replicates, unless specified. 
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conclude that miR-335 controls cell proliferation in a
pendent manner, thus connecting the activities of the
d p53 tumor suppressor pathways.
rials and Methods
ines and cell cultivation
cell lines used in this study were obtained from the
can Type Culture Collection (ATCC) and have not been
ed in the laboratory for longer than 6 months. ATCC
tication testing procedure includes Mycoplasma test,
ia or fungi contamination, cellular contamination, cyto-
e c oxidase subunit I testing, short tandem repeat anal-
ytogenetic analyses (G-banding, fluorescence in situ
ization), flow cytometry, and immunohistochemistry.
cells were cultured in RPMI medium, 10% (v/v) fetal
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Published OnlineFirst August 16, 2010; DOI:10.1158/0008-5472.CAN-10-0141serum (FBS), and 1% (v/v) penicillin/streptomycin. All
cell lines used in this study were maintained in DMEM,
v/v) FBS, and 1% (v/v) penicillin/streptomycin. Cell
was measured in triplicate after plating 5 × 104 cells.
mber was counted at the indicated time points using a
ytometer. Stable transfections of plasmids were per-
d using Fugene6 (Roche Applied Science); selection
one using blasticidin (10 μg/mL; U2OS-miR control
20S-miR-335). Cells were treated with etoposide (5
L), actinomycin D (5 nmol/L), nocodazole (50 ng/mL),
aza-cytidine (5 μmol/L) for the indicated duration.
ient transfections of miRNAs or siRNA oligos
S, H1299, MG-63, NIH 3T3, and C2C12 cells were tran-
transfected with hsa_miR-335 mimic (C-300708-05,
o Scientific Dharmacon), antagomiR-335 hairpin
IAN inhibitor (IH-300708-07, Thermo ScientificDharma-
r a mix of all miR-290 cluster mimics (mmu_miR-290,
miR-291-3b, mmu_miR-292-3b, mmu_miR-293, mmu_
94, and mmu_miR-295; Thermo Scientific Dharmacon)
ding to the manufacturer's suggestions. MiR-IDIAN
A mimic negative control miRNA (CN-00100-01-05,
o Scientific Dharmacon) was used as a negative control.
miRNAs resemble siRNA molecules that recapitulate
A function. Total RNA and protein were prepared
urs after transfection. U2OS cells were transiently
ected with a siRNA against Rb1 (Thermo Scientific
acon; sense sequence: GGAAGGACAUGUGAA-
UU, antisense sequence: UAAGUUCACAUGUCCUUU-
or siRNA control siGENOME Non-Targeting siRNA
001210-01-20, Thermo Scientific Dharmacon) accord-
the manufacturer's suggestions.
sis for miRNA expression
al RNA was extracted and purified using TRIzol reagent
/BRL) and reverse transcribed using the miR-335 and
TaqManMicroRNAAssay system (Applied Biosystems).
man snoRNA RNU48 was used as a reference. The stem-
eal-time PCR (RT-PCR) was performed according to
tions suggested by Applied Biosystems. Quantitative
expression data were analyzed using a StepOnePlus
nce Detection System (Applied Biosystems).
rn blot analysis and antibodies
tern blot analysis was performed according to stan-
rocedures using the following primary antibodies: pu-
mouse anti-human Rb1 (BD Pharmingen), monoclonal
53 (DO-1; Santa Cruz Biotechnology), mouse monoclo-
ti-p53 (1C12; Cell Signaling Technology), rabbit poly-
l anti-p14ARF (Abcam), and anti-actin (Sigma).
dary antibodies coupled to horseradish peroxidase
btained from Sigma (antirabbit IgG peroxidase conju-
-6154; antimouse IgG peroxidase conjugate A-4416).
nofluorescence analysis and 5-bromo-2′-
ruridine incorporation
unofluorescence and 5-bromo-2′-deoxyruridine
rd) incorporation were performed as previously de-
ated w
cells d
r Res; 70(17) September 1, 2010
American Association Copyright © 2010 
cancerres.aacrjournals.Downloaded from d (15). Slides were analyzed on a Leica DM 4000B fluo-
ce microscope.
mination of luciferase and cell cycle profile
iferase activity was determined using the Dual Lucifer-
it (Promega) and was performed as previously de-
d (16). Cell cycle profile was analyzed using a
scence-activated cell sorting (FACS) flow cytometer
Calibur, Becton Dickinson).
lts
35 as a novel regulator of the tumor
essor Rb1
recent study, miR-335 was predicted to target mouse
owever, biological evidence remained unaddressed (11).
we show that miR-335 is identical in a series of placental
alian species (Fig. 1A; Supplementary Fig. S1A). Impor-
, classic sequence features known to boost target recog-
, such as the seed region (nucleotides 2–10), additional
airing at nucleotides 13 and 16, and the AU-rich se-
e composition near the end of the miR-335 seed region,
hly conserved in the Rb1 3′UTR of placental mammals
7; Fig. 1A). We show by quantitative stem-loop RT-PCR
iR-335 is widely expressed in cell lines derived from hu-
umors (Fig. 1B). Of notice, miR-335 levels were close to
it of detection in the U2OS and MG-63 osteosarcoma
es (Fig. 1B). Due to the fact that U2OS cells carry Rb1
53 wild-type alleles, we used U2OS cells as a gain-of-
on model system to study the role of miR-335 in con-
g the Rb pathway.
nsient transfection of U2OS cells with miR-335 effi-
reduced Rb1 protein levels, as detected by Western
g and immunofluorescence analysis (Fig. 1C; Supple-
ry Fig. S1B). Control miRNA or the pooled mouse
90 cluster did not significantly affect Rb1 protein levels
C, left). Importantly, cotransfection of miR-335 with
35 antagomir molecules (antagomiR-335) rescues Rb1
n levels (Fig. 1C, right). In addition, miR-335 efficiently
d Rb1 protein levels in NIH 3T3 embryonic fibroblasts
2C12 myoblast cells, indicating that target recognition
R-335 is conserved also in mouse cells (Supplementary
C and D). Next, we aimed to show that miR-335 directly
ls human Rb1 expression by targeting the Rb1 3′UTR.
ient overexpression of miR-335 efficiently reduced the
sion of a luciferase reporter fused to a region of the
n Rb1 3′UTR containing the predicted miR-335 target-
gion (position 358–380; Fig. 1A), but did not have an
when the target region was deleted (Fig. 1D). We con-
that miR-335 efficiently controls Rb1 expression by di-
targeting a sequence motif in the 3′UTR of Rb1 in a
rved manner.
35 impairs proliferation and transformation
inoblastoma proteins play a major role in controlling
cle (5). Although loss of Rb1 is expected to be associ-
ith increased cell proliferation, we found that U2OS
isplay significantly reduced cell proliferation rates
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Published OnlineFirst August 16, 2010; DOI:10.1158/0008-5472.CAN-10-0141transiently transfected with miR-335 (Fig. 2A, left; Sup-
ntary Fig. S2A). Cell cycle profiles revealed that trans-
of miR-335 causes an accumulation of cells in G0-G1
and reduced cell numbers in S phase (Fig. 2A, bottom).
stent with this, we found that the incorporation of
d into the DNA of replicating cells was significantly re-
in these cells (Fig. 2A, right; Supplementary Fig. S2B).
tantly, transient overexpression of the Rb1 cDNA lack-
s 3′UTR rescues impaired proliferation, BrdUrd in-
ration, and cell cycle regulation in the context of
0.001 (Student's t test).cally increased miR-335 levels (Fig. 2B). We conclude
educed cell proliferation and delayed S-phase entry
resulti
tion in
acrjournals.org
American Association Copyright © 2010 
cancerres.aacrjournals.Downloaded from direct consequence of targeting Rb1 by miR-335. Soft-
olony formation assays are the most commonly used
o assays to determine anchorage-independent growth,
ark of cell transformation. We generated U2OS cells
overexpressing miR-335 (Fig. 2C, left) and show that
ed miR-335 levels are associated with a significant
rment of colony formation (Fig. 2C, right).
en together, our results indicate that increased miR-335
activate a cellular response that compensates the
h advantage arising from impaired Rb pathway activity,1. miR-335 is highly conserved in placental mammals and directly controls Rb1 expression. A, alignment of miR-335 with the predicted target
n the Rb1 3′UTR of placental mammals. B, determination of miR-335 expression levels in human cancer cell lines by quantitative stem-loop RT-PCR.
5 levels were normalized with the RNU48 snoRNA. C, top, immunoblot showing Rb1 levels 3 days after transfection of the indicated miRNAs.
, quantification of Rb1 protein levels against actin. D, Rb1 3′ UTR luciferase reporter assay in U2OS cells. miR-335 suppresses the expression
fly-luciferase reporter fused to the 3′UTR of human Rb1. No change on deletion of the miR-335 target sequence in the Rb1 3′UTR (3′UTR Δ).
se activity was assayed 72 h after transient cotransfection. n, number of independent experiments carried out; bars, SD. *, P < 0.05; **, P < 0.01;ng in reduced proliferation and neoplastic transforma-
vitro.
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Published OnlineFirst August 16, 2010; DOI:10.1158/0008-5472.CAN-10-014135 controls proliferation in a p53-dependent
er
ently, inactivation of the Rb pathway in the developing
retina was shown to lead to activation of the ARF-
-MDMX-p53 tumor surveillance pathway, thereby lim-
roliferation (18). To test whether miR-335 can induce
tion of the p53 pathway, we studied the Rb1 and p53
suppressor pathways in U2OS cells in the context of
miR-335 levels.
found that the transient transfection of U2OS cells
iR-335 is associated with a concomitant 5-fold in-
in p53 protein levels (Fig. 3A). In functional analogy,
-mediated knockdown of Rb1 in U2OS cells was found
e a marked increase of p53 protein levels whereas the
nt overexpression of Rb1 readily reduced the expres-
f p53 (Supplementary Fig. S3A and B), thus confirming
tional link between the Rb and p53 tumor suppressor
ays in our model system. Importantly, reporter con-
s containing a luciferase reporter under the control
moters of the p53 target genes Mdm2, PG13, PIG3,
epresentative images of soft-agar plates and quantification of total colony
.05; ***, P < 0.001 (Student's t test).nd Bax (16) were efficiently upregulated in U2OS cells
ncreased miR-335 levels (Fig. 3B). In line with this,
of mi
MG-63
r Res; 70(17) September 1, 2010
American Association Copyright © 2010 
cancerres.aacrjournals.Downloaded from ng Rb1 expression in NIH 3T3 mouse embryonic fibro-
and C2C12 cells using miR-335 is linked with a concom-
ncrease in p53 protein levels (Supplementary Fig. S1C
). We conclude that limiting Rb levels by miR-335 results
ompensatory activation of the p53 pathway, aimed to
t from loss of Rb-dependent cell cycle regulation and
trolled proliferation of human and mouse cells.
next addressed whether the activation of the p53 is re-
ible for reduced proliferation in the context of miR-335
pression. We reduced p53 levels in U2OS cells by stably
ssing shRNAs directed against p53 (U2OS sh p53;
mentary Fig. S3C) and used these cell lines to consti-
ly overexpress miR-335 or a control miRNA. miR-335
xpression was confirmed by quantitative stem-loop
R (data not shown). As expected, stable overexpression
-335 in U2OS sh Control cells resulted in significantly
d proliferation when compared with U2OS sh Control
hat stably express a control miRNA (Fig. 3C, left).
tantly, stable expression of miR-335 in U2OS cells with
d p53 levels (U2OS sh p53) and transient transfection
r in 6-cm plate. n, number of independent experiments; bars, SD.2. Rb1 downregulation by miR-335 impairs cell proliferation and transformation. A, proliferation and cell cycle of U2OS cells transiently transfected
R-335 or miR-control. Left, growth curve. Right, percentage of BrdUrd-positive cells in cultures of experimental cells. Bottom, cell cycle profile
rmined by FACS. Medium values (%) for each cell cycle phase are indicated (n = 3). B, overexpression of Rb1 rescues proliferation defects driven by
5. U2OS cells were transiently cotransfected with miR-335 and a Rb1 expression vector lacking the Rb1 3′UTR. Left, transient overexpression
as detected by Western blotting; middle, growth curve; right, percentage of BrdUrd-positive cells in cultures of experimental cells; bottom,
le profiles as determined by FACS. Medium values (%) for each cell cycle phase are indicated (n = 3). C, neoplastic transformation of U2OS cells in
ar assays. U2OS cells (105) stably expressing miR-control or miR-335 were plated on soft agar and the number of cell colonies was analyzed
s later. Left, verification of stable miRNA-335 overexpression by quantitative RT-PCR. miR-335 levels were normalized with the RNU48 snoRNA.R-335 into the p53-deficient osteosarcoma cell line
significantly accelerates cell proliferation (Fig. 3C,
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Published OnlineFirst August 16, 2010; DOI:10.1158/0008-5472.CAN-10-0141Supplementary Fig. S3D). Consistent with this, we
that reduced soft-agar colony formation of sh Con-
2OS cells overexpressing miR-335 (U2OS sh Control;
, left) was compensated by reducing p53 levels using
shRNAi (U2OS sh p53; Fig. 3D, right). We conclude
educing Rb1 protein by miR-335 overexpression acti-
the p53 tumor suppressor pathway to limit cell pro-
ion and in vitro transformation.
35 drives hyperproliferation in the
ce of p53
t, we wished to confirm that cell proliferation is con-
by miR-335 in a p53-dependent manner. The human,
ficient non–small cell lung carcinoma cell line H1299
ntly expresses miR-335, allowing the use of this cell
miR-335 gain-of-function and loss-of-function experi-
(Fig. 1B). Transient transfection of H1299 cells with
35 resulted in a significant reduction of Rb1 protein
, accelerated cell proliferation, and neoplastic cell
ormation due to the absence of the p53 tumor sup-
r pathway (Fig. 4A and B). These findings are in line
he results obtained with MG-63 cells (Supplementary
D). Importantly, we show that reducing endogenous
35 levels in H1299 cells by stable overexpression of
miR-335 results in a significant reduction of cell pro- actino
ar assay of cells described in C. Left, U2OS sh Control cells stably overexpressin
ressing miR-Control or miR-335. Bars, SD; n, number of independent experiments
acrjournals.org
American Association Copyright © 2010 
cancerres.aacrjournals.Downloaded from C). Elevated Rb1 protein levels in antagomiR-335–
sing H1299 cells were confirmed by Western blotting
D). Together, our results show that miR-335 induces
roliferation and increases transformation in vitro in
sence of the p53 tumor suppressor pathway. We pro-
hat miR-335 has an important role in balancing the
d p53 tumor suppressor pathways, affecting the con-
f proliferation and immortalization.
35 and p53 cooperate in a positive feedback loop
ve DNA damage–mediated cell cycle arrest
ular insults such as DNA damage or oncogenic stress
the activation of the p53 pathway to induce cell cycle
or apoptosis (19, 20). To address whether miR-335
a role in the induction of p53-dependent cell cycle
, we measured miR-335 expression levels after induc-
f DNA damage in U2OS cells. Treatment with the
amaging agents etoposide or actinomycin D causes
cle arrest in G1 or G2-M phase that is paralleled by
icient increase in p53 protein levels and miR-335 ex-
on (Fig. 5A; Supplementary Fig. S4A). In contrast, the
tubule-damaging agent nocodazole causes only a slight
ulation of p53 without significantly affecting miR-335
sion (Fig. 5A; Supplementary Fig. S4A). Importantly,
mycin D or etoposide treatment of U2OS cells withion and impaired colony formation in soft-agar assays reduced p53 levels (U2OS sh p53) and p53-deficient MG-63
3. p53 protein is crucial for miR-335 control on proliferation and transformation. A, U2OS cells were transiently transfected as indicated and
d p53 protein levels were determined by Western blotting 72 h after transfection. Left, representative images. Right, quantification of p53 protein
gainst actin. Transient transfection of miR-335 decreases Rb1 and increases p53 expression. miR-control and the mouse miR-290 cluster were
negative controls. B, reporter assay for p53 activity in U2OS cells stably expressing miR-335 or miR-control. Increased p53 reporter gene expression
tected 3 days after transfection. C, growth curve of U2OS sh Control or sh p53 cells stably expressing miR-335 or miR-Control. D, quantification ofg miR-Control or miR-335. Right, U2OS sh p53 cells stably
carried out. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Student's t test).
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Published OnlineFirst August 16, 2010; DOI:10.1158/0008-5472.CAN-10-0141oes not result in increased miR-335 levels (Fig. 5B;
mentary Fig. S4B and C). In addition, transient trans-
of MG-63 cells with p53 causes an efficient increase
-335 levels that is paralleled by upregulation of the
(mesoderm specific transcript) gene that encodes
35 in intron 2 (Supplementary Fig. S5A). Together,
data indicate that miR-335 levels are increased during
amage by upregulation of MEST in a p53-dependent
er. Importantly, MEST luciferase reporter assays in
cells transiently transfected with p53 confirmed the
ce of a p53-responsive promoter element at the tran-
onal start site of the MEST-002 transcript (Supplemen-
ig. S5B and C). To further investigate the role of p53 in
tivation of MEST transcription, we induced DNA dam-
U2OS cells and performed chromatin immunoprecip-
experiments. As expected, we found an efficient
ment of p53 at the p21 promoter in etoposide-treated
Supplementary Fig. S5B and D). However, we were not
detect p53 enrichment at consensus p53 binding sites
MEST locus of cells after the induction of DNA dam-
upplementary Fig. S5B and D). Our results indicate
53 controls miR-335 levels, but uses an indirect mech-
to control the transcription of the miR-335 encoding
EST gene.
nregulation of Rb1 by miR-335 mediates cell cycle
by activating the p53 tumor suppressor pathway
A and B). To test whether the upregulation of miR-335
ired for DNA damage–mediated cell cycle arrest, we as-
agar assays, the total number of colonies (>1.5 mm) on a surface of 16 m
out. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Student's t test).cell cycle profiles and BrdUrd incorporation of U2OS
tably overexpressing miR-335 or antagomiR-335 after
The
tumor
r Res; 70(17) September 1, 2010
American Association Copyright © 2010 
cancerres.aacrjournals.Downloaded from ent with etoposide. As expected, overexpression of
35 results in a significantly delayed S-phase entry and
ed BrdUrd incorporation in untreated U2OS cells
C and D, top; Supplementary Fig. S6). AntagomiR-335
ot affect cell cycle regulation due to the fact that miR-
els are close to the detection limit in U2OS cells (Fig. 5C
, top; Supplementary Fig. S6). In contrast, antagonizing
regulation of miR-335 in etoposide-treated U2OS by sta-
erexpression of antagomiR-335 causes a significant 50%
se in the number of cells in S phase, reduced cell number
phase, and a higher number of BrdUrd-positive cells,
compared with control cells or miR-335 overexpressing
cells (Fig. 5C and D, bottom; Supplementary Fig. S6). Of
, ectopic expression of miR-335 does not improve etopo-
duced cell cycle arrest, suggesting that the activation of
iR-335 pathway by DNA damage has already reached
tion in our model system. Together, our data show the
nce of an important connection between miR-335 and
3 tumor suppressor pathway during DNA damage re-
e. DNA damage activates the p53 pathway, driving the
ulation of miR-335. miR-335 represses Rb1 at the post-
riptional level, enforcing the activation of the p53 tumor
essor pathway. Together, these data indicate that miR-
d p53 operate in a positive feedback loop to ensure
nt cell cycle arrest upon DNA damage (Fig. 6).
ssion
s determined. Bars, SD; n, number of independent experiments4. Cells lacking p53 respond to miR-335 by increasing proliferation. A, Rb1 protein levels in H1299 cells transiently transfected with miR-335 or
ntrol 3 d after transfection. Top, representative image. Bottom, quantification of Rb1 protein levels normalized with actin. B, miR-335 promotes
liferation in p53-deficient cells. Left, growth curve of H1299 transiently transfected with miR-335 or miR-Control. Right, soft-agar assay of H1299
erexpressing miR-335. C, antagomiR-335 impairs proliferation in p53-deficient cells. Left, growth curve of H1299 transiently transfected with
miR-335 or control miRNA. Right, soft-agar assays of H1299 cells overexpressing antagomiR-335. D, increased Rb1 protein levels in H1299
nsiently transfected with antagomiR-335 and miR-Control at the indicated time points. Bottom, quantification of Rb1 levels normalized against actin.
2retinoblastoma and p53 pathways represent the major
suppressor pathways in mammals and are crucial for
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Published OnlineFirst August 16, 2010; DOI:10.1158/0008-5472.CAN-10-0141ntrol of cell proliferation and the response to cellular
(19–21). Rb is frequently mutated or expressed at low
in several tumors such as retinoblastoma, osteosarco-
well as small lung, prostate, bladder, and breast carci-
(22–26). Thus,miRNAs controlling Rb protein levels are
clinical interest. Here, we show that miR-335 efficiently
ls Rb1 (pRb/p105) protein levels by directly targeting a
ved region in the 3′UTR of Rb1 in placental mammals.
ta show that miR-335–mediated reduction of Rb1 pro-
In n
such a
miR-335 overexpression promotes S-phase entry. Bars, SD; n, number of independ
t's t test). Ctrl, control; Eto, etoposide; Act-D, actinomycin D; Noc, nocodazole.
acrjournals.org
American Association Copyright © 2010 
cancerres.aacrjournals.Downloaded from sults in the activation of the p53 pathway in human and
cells, impairing cell proliferation and neoplastic trans-
tion in vitro. In line with this, impairing the p53 pathway
cient to drive hyperproliferation and increased transfor-
n in the context of ectopically increased miR-335 levels.
nclude that miR-335 has an important role in balancing
3 and Rb tumor suppressor pathways.
ormal cells, the Rb and p53 pathways integrate stimuli
s DNA damage and other stress signals, leading to cell5. miR-335 is upregulated on DNA damage and cooperates with p53 in a positive feedback loop to induce cell cycle arrest. A, left, p53 protein levels
S sh Control cells on induction of DNA damage, as determined by Western blotting. The DNA-damaging agents etoposide and actinomycin D
fficient p53 upregulation. Induction of microtubule damage by nocodazole results in a modest p53 upregulation. Actin was used as a loading control.
iR-335 levels on induction of DNA damage as determined by quantitative stem-loop RT-PCR. Representative pictures of agarose gels after
e shown. Human snoRNA RNU48 was used as a loading control. B, left, reduced activation of p53 in U2OS sh p53 cells on DNA damage, as
ined by Western blotting. Actin was used as a loading control. Right, reduced p53 levels in U2OS sh p53 cells impair the upregulation of miR-335 on
mage. miR-335 levels were determined by quantitative stem-loop RT-PCR. Representative agarose gels of PCR products are shown. Human
RNU48 was used as a loading control. C, reduced miR-335 expression during DNA damage impairs p53-mediated cell cycle arrest. FACS cell cycle
of U2OS cells stably overexpressing miR-335, antagomiR-335, or miR-Control, untreated (top) or treated with etoposide for 24 h (bottom).
5 overexpression causes reduced S-phase entry in untreated cells. Antagonizing miR-335 upregulation during DNA damage by overexpression
gomiR-335 in U2OS cells impairs cell cycle arrest. Percentages of cells in different cell cycle phases are indicated. D, BrdUrd incorporation in
ed (top) and etoposide-treated (bottom) cells with stably altered miR-335 levels. Increased miR-335 levels in control cells impair S-phase entry;ent experiments carried out. *, P < 0.05; **, P < 0.01; ***, P < 0.001
°, excess primers in quantitative stem-loop RT-PCR.
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Published OnlineFirst August 16, 2010; DOI:10.1158/0008-5472.CAN-10-0141arrest and senescence. Activation of the p53 pathway
ents the primary defence system against DNA double-
breaks (27, 28). In this pathway, ARF inhibits HDM2
y, leading to p53 stabilization and transcriptional acti-
of p21-mediated cell cycle arrest. Activation of the Rb
ay was postulated to occur as a secondary event to the
tion of p53 by involving p21 (29, 30). The inhibition of
-dependent kinases (CDK) by p21 and p16 keeps pRb in
pophosphorylated form, thereby preventing E2F from
ribing S-phase genes (21). Several studies suggest that
3 and Rb pathways are functionally connected: high
tivity on Rb loss of function can lead to the activation
expression and activation of p53; in addition, p21 in-
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An Oct4-pRb Axis, Controlled by MiR-335, Integrates Stem Cell
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ABSTRACT
The pluripotency of mouse embryonic stem cells (mESCs)
is controlled by a network of transcription factors, miR-
NAs, and signaling pathways. Here, we present a new regu-
latory circuit that connects miR-335, Oct4, and the
Retinoblastoma pathway to control mESC self-renewal and
differentiation. Oct4 drives the expression of Nipp1 and
Ccnf that inhibit the activity of the protein phosphatase 1
(PP1) complex to establish hyperphosphorylation of the
retinoblastoma protein 1 (pRb) as a hallmark feature of
self-renewing mESCs. The Oct4-Nipp1/Ccnf-PP1-pRb axis
promoting mESC self-renewal is under control of miR-335
that regulates Oct4 and Rb expression. During mESC dif-
ferentiation, miR-335 upregulation co-operates with the
transcriptional repression of Oct4 to facilitate the collapse
of the Oct4-Nipp1/Ccnf-PP1-pRb axis, pRb dephosphoryl-
ation, the exit from self-renewal, and the establishment of
a pRb-regulated cell cycle program. Our results introduce
Oct4-dependent control of the Rb pathway as novel
regulatory circuit controlling mESC self-renewal and
differentiation. STEM CELLS 2013; 000: 000–000
Disclosure of potential conflicts of interest is found at the end of this article.
INTRODUCTION
The unlimited proliferative potential and pluripotent character
of mouse embryonic stem cells (mESCs) is characterized not
only by specific core transcriptional regulatory circuits com-
prising the pluripotency transcription factors Oct4, Sox2, and
Nanog but also by an atypical cell cycle structure [1–3]. In
addition to transcription factors, several miRNAs were identi-
fied to modulate mESC self-renewal by directly targeting plu-
ripotency transcription factors or cell cycle regulators [4–9].AQ1
Rapid cell division of self-renewing mESCs is mediated by a
muted oscillation of the Cdk2-Cyclin E complex resulting in
an increase in overall Cdk2 activity that holds Retinoblastoma
family proteins in a hyperphosphorylated and biochemically
inactive state, thereby ensuring rapid cell cycle progression
with remarkably short G1/G2 phases [2, 10–14]. Induction of
cell differentiation results in the repression of core self-
renewal transcription factors and is paralleled by the estab-
lishment of a classic Retinoblastoma pathway-dependent cell
cycle program [2, 10, 12, 13]. Recent studies indicate a role
for the Rb pathway in the control of mESC self-renewal: con-
stitutive pRB hyperphosphorylation due to the targeted dele-
tion of the Cdk2 inhibitor Cdk2ap1 results in an impaired cell
differentiation potential that can be rescued by expressing
nonphosphorylateable pRb [15]. In line with this, mESC lack-
ing a functional Rb pathway due to the combined targeted de-
letion of all Retinoblastoma protein family members display
differentiation defects in teratoma formation experiments [16].
Together, this suggests that the inactivation of the pRb path-
way antagonizes the initiation of mESC differentiation and
consequently enhances the self-renewal potential of mESC.
The concurrent repression of self-renewal transcription
factors and switch in cell cycle structure at the transition from
mESC self-renewal to differentiation suggest the existence of
specific pathways that connect developmental potential with
cell cycle regulation. However, functional evidence for such a
connection in mESCs is still missing.
Here, we demonstrate that Oct4 controls the cell cycle
program of self-renewing mESCs by protecting pRb from de-
phosphorylation by the protein phosphatase 1 (PP1) complex.
The self-renewal promoting Oct4-pRb axis is under tight con-
trol of miR-335 that targets conserved sequence motifs in the
30UTRs of Oct4 and pRb. At the onset of mESC differentia-
tion, transcriptional repression of Oct4 in conjunction with
post-transcriptional silencing of Rb/Oct4 by miR-335 causes
the collapse of the Oct4–PP1 self-renewal axis, leading to a
rapid dephosphorylation of p-pRb, the exit from self-renewal,
and the establishment of a cell cycle program of differentiated
cells.
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MATERIALS AND METHODS
Cell Culture
Feeder-independent mouse ES cells were cultured on 0.2% gelatin-
coated plates in mESC self-renewal medium (Dulbecco’s modified
Eagle’s medium supplemented with 15% knockout serum replace-
ment) (Gibco, Grand Island, NY, http://www.invitrogen.com), 1%
nonessential amino acids (Gibco), 1 mM sodium pyruvate (Invitro-
gen, Carlsbad, CA, http://www.invitrogen.com), 1% L-glutamine
(Invitrogen), 0.1 mM b-mercaptoethanol, 1% penicillin/streptomy-
cin (Invitrogen), and 1,000 U/ml mouse leukemia inhibitory factor.AQ2 AQ3
ES cell differentiation schemes are indicated in supporting informa-
tion. Self-renewing mESCs were transfected with pMSCV-miR-
335 (supporting information section) and subjected to selection
using blasctidine (Invitrogen, 2 lg/ml) to generate mESCs stably
overexpressing miR-335. To generate mESCs with reduced miR-
335 levels, cells were transfected with TW3-decoy-miR-335 (sup-
porting information) and subjected to selection using puromycin
(Invitrogen, 3 lg/ml).
Transient Transfections of miRNAs or siRNA Oligos
Mouse ES cells were transiently transfected with hsa_miR-335
mimic (C-300708-05, Thermo Scientific Dharmacon), antagomiR-
335 hairpin miR-IDIAN inhibitor (IH-300708-07, Thermo Scien-
tific Dharmacon) according to the manufacturer’s suggestions.
MiR-IDIAN miRNA mimic negative control siRNA (CN-00100-
01-05, Thermo Scientific Dharmacon) was used as a negative
control. Mimic miRNAs resemble siRNA molecules that recapitu-
late miRNA function. Total RNA and protein were prepared 72
hours after transfection. ES cells were transiently transfected with
siRNAs indicated in supporting information according to the
manufacturer’s suggestions.
Flow Cytometry
For fluorescence-activated cell sorting (FACS) analysis, self-
renewing and differentiating mESCs were collected and fixed in
ethanol. After rehydration, cells were resuspended in 1" PBS,
0.1% Nonidet P40 and treated with 200 lg/ml RNase A for 10
minutes; propidium iodide was added to a final concentration of
50 lg/ml. Cells were analyzed on a flow cytometer (FACSCali-
bur, Becton Dickinson, Franklin Lakes, NJ, http://www.bd.com).
FACS data were analyzed using ModFit LT 3.1.
Analysis of miRNA Expression
Total RNA was extracted and purified using TRIzol reagent
(Gibco/BRL) and reverse transcribed using the miR-335 and sno-
135 TaqMan MicroRNA Assay system (Applied Biosystems, Fos-
ter City, CA, http://www.appliedbiosystems.com). The mouse
snoRNA sno-135 was used as a reference. The quantitative stem-
loop real-time polymerase chain reaction (RT-PCR) was per-
formed according to conditions suggested by Applied Biosystems.
Quantitative miRNA expression data were analyzed using a Ste-
pOnePlus Sequence Detection System (Applied Biosystems).
Analysis of mRNA Expression
Total RNA from indicated cell lines was purified using TRIzol
reagent (Gibco/BRL). 1.5 lg of total RNA was treated with
DNAse (RQ1, Promega, Madison, WI, http://www.promega.com)
and subjected to reverse transcription using random primers
(Promega) and SuperScriptII Reverse Transcriptase (Invitrogen)
according to the manufacturer’s suggestions. Quantitative PCR
was performed using the SYBR Green Master Mix (Applied Bio-
system) and analyzed with a StepOnePlus real-time PCR machine
(Applied Biosystem). mRNA levels were normalized with gapdh.
qRT-PCR primer sequences are indicated in supporting
information.
Immunoprecipitation, Western Blot Analysis, and
Antibodies
mESC lysates were prepared with ice-cold lysis buffer containing
10 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1 mM PMSF, 20 mM
b-glycerophosphate, 1 mM Na3VO4, 1 mM Na2F, 5 mM EDTA,
and protease inhibitor mixture (Sigma) plus 1% Triton X-100. Af-
ter centrifugation and preclearing, lysates were incubated at 4#C
for 4 hours with 25 ll of protein A-Sepharose CL-4B (Amersham
Biosciences, Piscataway, NJ, http://www.amersham.com) plus
specific antibodies. The resin was washed, and bound proteins
were eluted in SDS-PAGE sample buffer. Western blot analysis
was performed according to standard procedures using the pri-
mary antibodies indicated in supporting information.
Chromatin Immunoprecipitation
ES cells were grown to a final count of 1 " 108 cells for each
chromatin immunoprecipitation (ChIP) analysis. ChIP was per-
formed as previously described [17]. A rabbit polyclonal anti-
Oct4 (ab19857; Abcam, Cambridge, U.K., http://www.abcam.-
com) and a rabbit polyclonal HA-probe (Y-11; sc-805; Santa
Cruz Biotechnology, Santa Cruz, CA, http://www.scbt.com) were
used in ChIP experiments. The oligos used for quantitative RT-
PCR on chromatin immunoprecipitates are specified in supporting
information. Quantitative PCR was performed using the SYBR
Green Master Mix (Applied Biosystem) and analyzed with a Ste-
pOnePlus real-time PCR machine (Applied Biosystem).
Luciferase Reporter Constructs and
Dual Luciferase Assay
The 30-UTR constructs are described in supporting information.
In luciferase reporter assay, 2 " 104 U2OS cells were transiently
transfected with 200 ng of UTR pGL3Control (Promega) and 20
ng of reference Renilla luciferase expression vector using
FUGENE 6 (Roche, Basel, Switzerland, http://www.roche-
applied-science.com) transfection reagent following the manufac-
turer’s protocol. The next day miRIDIAN miRNA mimics
(Thermo Scientific Dharmacon) were transfected with Lipofect-
amine RNAiMAX Transfection Reagent (Invitrogen) following
the manufacturer’s protocol at a concentration of 30 nM. Firefly/
renilla luciferase activity was assayed 72 hours after transfection
using the Dual Luciferase Assay kit (Promega).
Alkaline Phosphatase Assays and Colony
Reformation Assay
mESC colonies were stained with StemTAG Alkaline Phospha-
tase Staining Kit (CBA-302; Cell Biolabs) following manufac-
turer’s instruction. AQ4The self-renewal colonies stain positive for
alkaline phosphatase (AP), but differentiated colonies stain less or
negative for AP. For the photospectrometric measurement of AP
activity in experimental cells, p-nitrophenol levels were deter-
mined using StemTAG Alkaline Phosphatase Activity Assay Kit
(CBA-302; Cell Biolabs) following the manufacturer’s protocol.
For colony replating efficiency assays, ES cells were transi-
ently transfected with miRNA mimics and trypsinized and
counted 1 day after transfection. 5 " 103 cells were replated in
triplicate on gelatinized cell culture 30 mm petri dishes and
allowed to grow for 5 days. For staining, colonies were washed
in PBS and fixed in 4% PFA for 20 minutes. After washing, colo-
nies were incubated with 0.05% crystal violet in H2O for 30
minutes in the dark. Subsequently, plates were washed in H2O,
and the replating efficiency of colony reformation was determined
by counting colony number.
Flow Cytometry Analysis of Self-Renewal
and Immunofluorescence Analysis
For self-renewal analysis, mES cells were trypsinized into single
cell suspensions (5 " 105), washed with PBS, and fixed 1% para-
formaldehyde in PBS for 10 minutes at room temperature. Cells
were then washed in PBS, resuspended in PBS with 5% BSA,
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Figure 1. Oct4 and pRb cooperate to promote mESC self-renewal. (A): Western blotting of mouse embryonic stem cells (mESCs) transfected
with siRNAs targeting Oct4 or Rb using the indicated antibodies. Knockdown of Oct4 reduces total and phospho-pRb levels. Actin was used as a
loading control (left panel). Quantitative real-time polymerase chain reaction (PCR) analysis using mESCs transiently transfected with siRNAs
targeting Oct4 or Rb. Oct4 does not regulate Rb transcription; expression values were normalized against gapdh (right panel) (B): Western blot-
ting of mESCs stably transfected with a control or HA-Oct4 expression construct. Increased Oct4 levels augment total pRb and phospho-pRb
expression levels; Actin was used as a loading control. (C): siRNA-mediated reduction of Oct4 or Rb leads to reduced self-renewal potential as
determined by AP activity measurements. (D): Real-time PCR expression analysis of pluripotency marker genes after depletion of Oct4 or pRb
from mESCs. Expression values were normalized against gapdh. (E): Morphology of mESCs and mESC colonies described in (A). Arrows indi-
cate cells with differentiated morphology. Scale bars are indicated. (F): Growth curve of mESCs described in (A). Oct4 or Rb siRNA reduces
cell proliferation (G): Cell cycle FACS analysis of cells described in (A); knock down of Oct4 or Rb promotes the establishment of a cell cycle
program of differentiated cells (n ¼ 3). n, refers to the number of independent experiments carried out; error bars indicate SD; a Student’s t-test
was used for statistical analysis: *, p < .05; **, p < .01; ***, p < .001. In Western blots, actin was used as a loading control. Abbreviations:
AP, alkaline phosphatase; HA, l l l; LIF, l l l.AQ8
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Figure 2. An Oct4-Nipp1/Ccnf-PP1-pRB axis promotes mouse embryonic stem cell (mESC) self-renewal. (A): Quantitative real-time polymer-
ase chain reaction (PCR) after siRNA-mediated knockdown of Oct4. Oct4 drives the expression of Nipp1 and Ccnf. Expression values were nor-
malized against gapdh. (B): Ectopic HA-Oct4 expression during mESC differentiation (5 days in the absence of LIF) augments the expression of
Nipp1 and Ccnf; expression values were normalized against gapdh (quantitative real-time PCR, left panel) and rescues total and phospho-pRb
levels; actin was used as a loading control (Western blotting, right panel). (C): Chromatin immunoprecipitation (ChIP) using specific Oct4 anti-
body. Left panel: ChIP PCR products visualized on an agarose gel; Right panel: quantification of real-time PCR results. Oct4 is enriched at Ccnf
and Nipp1 promoter regions. An HA antibody was used as control. The Oct4 target gene Sox2 was used as a positive control, Dkk as negative
control. (D): pRb and phospho-Rb levels in mESC transiently transfected with the indicated siRNA oligos, as determined by Western blotting
using the indicated antibodies. Knockdown of Oct4 or Nipp1/Ccnf reduces total pRb and phospho-pRb protein levels. (E): Morphology of mESCs
and mESC colonies transfected with the indicated siRNA oligonucleotides. Knockdown of Nipp1/Ccnf promotes cell differentiation. Arrows indi-
cate cells with differentiated morphology. Scale bars are indicated. (F): Growth curve of mESCs described in (E). Nipp1/Ccnf siRNA reduces
cell proliferation. (G): Spectrophotometric analysis of AP activity after siRNA mediated reduction of Nipp1/Ccnf. Depletion of Ccnf/Nipp1 results
in reduced self-renewal potential. (H): Quantitative real-time PCR analysis of self-renewal marker genes in cells transfected with the indicated
siRNA oligonucleotides. siRNA-mediated reduction of Nipp1/Ccnf in self-renewing mESCs causes a reduced expression of pluripotency marker
genes; expression levels were normalized against gapdh. n, refers to the number of independent experiments carried out; error bars indicates SD;
a Student’s t test was used for statistical analysis: *, p < .05; **, p < .01; ***, p < .001. Abbreviations: Ccnf, cyclin F; HA, % % %; Nipp1, nu-
clear inhibitor of PP1; pRb, retinoblastoma protein.
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and incubated with primary antibody mouse anti-SSEA1 (550079;
BD Pharmingen, San Diego, CA, http://www.bdbiosciences.com/
index_us.shtml) at 10 lg/ml final concentration for 30 minutes at
room temperature. After washing, cells were resuspended in anti-
mouse FITC-conjugated secondary antibody (Sigma) in PBS with
0.5% BSA for 30 minutes, washed, and analyzed using a FACS
flow cytometer (FACSCalibur, Becton Dickinson).
For immunofluorescence stainings, cells grown on coverslips
were pretreated with 20 lg/ml polylysine (Sigma). After 12 hours,
cells were fixed with 4% PFA for 10 minutes, washed with PBS, and
incubated in PBS with 0.1% Triton X-100 for 5 minutes. After wash-
ing, PBS with 5% BSA was used to block for 30 minutes before the
addition of primary antibody against Oct4 (ab19857; Abcam), Rb1
(554136; BD Pharmingen), or SSEA1 (550079; BD Pharmingen).
Cells were washed twice in PBS and incubated with FITC- or
TRITC-conjugated secondary antibodies (Sigma) for 1 hour. For
SSEA1 staining, cells were not treated with Triton X-100. Slides
were analyzed on a Leica DM 4000B fluorescence microscope.
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Figure 3. miR-335 controls pRb and Oct4 expression in mouse embryonic stem cells (mESCs). (A): Oct4, pRb, and Nipp1 expression in self-
renewing mESCs at Day 0 and embryoid body aggregates (Day 3, 6) (see Material and Methods section). Left panel, Western blotting using the
indicated antibodies; actin was used as a loading control. Right panels, Quantitative real-time polymerase chain reaction (PCR) analysis for Oct4
and Rb; gapdh was used as a loading control. (B): Robust upregulation of miR-335 levels upon the induction of mESC differentiation during
embryoid body differentiation (left panel), withdrawal of LIF from the cell culture medium (central panel) or retinoic acid treatment (right panel).
miR-335 levels were measured by quantitative real-time PCR. Expression levels were normalized to sno-135. (C): Luciferase reporter assays
demonstrating miR-335 target specificity for the 30UTR of Rb and Oct4 (Rb-30UTR; Oct4-30UTR) in U2OS cells. Rb-30UTRD; Oct4-30UTRD are
control reporter vectors lacking the miR-335 target site. (D): Immunostaining and Western blotting for pRb, phospho-pRb, and Oct4 in mESCs 3
days after transfection with synthetic miR-335, antago-miR-335, or control oligonucleotides. A "60 magnification is shown. For Western blots,
actin was used as a loading control; n, refers to the number of independent experiments carried out; error bars indicates standard deviation; a Stu-
dent’s t test was used for statistical analysis: *, p < .05; **, p < .01; ***, p < .001. Abbreviations: DAPI, % % %; pRb, retinoblastoma protein;
Nipp1, nuclear inhibitor of PP1; LIF, % % %; UTR, % % %.
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Figure 4. miR-335 antagonizes mESC self-renewal. (A): mESC cell colonies 1, 2, and 3 days after transfection with the indicated RNAi oligo-
nucleotides. miR-335 transfected mESCs form smaller colonies and show the morphology of differentiated cells. At day 3 two different magnifi-
cations are shown; scale bars are indicated. Arrows indicate cells with differentiated morphology. (B): Images of mESC cell colonies. mESCs
described in (A, day 3) were trypsinized and replated in self-renewal medium for additional 3 days. Transient miR-335 transfection resulted in an
irreversible loss of self-renewal potential. Two different magnifications are shown; scale bars are indicated. Arrows indicate cells with differenti-
ated morphology. (C): FACS analysis of mESC 1, 2, or 3 days after transfection with the indicated mimic miRNA siRNAs. Ectopic miR-335
provokes a reduction of cells in S phase (n ¼ 3). (D): AP mESC colony staining (left panel) and photospectrometric measurement (right panel)
of AP activity of mESCs transfected with the indicated mimic miRNA siRNAs. miR-335 reduces self-renewal potential. (E): Quantitative real-
time polymerase chain reaction measurement of self-renewal marker gene expression using mESCs transiently transfected with the indicated
mimic-miRNA siRNAs, 1, 2, or 3 days post-transfection. Ectopic miR-335 reduces self-renewal marker gene expression. Control mimic-miRNA
siRNA values were set ‘‘100.’’ Expression values were normalized against gapdh. (F): Spectrophotometric measurement of AP activity in mESC
transfected with the indicated mimic miRNA siRNAs. miR-335 reduces self-renewal potential. (G): Spectrophotometric measurement of AP ac-
tivity in mESC stably overexpressing miR-335 and Oct4/Rb. Expression of Oct4/Rb in the context of miR-335 overexpression rescues self-
renewal potential. Error bars indicates SD; a Student’s t test was used for statistical analysis: *, p < .05; **, p < .01; ***, p < .001. Abbrevia-
tions: AP, alkaline phosphatase; mESC, mouse embryonic stem cell;
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Figure 5. Collapse of the Oct4-Nipp1/Ccnf-PP1-pRb axis at the onset mouse embryonic stem cell (mESC) differentiation. (A): Cell colonies 3
days after transfection with the indicated RNAi oligonucleotides. Cells were grown under differentiation conditions (LIF withdrawal). Ectopic
miR-335 accelerated mESC differentiation. Two different magnifications are shown; scale bars are indicated. Arrows indicate cells with differen-
tiated morphology. (B): fluorescence-activated cell sorting (FACS) analysis of mESC 3 days after transfection with the indicated mimic miRNA
siRNAs (n ¼ 3). Cells were cultivated under differentiation conditions (LIF withdrawal). Reducing miR-335 levels block the acquisition of a cell
cycle program of differentiated cells. (C): AP activity in differentiating mESCs after transfection with the indicated oligonucleotides. Ectopic
miR-335 accelerates the reduction of AP activity. (D, E): Expression of self-renewal marker genes (D) or early differentiation marker genes (E)
in mESCs transfected with the indicated mimic-miRNA siRNAs. Quantitative polymerase chain reaction was performed 1, 2, or 3 days post-
transfection; cells were grown under differentiation conditions (LIF withdrawal). Expression levels were normalized against gapdh. Gene expres-
sion levels from control mimic-miRNA siRNA transfected cells grown under self-renewal conditions were set ‘‘100’’. Ectopically increased miR-
335 levels promote the exit from self-renewal and initiation of differentiation gene expression programs. (F): Formation of contractile structures
in embryoid body outgrowths derived from control, miR-335 overexpressing, or decoy-miR-335 mESCs. (G): Western blotting of Oct4, total pRb
and phospho-pRb (p-pRb), and Nipp1 in self-renewing mESCs (Day 0), embryoid bodies (Day 3, 6), or embryoid body outgrowths overexpress-
ing miR-335 or a decoy-miR-335 construct. For Western blots, actin was used as a loading control; *nonspecific band; > specific Oct4 band; n,
refers to the number of independent experiments carried out; error bars indicates SD; a Student’s t test was used for statistical analysis: *, p <
.05; **, p < .01; ***, p < .001. Abbreviations: AP, alkaline phosphatase; LIF, % % %; pRb, retinoblastoma protein; Nipp1, nuclear inhibitor of
PP1.
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mESC Xenografting
200,000 ES cells resuspended in Matrigel Basement Membrane
Matrix (BD Bioscience, San Diego, http://www.bdbiosciences.-
com) were injected subcutaneously into the flanks of nude mice
(Charles River Laboratories). Six injections per cell line were
performed. Teratoma formation was followed during 3 weeks
before xenograft excision from the animal.
Statistics
A t test was performed so that p values for the difference
between the means of the experimental conditions and control
could be calculated. Error bars represent SD. Each finding was
confirmed by three independent biological replicates, unless
specified.
RESULTS
Oct4 and pRb Co-Operate to Ensure mESC
Self-Renewal
The loss of self-renewal potential of mESCs is paralleled by
an acquisition of a Retinoblastoma family protein-regulated
cell cycle program [12–14]. To identify a possible link
between Oct4-dependent transcriptional self-renewal circuits
and pRb-dependent cell cycle regulation, we used RNAi to
deplete Oct4 or Rb (encodes pRb protein) from self-renewing
mESCs. Interestingly, Oct4 siRNA provoked a rapid reduction
of total and hyperphosphorylated pRb (pRb and p-pRb-T356,
respectively) without altering total Rb mRNA levels (Fig.
F1 1A). In line with this result, ectopic overexpression of HA-
tagged Oct4 in self-renewing mESCs increased pRb hyper-
phosphorylation, resulting in pRb stabilization and augmented
total pRb levels (Fig. 1B). Of notice, knockdown of pRb does
not affect Oct4 mRNA or protein expression (Fig. 1A). To-
gether, these results suggest that Oct4 has a role in controlling
pRb levels in self-renewing mESCs (Fig. 1A). To test whether
this pathway has a relevance for mESC self-renewal, we stud-
ied self-renewal features in the context of Rb siRNA. RNAi-
mediated depletion of Rb from mESCs growing under self-
renewal conditions reduced AP activity to a similar extent
like the depletion of Oct4 (Fig. 1c). Of notice, the observed
reduction of AP activity in Rb siRNA-treated cells is similar
to that observed after 3 days of ES cell differentiation, con-
firming that pRb has a role in promoting mESC self-renewal
(supporting information Fig. 1). Impaired self-renewal was
also observed on the level of gene expression. In particular,
knockdown of Rb in mESCs provoked a downregulation of
self-renewal marker genes Nanog, Sox2, and Gdf3 but did not
affect Oct4 or Klf4 expression (Fig. 1D). Consistent with
reduced self-renewal potential, pRb-depleted cells display
reduced mESC colony size, altered cell morphology, and
reduced cell proliferation rate (Fig. 1E, 1F). The induction of
mESC differentiation is characterized by an extension of G1
and G2 phases of the cell cycle (Fig. 1G, [5, 10]). Consistent
with reduced cell proliferation, depletion of Rb from self-
renewing mESCs resulted in a reduction of cell numbers in S
phase and increase of cell numbers in G1 and G2/M phase of
the cell cycle, reflecting a shift toward the cell cycle status of
differentiated cells (Fig. 1G; supporting information Table 1).
We conclude that high pRb levels promote mESC self-
renewal potential.
Oct4 Drives the Expression of Nipp1/Ccnf
to Maintain pRb Hyperphosphorylation
Our data anticipate a functional link between Oct4 and the
phosphorylation status of pRb in self-renewing mESCs. We
found that Oct4 does not act as a transcription factor for Rb
and does not physically interact with pRb (Fig. 1A; support-
ing information Fig. F22A, 2B). We consequently validated
whether Oct4 impacts on pRb function by modulating its
phosphorylation status. pRb is a substrate for PP1 complex in
proliferating cells [18]. At mitotic exit, all three PP1 isoforms,
a, c1, and b bind to pRb and dephosphorylate its Ser/Thr sites
in a sequential and site-specific way [19–22]. Importantly,
PP1 activity is regulated by the PP1 subunit Nipp1 (nuclear
inhibitor of PP1); in addition Ccnf (cyclin F), a member of
the SCF ubiquitin ligase complex was associated with the
maintenance of pRb in an inactive status [23, 24]. In line
with a potential role in differentiation, Nipp1 and Ccnf were
found to be efficiently repressed during mESC differentiation
(supporting information Fig. 2C). To functionally validate a
role for Oct4 in controlling Nipp1/Ccnf expression, we
depleted Oct4 from self-renewing mESCs and measured
Nipp1 and Ccnf mRNA expression. As expected, Oct4 knock-
down caused a significantly reduced expression of Ccnf and
Nipp1 mRNA (Fig. 2A). Importantly, ectopic expression of
HA-tagged Oct4 in differentiating mESCs that do not express
endogenous Oct4 was able to not only rescue Ccnf and Nipp1
expression (Fig. 2B) but also restored hyperphosphorylation
of pRb and increased total pRb levels (Fig. 2B, right panel).
Finally, ChIP verified the presence of Oct4 at Ccnf and Nipp1
promoter regions (Fig. 2C). Altogether, our results demon-
strate that Oct4 promotes the expression of the PP1 inhibitors
Nipp1 and Ccnf in self-renewing mESCs.
To validate the relevance of Nipp1/Ccnf for controlling
the post-translational modification of pRb, we tested whether
alterations of Nipp1 or Ccnf expression impact on the phos-
phorylation status of pRb and mESC self-renewal potential.
RNAi-mediated reduction of Ccnf/Nipp1 resulted in an effi-
cient reduction of total pRb and phospho-pRb-T356 levels,
the accumulation of cells with differentiated cell morphology
and reduced cell proliferation rates, altogether recapitulating
the effect of combined Oct4 and Rb depletion (Fig. 2D–2F).
These effects were paralleled by a significantly reduced AP
Figure 6. Oct4 and miR-335 control the Rb pathway in mouse em-
bryonic stem cells (mESCs). Schematic presentation of the Oct4-
Nipp1/Ccnf-PP1-pRB axis in (A) self-renewal conditions and (B) dif-
ferentiating mESCs. See text for details. Abbreviations: Ccnf, cyclin
F; Nipp1, nuclear inhibitor of PP1; PP1, protein phosphatase 1; pRb,
retinoblastoma protein.
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activity and expression of self-renewal marker genes Nanog,
Sox2, Gdf3, and Klf4 (Fig. 2G, 2H). Consistent with the role
of PP1 in mediating pRb hypophosphorylation, RNAi-medi-
ated depletion of PP1/b significantly increased the abundance
of hyperphosphorylated pRb and total pRb (Fig. 2D). In order
to better address the relation between Oct4-dependent pRb-
phosphorylation and total pRb levels, we depleted Oct4 and
PP1b from self-renewing mESCs. We found that siRNA-
mediated knockdown of PP1b efficiently rescues pRb-phos-
phorylation levels in Oct4-depleted mESCs (supporting infor-
mation Fig. 2D). The rescue of pRb-phosphorylation in
siOct4/siPP1 knockdown cells is paralleled by a restoration of
total pRb protein to expression levels observed in control
mESCs (supporting information Fig. 2D). These results under-
line that PP1 not only controls pRb phosphorylation levels in
mESCs but also indicate that phosphorylation has a central
role in controlling total pRb levels in self-renewing mESCs.
Altogether, this set of experiments demonstrates that Oct4
drives the expression of Nipp1/Ccnf to protect hyperphos-
phorylated pRb from dephosphorylation by PP1 in self-renew-
ing mESCs. The novel Oct4-Nipp1/Ccnf-PP1-pRb axis pro-
motes mESC self-renewal potential and establishes a direct
link between self-renewal transcription circuits and the Rb
pathway.
MiR-335 Controls Oct4 and pRb Expression on the
Post-Transcriptional Level
Repression of Oct4, as occurring during mESC differentiation,
is expected to result in the collapse of the Oct4-Nipp1/Ccnf-
PP1 axis, leading to pRb hypophosphorylation, loss of self-
renewal gene expression patterns, and the acquisition of a cell
cycle profile of differentiated cells. In line with this Oct4,
pRb, p-pRb-T356, and Nipp1 protein levels were rapidly
repressed during mESC embryoid body (EB) differentiation
(Fig.F3 3A; supporting information Fig. 3C). However, the per-
sistence of considerable levels of Oct4 and Rb mRNA levels
at day 3 and 6 of EB differentiation suggest that post-tran-
scriptional regulatory mechanisms executed by miRNAs could
accelerate the collapse of the Oct4-pRb axis at the exit from
mESC self-renewal (Fig. 3A, right panel). Based on the pres-
ence of conserved target sites for miR-335 in the 30UTRs of
Rb and Oct4, we speculated that miR-335 could regulate the
Oct4-Nipp1/Ccnf-PP1-pRb axis by targeting Oct4 and Rb in
mESCs (supporting information Fig. 3A) [25]. Consistent
with the tight regulation of miRNAs controlling mESC func-
tion [26, 27], we found that miR-335 and its hosting gene
Mest were efficiently upregulated in diverse mESC differen-
tiation schemes (Fig. 3B; supporting information Fig. 3B)
[28]. As expected, the pluripotency transcription factors Sox2,
Nanog, and Klf4 together with Oct4 were downregulated dur-
ing mESC differentiation (supporting information Fig. 3C).
To validate a possible interaction between miR-335 and its
predicted target sites in the 30UTR of Oct4 and pRb, we per-
formed classic luciferase reporter assays. Ectopic miR-335
efficiently reduced the expression of a luciferase reporter
fused to the 30UTR of Oct4 or Rb in transient cotransfection
experiments using U2OS cells (Fig. 3C). Deletion of the miR-
335 target sites (Rb-30UTRD; Oct4-30UTRD) renders the Oct4
and Rb control reporter constructs resistant to ectopic miR-
335 (Fig. 3C). We conclude, that miR-335 targets conserved
sequence motifs in the 30UTR of Oct4 and Rb to control Oct4
and pRb protein levels in mESCs.
Transient transfection of mESCs with miR-335 mimic
siRNAs efficiently reduced pRb and Oct4 protein levels under
self-renewal conditions whereas antago-miR-335 siRNAs had
an opposite effect (Fig. 3D). Importantly, ectopically elevated
miR-335 levels antagonized pRb hyper-phosphorylation, reca-
pitulating the effect of Oct4 siRNA-mediated pRb dephospho-
rylation (Figs. 1A and 3D). We conclude that miR-335 can
control the expression of Oct4 and pRb on the post-transcrip-
tional level and impacts on the phosphorylation status of pRb.
MiR-335 Antagonizes mESC Self-Renewal
The sharp upregulation of miR-335 during mESC differentia-
tion anticipates an important role for miR-335 in antagonizing
the activity of the self-renewal promoting Oct4-Nipp1/Ccnf-
PP1-pRb axis. To test this hypothesis, we performed miR-335
gain and loss of function experiments in self-renewing mESCs
(supporting information Fig. 3D). mESCs transfected with
mimic miR-335 siRNAs showed reduced cell proliferation
rates and formed smaller colonies that contained a significant
fraction of cells with a morphology of differentiated cells
(Fig. F44A). Importantly, when experimental cells were replated
in self-renewing promoting mESC medium 3 days post-trans-
fection, miR-335 transfected cells displayed a severe impair-
ment in the formation of colonies containing self-renewing
mESCs (Fig. 4B). In line with increased cell differentiation,
we found that ectopically increased miR-335 levels reduced
the number of cells in S phase, indicating a shift toward the
cycle profile of differentiated cells (Fig. 4C; supporting infor-
mation Table 2). Reducing endogenous miR-335 levels by
transfecting antago-miR-335 did not have an impact on cell
morphology or cell cycle regulation (Fig. 4A–4C; supporting
information Table 2).
To validate whether miR-335 antagonizes the expression
of molecular markers of mESC pluripotency, we transfected
self-renewing mESCs with mimic-miR-335 siRNAs and
antago-miR-335 siRNAs. Introducing ectopic miR-335 into
self-renewing mESCs reduced AP activity, SSEA-1 expres-
sion, colony re-plating efficiency, and significantly reduced
the expression of the self-renewal marker genes Sox2, Oct4,
Gdf3, and Klf4. (Fig. 4D, 4E; supporting information Fig. 4A,
4B). Of interest, ectopic introduction of miR-335 also induced
the expression of primitive ectoderm marker genes Nestin and
Otx2 (supporting information Fig. 4C). This suggests that
reduced self-renewal potential in the context of elevated miR-
335 levels lowers the barriers to the induction of cell differen-
tiation programs. As expected, reducing cellular miR-335 lev-
els by introducing antago-miR-335 did not impact on any of
the investigated markers for mESC self-renewal potential
(Fig. 4D, 4E; supporting information Fig. 4A, 4B).
After discovering a role of miR-335 in opposing mESC
self-renewal, we evaluated the separate contribution of the
pRb and Oct4, both targets of miR-335, to the observed alter-
ations in mESC self-renewal potential. Individual siRNA-
mediated knockdown of Oct4 or Rb significantly reduced AP
activity (Fig. 4F). This effect was enhanced by the cotransfec-
tion of si-Oct4 and si-Rb oligonucleotides or mimic miR-335
siRNAs (Fig. 4F). This demonstrates that concurrent targeting
of Oct4 and Rb by miR-335 is an efficient mechanism to
reduce self-renewal potential. Importantly, ectopic expression
of pRb or HA-tagged Oct4 rescued the impaired self-renewal
potential of miR-335 overexpressing mESCs as shown in AP
assays and pluripotency marker gene expression analysis (Fig.
4G; supporting information Fig. 4D–4F). Consequently, we
exclude that alternative miR-335 targets drive the observed
effects in self-renewal assays.
Together, this set of experiments demonstrates that miR-
335 is a novel antagonizer of mESC self-renewal that limits
pluripotency potential by concomitant targeting of Oct4 and
pRb at the post-transcriptional level.
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Targeting of Oct4 and Rb by MiR-335 Promotes
the Exit from mESC Self-Renewal
The dramatic increase of miR-335 expression at the onset of
mESC differentiation indicates that miR-335 dependent
repression of Oct4 and pRb is an important step to facilitate
the exit from self-renewal (Fig. 3B). To further validate this
model, we ectopically altered miR-335 expression during
mESC differentiation and studied the kinetics of mESC self-
renewal potential, cell cycle structure, and the upregulation of
differentiation markers.
Ectopic introduction of miR-335 accelerated the appear-
ance of cells with differentiated morphology, further underlin-
ing that miR-335 promotes mESC differentiation (Fig.F5 5A). In
contrast, antagonizing the upregulation of miR-335 during
mESC differentiation by introducing antago-miR-335 oligonu-
cleotides prior to the induction of mESC differentiation
enabled mESCs to retain an undifferentiated cell morphology
(Fig. 5A). In line with this, mESCs treated with antago-miR-
335 maintained a self-renewal cell cycle program even under
differentiation conditions; in contrast, ectopic introduction of
miR-335 accelerated the reduction of cell numbers in S phase
during mESC differentiation (Fig. 5B; supporting information
Table 3). The differentiation promoting effect of miR-335
was also confirmed on the molecular level. The induction of
differentiation in control miRNA transfected cells induced a
30% reduction of AP activity. Whereas, the introduction of
antago-miR-335 under the same conditions significantly
delayed the reduction of AP activity during mESC differentia-
tion, ectopic introduction of miR-335 accelerated the differen-
tiation associated loss of AP activity (Fig. 5C). Similar results
were obtained for the expression of SSEA-1, a classic marker
for self-renewing mESCs (supporting information Fig. 5A).
Expression analysis of marker genes for mESC pluripotency
and early differentiation events confirmed the relevance of
miR-335 at the exit from self-renewal. The introduction of
miR-335 prior to the induction of mESC differentiation effi-
ciently reduced the expression of self-renewal markers such
as Oct4, Sox2, Klf4, and Gdf3 and increased the expression of
marker genes for primitive ectoderm (Fgf5, Otx2, Nestin) and
mesoderm (Bmp4) when compared to control cells (Fig. 5D,
5E). In contrast, antagonizing the upregulation of miR-335
during mESC differentiation by transfecting antago-miR-335
significantly delayed the downregulation of self-renewal
marker genes and resulted in an impaired induction of early
differentiation marker genes at day 3 of mESC differentiation
(Fig. 5D, 5E). In line with a role of miR-335 in promoting
cell differentiation, miR-335 overexpression promoted the for-
mation of contractile cardiomyocyte structures during EB dif-
ferentiation; in contrast expressing a decoy-miR-335 construct
significantly impaired the formation of pulsating cardiomyo-
cytes (Fig. 5F). In addition to altered in vitro differentiation,
we observed that mESC overexpressing miR-335 form EB
aggregates with reduced growth potential in long-term suspen-
sion cultures and teratomas with reduced size when subcuta-
neously injected into immune-compromised mice (supporting
information Fig. 5B, 5C). Together, this suggests that a tight
control of miR-335 expression is essential to execute long-
term cell differentiation events.
Together, our data indicate that upregulation of miR-335
promotes the exit from self-renewal toward cell differentiation
by targeting the expression of Oct4 and pRb. To investigate
whether miR-335 plays a role in controlling the Oct4-Nipp/
Ccnf-PP1-pRb axis at the exit from self-renewal, we used
mESC stably overexpressing miR-335 or a decoy-miR-335
and followed the expression of Oct4, pRb, pRb-T356, and
Nipp1 during EB differentiation.
Under self-renewal conditions, control mESCs (day 0)
express high levels of total pRb (pRb) and hyperphosphory-
lated pRb (pRb-T356) (Fig. 5G). Consistent with reduced
Oct4 protein levels, we found decreased Nipp1 expression
and a reduced abundance of total and hyperphosphorylated
pRb in miR-335 overexpressing cells. Reducing endogenous
miR-335 levels by overexpressing a decoy-miR-335 construct
increases Oct4, Nipp1, and pRb expression and leads to aug-
mented pRb hyperphosphorylation in self-renewing mESCs
(Fig. 5G, lanes 1–3). Upon induction of differentiation, tran-
scriptional repression combined with targeting by miR-335
efficiently reduces Oct4 expression, leading to low Nipp1 pro-
tein permitting the dephosphorylation of pRb by PP1. Desta-
bilization of pRb by dephosphorylation and targeting of Rb
by endogenous miR-335 finally reduces total pRb expression
levels (Fig. 5G, lane 4). Of notice, this effect is aggravated
upon miR-335 overexpression (Fig. 5G, lane 5). In contrast,
antagonizing miR-335 upregulation by expressing a decoy-
miR-335 construct partially rescues Oct4 and Nipp1 expres-
sion leading to increased phosphorylation of pRb at day 3 and
6 of mESC differentiation, indicative for an inefficient exit
from mESC self-renewal programs (Fig. 5G, lanes 6, 9).
Altogether, our data demonstrates that Oct4 in conjunction
with miR-335 controls the activity of the pRb pathway in
mESCs. In self-renewing mESCs, high Oct4 expression drives
the expression of Nipp1 and Ccnf that antagonize the enzy-
matic activity of the PP1 complex, leading to pRb hyperphos-
phorylation as hallmark feature of self-renewing mESCs (Fig.
F66A). Upon induction of cell differentiation, transcriptional
repression of Oct4 in conjunction with targeting of pRb and
Oct4 by upregulated miR-335 causes the collapse of the
Oct4-Nipp1/Ccnf-PP1-pRb axis promoting the exit from self-
renewal and establishment of a Retinoblastoma regulated cell
cycle program (Fig. 6B).
DISCUSSION AND CONCLUSION
Self renewing mESCs are characterized by the coordinated
expression of core pluripotency transcription factors and the
establishment of a specific cell cycle program that allows
rapid cell proliferation [1–3, 13, 14]. Here we present a novel
pathway that links Oct4 and miR-335 with the Retinoblastoma
pathway in self-renewing and differentiating mESCs.
In self-renewing mESC, cell cycle regulation is mainly
executed by Cdk2 that mediates the hyperphosphorylation and
biochemical inactivation of Retinoblastoma family protein
[12–14]. The induction of cell differentiation is paralleled by
a massive downregulation of total Oct4 and pRb levels and
the acquisition of a Retinoblastoma pathway-regulated cell
cycle program [11–14]. We show that RNAi-mediated knock-
down of pRb from self-renewing mESCs reduces self-renewal
potential, recapitulating effects normally observed upon Oct4
depletion or the induction of mESC differentiation. This indi-
cates that high pRb protein levels improve the self-renewal
potential of mESCs. In line with these data, mESC derived
from a mouse model with constitutive activity of Cdk2 accu-
mulate total pRb and hyperphosphorylated pRb and show a
severely impaired differentiation potential [15]. Together, this
implies that pRb does not only impact on cell cycle regula-
tions but also enhances the self-renewal potential of mESCs
by limiting the initiation of cell differentiation programs. We
further show in gain and loss of function experiments that
Oct4 has a critical role in ensuring the hyperphosphorylation
of pRb under self-renewal conditions by impairing its dephos-
phorylation by the PP1. In mammals, PP1 is the major pRb
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cell cycle-related phosphatase that binds to pRb and dephos-
phorylated pRb at the mitotic exit [18]. Several PP1 interact-
ing proteins have been reported that either increase or inhibit
phosphatase activity [18, 23]. Here, we provide evidence that
Oct4 drives the expression of the reported PP1 inhibitors
Nipp1 (nuclear inhibitor of PP1) and Ccnf (Cyclin F) in self-
renewing mESCs. This results in the protection of pRb from
dephosphorylation by PP1. In line with our data, Nipp1 and
Ccnf expression were previously shown to correlate with Oct4
expression in somatic cells [24]. Nipp1 is a negative regula-
tory subunit of the PP1 complex, and Ccnf is anticipated to
modulate the stability of PP1 via its presence in the SCF
ubiquitin ligase complex [23, 29, 30]. Importantly, consistent
with a role in inhibiting PP1 activity, depletion of Nipp1 and
Ccnf results in efficient dephosphorylation of pRb that is
associated with a loss of mESC self-renewal potential, pRb
dephosphorylation and the acquisition of a cell cycle program
of differentiated cells. The function of Nipp1 in inhibiting
pRb dephosphorylation also provides an explanation for
unsuccessful attempts in establishing mESC lines from Nipp1-
deficient blastocysts [31]. In line with a role in modulating
early differentiation events, mice carrying a targeted deletion
of Ccnf or Nipp1 die at day E6.5–E-8.5 or E10 of embryogen-
esis, respectively [31, 32].
Altogether, our data indicate that in self-renewing mESCs
high Oct4 expression levels drive the expression of Nipp1 and
Ccnf to inhibit the activity of PP1, thereby establishing pRb
hyperphosphorylation as a key feature of mESC pluripotency.
Several miRNAs have been identified to control self-
renewal or differentiation of mESCs [6–9, 33]. Here, we dem-
onstrate that miR-335 is an important regulator of the Oct4-
Nipp1/Ccnf-PP1-pRb axis that targets Oct4 and pRb on the
post-transcriptional level at the onset of mESC differentiation.
miR-335 is hosted by the imprinted Mest gene and we show
that expression levels of both RNAs are dramatically upregu-
lated during mESC differentiation. Impairing miR-335 upreg-
ulation during differentiation leads to ectopic Oct4, Nipp1,
and pRb expression that finally leads to a reappearance of
hyperphosphorylated pRb, impaired silencing of self-renewal
gene expression patterns, and a delayed upregulation of genes
involved in cell differentiation. In contrast, ectopically
increased miR-335 levels efficiently reduced mESC self-
renewal potential. Together, this identifies miR-335 as a novel
self-renewal antagonizing miRNA. Interestingly, the fact that
Mest is subjected to genomic imprinting could suggest that
monoallelic expression of miR-335 could be important for
early embryogenesis. A mouse model carrying a lacZ inser-
tion into the Mest locus has been reported; however, the
applied targeting strategy does not affect the miR-335 coding
sequence [28]. Consequently, new mouse models are required
to investigate the relevance of miR-335 for the regulation of
the Oct4-Nipp1/Ccnf-PP1-pRb axis during early embryonic
development in vivo.
On the basis of our data, we propose a model where high
Oct4 expression drives the expression of inhibitors of the
major pRb phosphatase PP1 to ensure the hyperphosphoryla-
tion of pRb as hallmark-feature of self-renewing mESCs. The
induction of differentiation leads to a contemporary repression
of Oct4 and upregulation of miR-335 leading to the collapse
of the self-renewal promoting pRb-Nipp1/Ccnf-PP1-pRb axis,
the exit from self-renewal and the establishment of pRB-regu-
lated cell cycle profile of differentiated cells. Our work not
only integrates mESC cell cycle control into the functional
repertoire of Oct4 but also anticipate an important role for
Oct4 in the inactivation of the Retinoblastoma tumor suppres-
sor pathway in human cancers with embryonic stem cell gene
expression signatures. AQ5
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